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Summary 
 
Schizophrenia is a complex disorder, with several genes putatively associated 
with the pathogenesis of the disorder. A large genome-wide association study 
(O’Donovan et al. 2008) identified ZNF804A as a candidate gene for 
schizophrenia (meta-analysis p = 1.61 x 10-7). The association of the gene with 
schizophrenia (and bipolar disorder) has since been successfully replicated 
several times, confirming the association (Riley et al., 2010; Steinberg et al., 
2010; Zhang et al., 2010, Williams et al., 2011). 
 The aim of this thesis is to create and provide preliminary assessments of 
a mouse model of the murine form of ZNF804A, Zfp804a.  A mutagenised DNA 
archive derived from mice treated with N-ethyl-N-nitrosourea (ENU) held at the 
MRC Mammalian Genetics Unit, Harwell, was screened for mutations in Zfp804a.  
Two mutations (C59X and C417Y) were selected for re-derivation based upon 
the estimated impact upon the protein. The mutations were backcrossed onto a 
C57Bl/6J background for three successive generations  using a panel of genetic 
markers to aid selection for the highest level of C57Bl/6J congenicity (and 
therefore speed up the backcrossing process). G4 mice were tested in the study. 
 Preliminary assessments of the fourth generation intercross cohort 
revealed, most notably, that the mice breed well, have no gross physical deficits 
and that male Zfp804aC59X/C59X mutants appeared less anxious than other groups 
in the elevated plus maze and performed better than other groups on the 
RotaRod. 
 Initial indications show that Zfp804a may indeed influence behaviour and 
cognition however further work is necessary to expand upon these findings with 
larger samples.  
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 1 
CHAPTER 1: General Introduction 
 
Schizophrenia is a severe and disabling psychiatric disorder that is amongst the 
top ten leading causes of disability worldwide (Murray & Lopez, 1996; World 
Health Organisation, 2001). The disorder and the deficits associated with it are 
frequently life-long in course and current treatments are only, at best, 
moderately effective. 
The problem of schizophrenia in society is not restricted to the disruption 
in everyday life the symptoms cause the sufferer; problems associated with the 
disorder are substantial and far-reaching. Schizophrenia, according to Saha et 
al. (2007), reduces lifespan by about 12 to 15 years on average. This is mainly 
due to suicide but other causes include increased risk of murder (Hiroeh et al. 
2001) and increased risk of death due to natural causes (Hewer et al., 1995; 
Hewer and Rössler, 1997). There is also a substantial burden on patients, 
families and communities due to schizophrenia. Patients suffer not only from 
the vastly debilitating nature of the disorder but also from stigma and 
discrimination in society associated with mental health problems. The burden 
on families and close friends is also substantial, encompassing practical 
difficulties such as disruption of routine, reduced leisure time and restricted 
social activities, emotional and stress-related reactions, economic 
considerations and dealing with prejudice associated with mental illness. 
Costs associated with schizophrenia are also high with Knapp (1997) 
estimating that 1.5% of national health expenditure is spent on the disorder, 
with a high rate of spending being due to the nature of the disorder (e.g. chronic 
course and frequent readmissions to hospital). Additional costs to the economy 
 2 
are associated with the economic burden on relatives and caregivers, early 
retirement and reduced ability to work of the patient. Schizophrenia is a 
relatively common problem with a high financial cost to society and devastating 
effects on the lives of the sufferer and those close to them. For such a 
problematic and prominent disorder, we know very little about the aetiology and 
pathogenesis of the disorder.  
 
 
1.1 Schizophrenia epidemiology 
 
Schizophrenia affects approximately 1% of the world population in a lifespan 
with an incidence of roughly 15 per 100 000 per year (e.g. Tandon et al., 2008). 
The disorder affects both males and females although males are more 
frequently affected with McGrath et al. (2004) reporting a male to female 
prevalence rate of 1.40. Schizophrenia is a problem that affects all nationalities 
and races fairly equally although there are findings indicating that certain 
groups in the UK are more severely affected than others such as migrants (and 
their second generation offspring) from Africa and the Caribbean being up to 10 
times more likely to develop schizophrenia than in the populations in the 
countries of origin and in the UK (Eaton & Harrison, 2000). Other factors  are  
also involved in the risk for developing schizophrenia including season of birth, 
birth complications, immune system and autoimmunity, cannabis use, 
urbanicity and genetics (discussed further in 1.5 Genetics of schizophrenia).  
 
1.2 What is schizophrenia? 
Schizophrenia is a severe mental health disorder that has been recognised 
since Emil Kraepelin (1896 -1987) described dementia praecox in the fifth 
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edition of his textbook.  Prior to this early work, no clear, consensual 
demarcation was made between dementia praecox and affective psychosis. 
Kraepelin’s work focused around clustering symptoms commonly co-occurring 
into a disease classification. He introduced a simple distinction between 
conditions characterised by mental deterioration and the affective disorders 
which were more episodic. The mental deterioration (named dementia praecox) 
was characterised as a psychological rather than physical impairment and 
included symptoms recognised in schizophrenia today such as auditory 
hallucinations, delusions, thought disorder and blunted affect (Wing & Agrawal, 
2003). The term ‘schizophrenia’ derives from Eugen Bleuler (1911 -1950). He 
maintained Kraepelin’s ideas of distinguishing schizophrenia from manic-
depressive psychosis but pointed out that affective symptoms could co-exist 
and substantially widened the boundaries of the classification of the disease 
(Wing & Agrawal, 2003).  
In modern psychiatry, schizophrenia is diagnosed solely upon the 
presentation and reporting of symptoms and a diagnosis is made upon the 
reported intensity and duration of symptoms (Wing & Agrawal, 2003). In the 
UK, the American Psychiatric Association’s Diagnostic and Statistical Manual of 
Mental Disorders, version DSM-IV-TR is used to provide the criteria of a 
diagnosis of schizophrenia. Two or more ‘characteristic symptoms’ must be 
present, including positive symptoms such as delusions, hallucinations and 
disorganised speech and behaviour, and negative symptoms such as a 
flattening of affect, an inability to experience pleasure in daily life and a lack of 
motivation for a diagnosis of schizophrenia. These symptoms must, in addition, 
cause a significant impairment in daily functioning socially and/or at work and 
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there must have been at least a six-month period where behaviour has been 
disturbed, including a minimum of one month (if untreated) of characteristic 
symptoms being present. 
Schizophrenia cannot be diagnosed if there are apparent symptoms of a 
mood disorder or pervasive developmental disorder, or the symptoms are the 
direct result of another medical condition or a substance, such as abuse of a 
drug or medication. Symptoms of schizophrenia are generally grouped under 
three subheadings: positive, negative and cognitive symptoms. ‘Positive 
symptoms’ are features of the disorder that are not present in healthy 
individuals including hallucinations in any modality, delusional thinking, 
disorganised speech and behaviour and catatonia. ‘Negative symptoms’ refers 
to features normally present in healthy people that are missing in people with 
schizophrenia such as a flattening of affect, avolition and anhedonia. Cognitive 
symptoms describe the difficulties in processing many people with 
schizophrenia experience in attention, memory and concentration (Cutting, 
2003). 
Schizophrenia is clinically understood as a discrete disorder and a 
distinct diagnosis from schizoaffective disorder and bipolar disorder. The 
diagnosis given to the presenting patient depends upon nature of the psychosis 
and mood disturbances present. Essentially schizophrenia is diagnosed where 
psychosis is present without a prominent depressive, manic or mixed episode. 
Schizoaffective disorder may be diagnosed with both, one or more prominent 
mood episode/s and psychosis. Finally, bipolar disorder is diagnosed where 
mood disturbances are the prominent feature. Psychosis may or may not be 
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present but in a diagnosis of bipolar disorder, will never meet the DSM IV 
criterion A requirement for schizophrenia (Cutting, 2003).  
The nosology of schizophrenia has recently been called into question in 
the light of converging genetic evidence that there is some shared susceptibility 
on the psychosis-mood disorder diagnostic spectrum. Schizophrenia is a 
syndromic diagnosis. That is, it is diagnosed when a person presents with a 
collection of symptoms characteristic of schizophrenia. Many, if not all, of these 
symptoms could be present in other psychiatric disorders, albeit in differing 
proportions. Owen et al.(2007) highlight the need to re-consider traditional 
diagnostic boundaries and argue persuasively that genetic evidence doesn’t 
comply with current classifications.  
Although traditional family studies provide some support to the 
schizophrenia –bipolar divide (e.g.Gottesman, 1991; Tsuang et al. 1990), family 
studies looking at schizoaffective disorder have found similar rates of the 
disorder in both families with predominantly bipolar illness (Rice et al., 1987) 
and families with schizophrenia (Kendler et al. 1998). Cardno et al. (2002) 
found that in twin studies, results are skewed as schizophrenia-like symptoms 
tend to “trump” those of mood disorder (forming a diagnostic hierarchy for each 
individual lifetime diagnosis). When they defined syndromes non-hierarchically, 
they unveiled a clear overlap between syndromically defined mania and 
schizophrenia. Moreover, employing linkage analysis Hamshere and 
colleagues (2005) showed that schizophrenia and bipolar families contributed 
equally to genome-wide significant linkage at 1q42 and suggestive linkage at 
22q11; DISC1 and COMT map to these regions respectively.  
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Individual gene studies have also been informative in the area of 
nosology (see Owen et al., 2007) and although some genes do provide 
evidence for specific susceptibility to prototypical schizophrenia (e.g. DTNBP1) 
or prototypical mood disorder (e.g. DAOA) there is again clear overlap in 
genetic susceptibility across the traditional Kraeplinian divide.  For example, the 
recent association of schizophrenia with ZNF804A, a strong statistical 
candidate gene, is strengthened to genome-wide significance when bipolar 
cases are added to the sample (O’Donovan et al., 2008).  
Currently, the issue of biological overlap of diagnostic boundaries in 
brain diseases is a hot topic which may go beyond schizophrenia and bipolar 
disorder to include other psychopathology, and even extend to certain 
neurological conditions. Craddock et al. (2009) review the evidence from 
genetic epidemiological, common single-nucleotide polymorphism (SNP) 
studies and genomic structural variation studies and conclude that there is 
substantial overlap in possible aetiology between the traditional boundaries for 
schizophrenia, bipolar disorder, unipolar depression, autism and epilepsy. 
Whilst far from settled, it is clear that the increasing knowledge about the 
biological aspects of psychiatric disorder highlights the need for more complex 
diagnostic models.    
Schizophrenia has no known biomarkers meaning it cannot be 
diagnosed by laboratory tests. This lack of biomarkers for the disorder is 
indicative of our lack of knowledge about the underlying biological pathways 
that lead to its clinical presentation. There are numerous theories of the 
biological pathways impacting on the symptoms of schizophrenia such as the 
dopamine and glutamate hypotheses. However, none as yet have been shown 
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to be definitive for schizophrenia and so cannot be exploited for diagnostic 
purposes.  Schizophrenia is currently diagnosed by psychiatrists on the basis of 
self-report of symptoms, behaviours observed, and reports of those close to the 
patient. 
 
1.3  Clinical presentation of schizophrenia 
The criteria for a diagnosis of schizophrenia encompass the three core 
symptom-groups of schizophrenia: positive, negative and cognitive symptoms. 
 
1.3.1 Positive symptoms in schizophrenia 
Schizophrenia is a heterogeneous disorder characterised by an array of 
possible symptoms .There is no single prescriptive symptom that every person 
diagnosed with schizophrenia must exhibit. Between people with schizophrenia 
therefore, there can be varying degrees of symptom overlap (Cutting 2003).  
Auditory hallucinations (usually voices), for example, are often thought of as 
characteristic of schizophrenia yet only 50% of people with schizophrenia 
studied experienced these (Cutting 1990). Other hallucinations were less 
common (visual, 15% and tactile, 5%). Delusions are more common; 90% of 
those with schizophrenia have had delusions at some point (Cutting, 2003). 
Thought disorder is another major category of symptoms in schizophrenia and 
refers to aberrant form and content of thoughts. Thought disorder includes 
some positive (such as inappropriate affect) and some negative (such as 
derailment and tangentiality) symptoms. The positive symptoms of 
schizophrenia are generally measured by self-report or tests that require 
language and/or writing skills (Cutting, 2003). It is therefore the general opinion 
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in the scientific community that these symptoms, even if they were to exist in 
non-human animals, cannot be easily measured and are unsuitable for 
examination in a mouse model for schizophrenia (Desbonnet, et al., 2009).  
 
1.3.2   Affect in schizophrenia 
Although mood disturbances cannot be the dominant feature of schizophrenia 
(or the diagnosis would not be one of schizophrenia, see earlier), affective 
abnormalities can be both predictive of (e.g. Johnstone et al., 2005; 
Cunningham Owens et al., 2005), and co-morbid with schizophrenia (discussed 
in Cutting, 2003, Buchanan, 2007). Interesting work emerging from the 
Edinburgh High Risk Study showed that affective abnormalities are one of the 
best predictive pre-morbid symptoms for predicting the development of the 
disorder in those deemed to be at high genetic risk (Cunningham Owens et al., 
2005; Johnstone et al., 2005). In a longitudinal study of those people at ‘high 
genetic risk’ of developing schizophrenia, those who went on to become ill, had 
higher pre-morbid levels of situational and social anxiety, nervous tension, 
depression and withdrawal. Post illness-onset, the affective symptomatology in 
the group remained high but stable.  
 Other researchers have also found that affective abnormalities do not 
disappear or lessen after the onset of schizophrenia. Buchanan (2007) 
discusses the prominent and persistent nature of negative symptoms 
throughout the course of the disorder. Furthermore, the negative and affective 
disturbances in schizophrenia are deemed to be such an integral part of the 
disorder that Carter et al., (2009) as part of the CNTRICS (Cognitive 
Neuroscience Treatment Research to Improve Cognition in Schizophrenia) 
 9 
group, recommend using social cognition and affective neuroscience-based 
measures as part of the assessment of the cognitive deficits of schizophrenia, 
in particular, looking at the ability to identify and respond to emotions.  
 
1.3.3 Cognitive deficits in schizophrenia 
There is a substantial body of recent research that has acknowledged on 
focused on the role of cognitive deficits in schizophrenia. Wilk et al. (2005) 
suggest that those apparently ‘spared’ the deficits are those people who had 
higher or superior pre-morbid abilities.  People with earlier-onset schizophrenia 
(presenting during youth, rather than adulthood) tend to have higher levels of 
cognitive impairment. Later-onset appears to be associated with preserved 
cognitive function to some extent (Rajji et al., 2009).  
It is debatable whether or not the cognitive profile of an individual with 
schizophrenia is static throughout the lifespan or whether it is subject to decline 
during the course of the illness with anti-psychotic treatment and 
hospitalisation. The literature suggests a mixed picture with some studies (e.g. 
Heaton & Drexler, 1987) showing evidence for a static picture throughout the 
lifespan and other studies show a more undulating picture of impairment that 
varies according to illness status (e.g. Harvey, 2001). Interestingly, in their 
longitudinal study of IQ in people with schizophrenia, Van Winkel et al. (2006) 
showed that IQ was lower than estimated pre-morbid levels at the onset of 
illness but 10 years following that, IQ had returned to pre-morbid estimated 
levels.  This finding serves as an indicator that cognitive endophenotypes in 
schizophrenia need to be defined not only at illness onset but measured at 
time-points throughout illness course in order to be valid markers. At present, 
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there are too few longitudinal studies to draw any definitive conclusions as to 
the stability of cognitive subtypes in schizophrenia (Joyce & Roiser, 2007) and 
further investigation is needed.  
 Another matter to be considered is the nature of the cognitive 
impairments; is there a global cognitive impairment or are specific functions 
affected more severely than others? Goldberg et al., (2004), suggest that 
patients with schizophrenia typically exhibit abnormalities in attention, executive 
function and memory which stand out against a background of diffuse 
impairment. Fioravanti et al., (2005) suggest that cognitive deficits are more 
widespread and specific than this with significant impairments in people with 
schizophrenia seen in IQ, memory, language, executive function and attention 
although there was much heterogeneity between the individual studies 
examined. A more recent review (Reichenberg, 2010) describes the specific 
deficits in processing speed, learning, working memory, executive functions 
and attention that are evident in people with schizophrenia on a background of 
a general cognitive deficit. These specific impairments are reflected in the 
design of The Matrics Consensus Cognitive Battery (Nuechterlein et al., 2008, 
Kern et al., 2008), a battery of cognitive tasks designed specifically to assess 
cognitive function in people with schizophrenia. 
 
1.4 Neurobiology of schizophrenia 
That schizophrenia may have a neurobiological basis has been suspected for 
over a century (Kraepelin, 1919; 1971; Spielmeyer, 1930) yet it is still poorly 
understood. Increased understanding of the neurobiology and underlying 
pathogenesis of schizophrenia should lead to improved diagnosis and 
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nosology, prediction of illness course and outcome, identifying causative and 
secondary mechanisms and, most importantly, identifying valid targets for 
treatment and developing better drug therapies.  
 
1.4.1 Neuropathological findings 
Despite the neuropathology of schizophrenia remaining elusive, the null 
hypothesis, that is, that there is no neuropathology in schizophrenia can be 
rejected (Harrison, 1999b). Strong evidence from post-mortem studies exists 
for overall effects including decreased brain weight (Brown et al., 1986; 
Pakkenberg, 1987; Bruton et al., 1990), shorter brain length (Bruton et al., 
1990) and reduced volume of the cerebral hemispheres (Pakkenberg, 1987). 
More specific structures have also been found to be affected in schizophrenia, 
including enlarged lateral ventricles (Brown et al., 1986; Pakkenberg, 1987; 
Crow et al., 1989), decreased thalamic volume (Pakkenberg, 1990, 1992; 
Danos et al., 1998) and reduced temporal lobe volume (Bogerts et al., 1985, 
1990; Brown et al., 1986; Falkai & Bogerts, 1986; Falkai et al., 1988; Jeste & 
Lohr, 1989; Altshuler et al., 1990; Vogeley et al., 1998). This evidence is largely 
corroborated by neuroimaging findings taken in life (Harrison, 1999b, see 1.4.3 
for a summary).  
 Some authors such as Stevens (1982) have suggested a role for gliosis 
in schizophrenia neuropathology. Gliosis is a sign of previous damage or scar 
tissue (Kreutzberg et al., 1997). Such damage would contradict the 
neurodevelopmental hypothesis of schizophrenia (which would suggest 
hallmark pathology developed and was not as the result of an insult) and would 
support an infectious, autoimmune or neurodegenerative hypothesis of 
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schizophrenia (Harrison, 1999b). Harrison discusses the evidence in his review 
(1999b) and remarks that many subsequent studies have not found gliosis (e.g. 
Roberts et al., 1986, 1987, Stevens et al., 1988; Casanova et al., 1990, Arnold 
et al., 1996) and one interesting study, Bruton et al. (1990) found that those 
schizophrenia cases with gliosis had accompanying neurocognitive deficits 
where gliosis was present. Currently, the evidence against gliosis outweighs 
the evidence for the process having an involvement in schizophrenia (Harrison, 
1999b).  
 
1.4.2 Neurochemistry and neuropharmacology in schizophrenia 
The observed psychoactive effects of certain compounds and their similarity to 
aspects of schizophrenia symptoms have largely driven neurochemical 
hypotheses in schizophrenia. The dopamine hypothesis of schizophrenia, 
which is the hypothesis that dopaminergic overactivity contributes to the 
schizophrenia phenotype, emerged with the observation that all available and 
effective anti-psychotic drugs are D2 dopamine receptor antagonists. This was 
strengthened by the observation that amphetamine, a substance which triggers 
the release of dopamine, can induce a form of paranoid psychosis (Harrison, 
1999a). Roberts et al. (1997) review evidence for the dopamine hypothesis and 
highlight the support for findings of higher density D2 receptors in 
schizophrenia. However, as Davis et al. (1991) and Joyce and Meador-
Woodruff (1997) point out, despite all the correlational data, there is still no 
consensus on the specifics of the abnormality. D2 receptors have received the 
most attention in the dopamine hypothesis and there is some evidence for 
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involvement of D1,3,4 receptors also (reviewed in Harrison, 1999a), although 
again none of the evidence is conclusive. 
 Serotonin, or 5-HT, has also been implicated in schizophrenia due to the 
hallucinogenic effects of the 5-HT agonist, LSD. Interest, as of late, has 
particularly focussed on the 5-HT2A receptor (Harrison & Burnet, 1997). The 
gene encoding the 5-HT2A receptors has been found to have an association 
with schizophrenia (Williams et al.1997) and has been also associated with 
differential responses to the antipsychotic clozapine (Arranz et al., 1998). In 
terms of neurochemical evidence, Harrison (1999b) reviews strong evidence for 
lowered 5-HT2A receptor expression in the pre-frontal cortices of people with 
schizophrenia. 
 The glutamate hypothesis of schizophrenia is another strong 
neurochemical hypothesis of schizophrenia that is again, driven by the 
observation that the drug phencyclidine (an NMDA receptor antagonist) given 
systemically can evoke a schizophrenia-like psychosis (Javitt & Zukin, 1991).  
The glutamate ‘hypothesis’ is not straightforward and findings vary between 
different brain regions (Taminga, 1998 Harrison, 1999b). There is some 
suggestion (e.g. Carlsson & Carlsson, 1990), that the mechanism by which 
glutamate acts in schizophrenia is through its interactions with dopamine.  
 
1.4.3 Neuroimaging in schizophrenia 
MRI technology has allowed the rapid development of this field over the last 30 
years.  Structural MRI has confirmed (as previously thought from post-mortem 
studies) that there is a reduction in overall brain and grey matter volume. 
Ventricles in the brain have also been found to be larger (e.g. Daniel et al., 
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1991; Shenton et al., 2001; Steen et al., 2006; Ward et al., 1996; Wright et al., 
2000). In addition to a reduction in overall brain volume, certain temporal lobe 
structures have been found to have notably reduced volume including the 
hippocampus, amygdala and the superior temporal gyri (STG) (Lawrie & 
Abukmeil, 1998, Nelson et al., 1998). The prefrontal cortex and thalamus 
(Konick & Friedman, 2001) and the anterior cingulate (Baiano et al., 2007) and 
corpus callosum (Woodruff et al., 1995) have also been identified as being 
reduced in volume in people with schizophrenia. 
           Most of these findings are however from region-of-interest studies, 
rather than a whole brain approach. Voxel-based morphometry has helped 
validate these findings with a reduction in STG volume found (correlating with 
positive symptoms) and a reduction in medial temporal lobe volume (correlating 
with memory impairments) (Honea et al., 2005; Antonova et al., 2004). Brain 
volume and hippocampal volume findings seem to hold when first episode 
patients (who have limited exposure to antipsychotics) are compared with 
controls (Steen et al., 2006; Vita et al., 2006). Many other findings described 
above do not, and some have been demonstrated to be due to drug treatment 
effects (Liddle & Pantelis, 2003). Brain volume changes are highly heritable 
(Baare et al., 2001; Bartley et al., 1997). 
           One caution with these findings is that many of these imaging changes 
in schizophrenia such as ventricular enlargement, are also seen in affective 
disorders (such a as bipolar disorder) although perhaps to a lesser extent (Elkis 
et al., 1995; Strasser et al., 2005) rendering brain volume/ventricle size 
unsuitable as a biomarker as it is a non-specific facet of schizophrenia.  
 15 
Disorder presentation and course is so diverse in schizophrenia that it is 
not surprising that the literature reflects this with many different brain regions 
and systems implicated. There are some areas of convergence however. 
Harrison and Weinberger (2005) and Owen et al. (2005) review the evidence 
and there is consensus among the literature that whole brain volume is 
reduced, ventricles are enlarged and thalamic-hippocampal-prefrontal circuitry 
is altered in schizophrenia. There is additional data from genetic studies that 
implicate genes involved at the synapse, which has led to the hypothesis that 
schizophrenia may be a disorder of the synapse; a hypothesis gaining 
increasing support (reviewed in Owen et al., 2005). More recently, Kirov et al., 
(2012) have again implicated genes involved at the synapse through the 
observation of copy number variations in schizophrenia cases. 
A degree of caution should be taken when approaching neurobiological 
data alone. Networks and pathways in the brain are inextricably interlinked and 
interact with each other, with one system bearing an influence upon another. It 
is therefore very difficult to dissociate primary from secondary effects and 
support from other fields is needed to validate neurobiological findings.  
 
1.4.4     A neurodevelopmental hypothesis of schizophrenia 
The neurodevelopmental hypothesis of schizophrenia is not at odds with the 
neurodegenerative profile of schizophrenia. In a recent meta-analysis of MRI 
studies, Olabi et al. (2011) state that there is no neurodevelopment-
neurodegeneration dichotomy as both processes can co-exist in schizophrenia 
(Balla and Frecska, 2011). Keshavan and colleagues review pathogenesis 
theories of schizophrenia in terms of timing, stating that neurodevelopmental 
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and neuroprogressive deficits in schizophrenia can co-exist and that any 
integrative approach to understanding schizophrenia needs to account for 
premorbid abnormalities as well as accounting for observations of the course 
and progression of the disorder (Keshavan et al., 2008). 
 The neurodevelopmental hypothesis views schizophrenia as the 
consequences of aberrant neurodevelopment that took place early in life 
(during pre-, peri-, post-natal, childhood and/or adolescent brain development), 
processes which take place long before the onset of clinically diagnosed 
schizophrenia. (Cardno et al., 1999, Singh et al., 2004). Several diverse lines of 
evidence support this model (Weinberg et al., 2007) including epidemiological 
studies of environmental insults such as in utero influenza infection and stress 
exposure (reviewed in Cannon et al., 2004) and the presence of obstetric 
complications (McNeil et al., 2000; Cannon et al., 2002). In addition to 
environmental pre-natal influences, a major influence on neurodevelopment is 
genetic variation in genes that influence neurodevelopmental processes such 
as synapse formation and neuronal migration (e.g. Stahl, 2000, Owen et al., 
2005, Debnath et al., 2012). Many genes that influence such processes have 
shown association with schizophrenia.  
 One such gene is DISC1 or disrupted in schizophrenia 1. A balanced 
translocation (chromosome 1:11, q42.1:q14.3) was discovered in a large 
Scottish family, co-segregating with schizophrenia and mood disorders (St Clair 
et al., 1990, Millar et al., 2000). DISC1 is discussed further in 1.5.2.4 and 1.6.  
 DISC1 has been shown to affect neural development particularly through 
its role in neurite and dendrite outgrowth (reviewed in Bellon, 2007) and 
variants in the gene have been associated with deficits in memory and 
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decreased prefrontal and hippocampal grey matter volume (Cannon et al., 
2005). DISC1 is very likely to be a true susceptibility gene for schizophrenia 
although the extent of its influence on schizophrenia risk is as yet unknown 
(Walters et al., 2011). Although the studies described are interesting in the 
context of a neurodevelopmental hypothesis of schizophrenia, the lack of 
knowledge on the extent of its action should be borne in mind. 
 Neuregulin 1 was identified as a putative susceptibility gene for 
schizophrenia in a follow-up association study of putative linkage at 8p22-p11 
(Stefansson et al., 2002) that has since been twice replicated (Stefansson et 
al., 2003, Williams et al., 2003). The gene has been shown to have a wide 
range of roles in development. It has been shown to influence neuronal 
migration, synaptic development and function, oligodendrocyte function and 
myelination (Harrison & Law, 2006). Other findings have improved the standing 
of NRG1 as a risk gene. Variants have been shown to be associated with 
altered frontal and temporal cortex activation and white matter structure (Hall et 
al., 2006, McIntosh et al., 2008 respectively). These results should however be 
treated with caution as there have been many negative reports showing no 
association with schizophrenia or association of different variants in the gene 
with schizophrenia (reviewed in Munafo et al., 2008) 
Dysbindin is another putative susceptibility gene that follows a similar 
pattern of findings to NR1. Following discovery through linkage (Straub et al., 
2002), the gene has been shown to play a role in vesicular transport of 
neurotransmitters (Li et al., 2003) and it may also be involved with  dopamine 
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D2  receptor internalisation (Iizuka et al., 2007). There are however, many 
negative findings (e.g. Williams et al., 2005, Mutsuddi et al., 2006). 
There are many other candidate genes for schizophrenia susceptibility 
that play a role in neural development including BDNF (Gall et al., 1992), reelin 
(Shifman et al., 2008), and NR1 (Eastwood et al., 1994), all well-researched 
schizophrenia candidate genes. This plethora of genes implicated in the 
disorder that are involved with neurodevelopmental processes provides strong 
support for the neurodevelopmental hypothesis of schizophrenia. 
CNV analysis has also strengthened the case for the neurodevelopment 
hypothesis of schizophrenia. Many CNVs in schizophrenia also confer risk to 
other neurodevelopmental disorders such as autism, epilepsy leanring 
difficulities. (reviewed in Walters et al., 2011. Refer  to 1.5.2.4 for further 
discussion on CNVs in schizophrenia). 
 
1.5         Genetics of schizophrenia 
 
1.5.1 Genetic epidemiology  
A heritable component to schizophrenia has been suspected for a long time. 
The first systematic family study implicating genetics was Rudin (1916). 
Schizophrenia, then known as dementia praecox was found to be more 
common in siblings of probands than in general population. Kallman, 1938, 
extended these findings to the offspring of probands. It was not until some 
years later that quantification of risk for the disorder was estimated. Kendler et 
al.(1985) suggested that the general population have a lifetime risk of 
developing schizophrenia of 0.2%, (although current estimates of the risk are 
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close to 1%, see 1.1) whereas in first degree relatives, this risk is elevated to 
3.7% and further increased to a risk of 8.6% if non-affective psychosis and 
schizoaffective disorder were also included. There was however substantial 
variation in reports of risk to first degree relatives ranging from 3.1% to 16.9% 
(Gershon et al., 1988).  
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Figure 1.1: Risk of developing schizophrenia by relation to a proband (taken from Gottesman, 
1991) 
           Sullivan et al. (2003) in their meta-analysis more recently demonstrated 
support for the idea that there are both genetic and environmental influences on 
developing schizophrenia, concluding that susceptibility to schizophrenia lies 
81% in heritability and 11% in shared environmental influences. Thus the 
majority of variance in susceptibility to schizophrenia lies in genetic effects. 
Twin and adoption studies are especially useful in studying heritability and 
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allow the disentanglement and dissociation of genetic and environmental 
influences by looking at shared phenotypes amongst twins reared apart, 
offspring adopted from parents with schizophrenia or adopted into a family with 
schizophrenia and so forth. There is a vast body of literature which has 
investigated schizophrenia in families. Sullivan (2005) reviews this evidence 
succinctly, concluding that the smaller but important environmental influences 
are likely prenatal in origin (due to the higher rates of schizophrenia in fraternal 
twins compared with non-twin siblings and that schizophrenia is generally 
assumed to be neurodevelopmental). Sullivan also importantly highlights the 
need not to over-interpret family data, it merely rationalises genetic studies into 
schizophrenia and still leaves us in the dark with regards to the mechanism by 
which schizophrenia develops, or the genes that may influence risk for 
schizophrenia.  
           More detailed analysis of the genetic epidemiology of the disorder 
consistently concluded that monozygotic (MZ) twins were approximately three 
times more likely than other first degree relatives to develop the disorder. 
(Tienari, 1971; Kringlen, 1976; Fischer, 1971; Pollin et al. 1969; Gottesman & 
Shields, 1972). The findings were however criticised for their variability which 
was, in a large part, put down to the failure to employ strict operational 
diagnostic criteria to diagnose schizophrenia. Researchers called for a more 
rigorous approach to data collection, allowing other researchers to apply 
different operational criteria to the same dataset and to allow for meta-analysis 
(McGuffin & Owen, 1991). 
          One example of how important definition of the phenotype under study is 
comes from a Norwegian study looking at concordance in MZ and dizygotic 
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(DZ) twins. Expanding the phenotype (using DSM-III criteria) to include other 
psychotic disorders (schizoaffective disorder, atypical psychosis and 
schizotypy) resulted in a large difference between MZ and DZ concordance 
rates (concordance rates in MZ twins were higher) whereas when the 
phenotype included affective and personality disorders and excluded psychotic 
disorders, this difference decreased as concordance rates in DZ twins 
increased to narrow the gap (Onstad et al., 1991). 
 In a frequently cited study, Cardno & Gottesman (2000) pooled their 
data with four other twin studies (Kläning et al., 1996, Cannon et al., 1998, 
Franzek & Beckmann, 1998, Tsujita et al., 1992). Concordance rates for MZ 
twins reached 50%, and 4.1% for DZ twins using the (then current) DSM-III-R  
criteria for schizophrenia. Using ICD-10 criteria altered concordance rates to 
42.4% and 3.9% for MZ and DZ twins respectively. The authors also provided 
heritability estimates of 88% for DSM-III-R schizophrenia and 83% for ICD-10 
schizophrenia. It is important to note that these heritability estimates do not 
suggest that this proportion of schizophrenia is genetic in origin in any 
individual; rather that the difference between one person developing 
schizophrenia and the next, is approximately 80 – 90% due to genetic variation 
between individuals. In reality however, genetics and environment cannot be 
separated in this manner and the schizophrenia phenotype is likely to be 
caused by a complex cascade of interactions between the two. 
           The evidence for a genetic basis of schizophrenia is nonetheless 
compelling. Further evidence from Cardno & Gottesman (2000) suggests even 
unaffected MZ twins of a proband can confer increased risk for schizophrenia to 
offspring, risk that is as great as would be expected should the proband be the 
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parent. The same direction of effect was not however seen in DZ twins though. 
This study is very interesting as it strongly supports genetic susceptibility to 
schizophrenia, yet it also reminds us of the importance of the environment in 
the development of the disorder as having genetic variants that could result in 
schizophrenia, does not mean the onset of the disorder is inevitable. This is an 
important consideration to bear in mind. 
 
1.5.2 Schizophrenia gene discovery 
 
1.5.2.1 Methodological overview 
Linkage analysis has traditionally been the starting point for identifying specific 
genetic loci involved in a disease. The premise behind linkage analysis is that a 
genetic marker, or several genetic markers, and the resultant disease 
phenotype co-segregate within either many independent families, or in an 
extended pedigree through the principle of genetic linkage. In linkage, genetic 
material is inherited in a non-random fashion, occurring when homologous 
chromosomes are paired in gametogenesis. Pairing occurs in such a way that 
the chromosomes of the gamete consist of alternating segments of 
chromosome from the mother and father. Segments of chromosomes, rather 
than individual genes tend to be inherited together. Linkage analysis exploits 
this phenomenon by examining genotypes at genetic markers (generally 
microsatellites) at evenly placed locations throughout the genome, looking for 
the co-segregation of the phenotype with specific genotypes (Sham and 
McGuffin, 2002, Strachan and Read, 2003). If the phenotype does indeed co-
segregate with specific genotypes, then the linkage analysis may be refined to 
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that region for further investigation (positional cloning). Linkage has been 
especially promising in identifying rare variants in genes of large effect in 
single-gene disorders (Owen et al., 2004). Although this situation is unlikely the 
case in the majority of genetic risk for schizophrenia, the hope in using linkage 
is that it will detect rare alleles of large effect (Owen et al., 2004). 
 Association is another method of gene discovery and works on the 
basic premise of comparing genotypes of markers between one set of people 
and the next (usually those with a disease or disorder, compared with those 
without). Association of a particular genotype with a particular state is then 
tested for statistical significance. Association has largely been used on 
positional and functional candidate genes to date and has the advantage of 
being able to pick up common alleles of weak to moderate effect. However, one 
disadvantage of association is the potential for false negatives. Many 
associations are often discovered, then fail to replicate. However, Owen et al. 
(2004) warn against considering a negative report a definite exclusion of a 
marker or candidate.  
 A third approach researchers have used to locate susceptibility genes 
for schizophrenia is through looking for cytogenetic abnormalities, such as 
translocations, insertions, deletions and inversions, which may cause direct 
disruption of a gene, formation of a new gene, indirect disruption of genes via a 
position effect or altered gene dosage and are identified through linkage. The 
field of chromosomal abnormalities has made some positive contributions to 
schizophrenia genetics but it is prudent to remember that it is possible for a 
chromosomal abnormality to be merely linked to an anomaly in a family and this 
doesn’t necessary indicate that the chromosomal abnormality is pathogenic for 
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schizophrenia (Owen et al., 2004). Similar caution must be taken with 
searching for genomic copy number changes, although when the abnormalities 
are observed in more than one pedigree, the evidence is persuasive (Owen et 
al., 2004). 
 
1.5.2.2 Linkage analysis in schizophrenia 
Psychiatric genetics began with linkage studies looking for highly penetrant 
alleles, that is, alleles responsible for a high proportion of disease cases. Many 
putative candidate genes have been discovered but replication has proved to 
be very difficult and no strongly replicated findings emerged from the early 
linkage studies (Owen et al., 2009). One major problem has been the power of 
the studies, or their intrinsic ability to detect significant linkage. Positional 
cloning studies, increasingly refining the putative disease region to increasingly 
small chromosomal segments have however, had more success and identified 
some promising putative susceptibility genes including DTNBP1, DAOA, and 
DISC1 (Straub et al., 2001, Hattori et al., 2003, St Clair et al., 1990 
respectively). Data to support the involvement of these genes in schizophrenia 
has come from cognitive (e.g. Burdick et al., 2006, Opgen-Rhein et al., 2008, 
Burdick et al., 2005 respectively), neuroimaging (e.g Narr et al., 2009, Jansen 
et al., 2010, Prata et al., 2008 respectively) and animal model studies (e.g. 
Feng et al., 2008, Otte et al., 2009, Ma et al., 2002 respectively), although no 
specific risk alleles in these genes have been identified and unambiguously 
replicated. 
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1.5.2.3 A priori candidate gene approaches 
The most investigated a priori candidate genes originate from the neuro-
pharmacological literature and are genes involved in dopaminergic and 
serotonergic neurotransmission. The majority of findings have failed to replicate 
consistently and confidence in the finding is therefore reduced, with two 
exceptions. Inayama et al (1996) provided the first genetic evidence for the 
involvement of the serotonergic system in schizophrenia in the gene encoding 
the 5HT2a receptor. These findings were replicated by Williams et al.,(1996) 
and again by Williams et al.,(1997) in their meta-analysis. However, no variants 
have yet been detected in the genes that alter receptor function or expression.  
 A second stand-out finding relates to DRD2, a D2 receptor gene and a 
polymorphism in the promoter which affects in vivo expression. Three groups 
have implicated this polymorphism (Arinami et al., 1997; Ohara et al., 1998; 
Jonsson et al., 1999). However, some studies (e.g. Li et al., 1998) have found 
no evidence for association here with some suggesting that the polymorphism 
is merely a marker for the true susceptibility variant and that the association is 
due to linkage disequilibrium.  
 However, perhaps the best-studied candidate (and arguably best a priori 
candidate, Williams et al., 2007) gene is COMT (catechol-O-methyl transferase) 
which codes for an enzyme that catabolises dopamine (Walters et al., 2011). 
The gene is an attractive candidate due to its direct involvement in the 
regulation of dopamine levels and its position on chromosome 22q11 (see 
1.5.2.4 below). The gene has been demonstrated to show linkage with 
schizophrenia several times (reviewed in Wiliiams et al., 2007). The gene 
contains a polymorphism resulting in a valine-to-methionine substitution (which 
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alters the action of the enzyme, Lachman et al., 1996) which has shown both 
positive and negative associations with schizophrenia (Williams et al., 2007) 
although evidence is currently weakening for an association of this 
polymorphism with schizophrenia (Walters et al., 2011). However, the 
interaction of COMT with other candidate genes and environmental influences, 
such as smoking and antipsychotics as well as its role in cognitive function 
(Egan et al., 2001) make the gene an interesting candidate nonetheless (see 
Ŝagud et al., 2010 for a review). There have also been many mouse models 
looking at the effects of altered COMT with some interesting findings (see 1.6 
for discussion of these). 
 
1.5.2.4  Chromosomal abnormalities 
 
Copy Number Variation 
Copy number variations (CNV) (operationally speaking) refer to deletions, 
duplications, insertions and inversions that are  >1kb in size (Alkan et al., 2011, 
Zhang et al., 2011), although structural variations can be much smaller and 
exist on a continuum (Malhotra & Sebat, 2012). CNVs represent another type 
(alongside SNPs) of genetic variation between individuals. Sebat et al., (2004) 
demonstrated that small (<500kb) CNVs are widespread in healthy human 
genomes, with an average of >1000 CNVs accounting for ~4 million base pairs 
of difference between two ‘average’ individuals (Conrad et al., 2010, Mills et al., 
2011). Although CNVs are less frequent in humans than SNPs on the whole, 
the relative contribution to genomic variation (measured in nucleotides) is 
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similar between SNPs and CNVs due to the larger size of a CNV (Malhotra & 
Sebat, 2012). 
Studies have established a role for rare (<1% frequency), large (>100kb) 
CNVs in schizophrenia risk in the last decade or so (Sebat et al., 2009) with the 
variations being estimated as 1.1 to 3 times more common in people with 
schizophrenia compared with controls (ISC, 2008, Walsh et al., 2008 
respectively).  
One well-researched large 3Mb deletion has long been known about 
(since Karayiorgou et al., 1995) at chromosome 22q11.21 as a significant risk 
factor for schizophrenia. Small interstitial deletions at this locus are associated 
with velocardiofacial syndrome (VCFS) and approximately 25% of deletion 
carriers demonstrate psychosis symptoms qualifying for a diagnosis of 
schizophrenia (Shprintzen et al., 1992; Pulver et al., 1994; Papolos et al., 1996; 
Murphy et al., 1999). Some studies have suggested a general schizophrenia 
susceptibility locus on 22q, although most suggest that this maps outside the 
‘VCFS region’ (Owen, O’Donovan & Gottesman (2004). 
There have been several other major regions of the genome CNVs have 
been found to co-segregate with schizophrenia. Interestingly, CNVs in all of 
these regions have also been associated with autism (albeit in some cases a 
duplication in associated with schizophrenia and deletions associated with 
autism, Walters et al., 2011). The table below (Table 1.1) summarises findings 
relating to these four regions. The rate of CNVs in the region in cases of 
schizophrenia and controls varies from 0.19 to 0.7% in cases compared with 
0.02% to 0.24% in controls. Perhaps the most interesting thing to emerge from 
these results however, is the prevalence of neurodevelopmental disorders such 
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as autism, epilepsy and learning difficulties that are also associated with CNVs 
in this region (and the lack of mood disorders showing association, Grozeva et 
al., 2010). 
Earlier studies (Walsh et al., 2008) demonstrated that CNVs in 
schizophrenia tended to impact upon genes involved in neuronal function,  
particularly synaptic activity and neurodevelopment (Malhotra et al., 2011, 
Walsh et al., 2008). Kirov et al., 2012 extended this finding by demonstrating 
that de novo CNVs in schizophrenia were particularly enriched for components 
of the N-methyl-d-aspartate receptor (NMDAR) and post-synaptic signaling 
complexes.  Interestingly for nosology, the prominence of CNVs seems to be 
one point of difference between schizophrenia and bipolar disorder with CNVs 
being more frequently discovered in schizophrenia cases compared with bipolar 
cases (Grozeva et al., 2010).   
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Studies Chromosomal 
region 
Rate in SZ 
(average % 
across 
studies) 
Rate in ctrl 
(average % 
across 
studies) 
CNV type Additional phenotypes associated with 
this region 
Stefansson et al., 2008 
Walsh et al., 2008 
ISC, 2008 
1q21.1 0.2 0.02 Deletion Cardiac defects, neuroblastoma, 
microcephaly, autism, ADHD (Mefford et 
al., 2009). 
Kirov et al., 2008 
Walsh et al., 2008 
Rujescu et al., 2009 
2p16.3 0.19 0.04 Deletion Autism (Weiss et al., 2008, Kim et al., 
2008) 
Stefansson et al., 2008 
Kirov et al., 2009 
15q11.2 0.6 0.22 Deletion Speech problems, ADHD, obsessive 
compulsive disorder, autism, learning 
difficulties (Mefford et al., 2009, Doombos 
et al., 2009) 
Stefansson et al., 2008 
ISC, 2008 
Kirov et al., 2009 
15q13.3 0.2 0.02 Deletion Epilepsy, learning difficulties, ADHD, 
autism (Miller et al., 2009, Dibbens et al., 
2009, Sharp et al., 2008) 
Ingason et al., 2009 
ISC, 2008 
Kirov et al., 2009 
Ikeda et al., 2009 
16p13.1 0.3-0.7 0.09-0.24 Duplications associated 
with schizophrenia, 
deletions with more 
severe cognitive 
phenotypes such as 
learning difficulties, 
epilepsy and autism 
Autism, learning difficulties (Ullmann et 
al., 2007, Mefford et al., 2009) 
McCarthy et al., 2009 16p11.2 0.3 0.03 Duplications associated 
with schizophrenia, 
deletions with more 
severe cognitive 
phenotypes such as 
learning difficulties and 
autism 
Autism, learning difficulties (Weiss et al., 
2008, Abrahams & Geschwind, 2008, 
Glessner et al., 2009, Mefford et al., 2009) 
Table 1.1: Summary of findings of major CNV regions for schizophrenia showing the rate of discovery in schizophrenia cases and controls, type of CNV 
found and additional phenotypes associated with the region.  
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1.5.2.5 Association studies 
Association studies have traditionally followed linkage analysis in the search for 
putative disease genes. Essentially, association studies look for significantly 
different marker allele frequencies between people affected by the disease, and 
healthy controls. The association of the marker, if significant can be explained 
by one of two mechanisms (provided cases and controls are well-matched for 
factors such as ethnicity): either that marker is directly associated with the 
disease and has functional relevance, or the marker is indirectly associated 
with the disease through linkage disequilibrium. Indirect association means the 
marker and the disease-causing locus/loci are sufficiently close so that they are 
inherited together, an association that has not yet been eroded in the 
population by recombination.  Genetic association studies are better placed 
than linkage analysis to detect small effect sizes due to the smaller critical 
region detected by association studies. Recently, high-throughput genotyping 
technology, whereby upwards of a million SNPs and CNVs can now be 
genotyped on a single array, has drastically improved and genome-wide 
association studies (GWASs) are now a possibility for disease gene discovery 
with the advantage that they are not hypothesis driven, an important 
consideration for a disorder such as schizophrenia where the pathogenesis is 
highly complex and largely unknown. The HapMap, a public database 
describing genome-wide known SNPs has greatly aided marker choice and 
distribution. 
 The few genome-wide association studies of schizophrenia published 
to date have not been without problems. Lencz et al. (2007), for example 
reported significant association in an intergenic region between CSG3RA and 
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SHOX. CSG3RA (or colony stimulating factor 2 receptor alpha) is a subunit of a 
cytokine receptor which regulates granulocytes and macrophages, types of 
white blood cell. SHOX is thought to be transcription factor which has some 
influence upon height. The authors sequenced CSG3RA and the flanking 
IL3RA in a smaller sample and found several significant associations with 
schizophrenia. The effect sizes of these associations are however are much 
larger than would be expected for a locus implicated in a complex disease. 
Sullivan et al. (2008), in their GWAS of 738 cases with DSM-IV schizophrenia 
and 733 controls, genotyped approximately 500 000 SNPs.  The authors failed 
to discover any putative disease loci showing association surpassing the 
genome-wide threshold of significance of p= 5 x 10-8. A potential problem here 
may have been the ethnic heterogeneity of the samples which may have added 
‘noise’ to the study and potentially produced false negative (in terms of not 
reaching genome-wide significance) results. 
 GWAS for schizophrenia are notoriously difficult to conduct due to the 
poor characterisation of the phenotype. As previously mentioned, there are no 
biomarkers for the disorder that may be used as discrete inclusion/exclusion 
criteria for a ‘case’ in a genome-wide association study. There is also growing 
evidence that schizophrenia is not a unitary disorder and exists on a continuum 
with affective disorders, autism and mental retardation (Carroll and Owen, 
2009). Diagnoses may therefore be overlapping which may cause ambiguity in 
findings. One way to control for these potential confounds is through replication. 
Successful replication of association at loci is taken as indicative of true 
schizophrenia susceptibility loci.  
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1.5.2.6 Discovery of the schizophrenia risk gene ZNF804A 
In a large-scale GWAS for schizophrenia, O’Donovan and colleagues 
genotyped 479 schizophrenia cases and 2 937 controls using a mapping array 
of 500 000 SNPs (of which 362 532 passed quality control measures). SNPs 
showing ‘moderately strong’ association (p<1 x 10-5) were selected for follow-up 
investigation and put through two replications with larger sample sizes (see 
results presented in figure 1.2). The table below shows results from the study. 
The SNP rs1344706 in the gene coding for ZNF804A was the only locus to 
achieve strong (p=1.51 x 10-7) support in the meta-analysis and surpassed the 
genome-wide significance 
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Figure 1.2: Table of most significant results (‘moderately strong association’) and follow-up from 
O’Donovan et al. (2008) 
 
threshold when bipolar cases were added to the disease sample             
(p=9.96 x 10-9) suggesting the gene variant may confer risk to bipolar disorder 
as well as schizophrenia.  
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 In addition to replication embedded in the original study, the 
association of ZNF804A variants with psychopathology has since received 
support from three independent studies. The first replicated the association of 
rs1344706 with schizophrenia, reporting a p-value of 0.0113 (Riley et al. 2010). 
Steinberg et al. (2010) also replicated the association with schizophrenia (p = 
0.0029) and with schizophrenia and bipolar disorder (p=0.00065). Genotyping a 
Han Chinese sample for association of the SNP rs1344706 with schizophrenia, 
Zhang et al. (2010) added to the evidence, reporting a p-value of 0.00083. Thus 
ZNF804A appears to be a true susceptibility locus for schizophrenia 
(O’Donovan et al., 2009).  
 
1.5.2.7 ZNF804A 
ZNF804A or Zinc finger protein 804a is a 4-exon gene found on chromosome 
2q32 of unknown function that is largely uncharacterised and is, at the time of 
writing, definitely within the ‘annotation gap’. The SNP rs1344706 is located in 
intron 2 of the gene, within a short region that is conserved between 
mammalian species. High levels of conservation indicate that the sequence has 
important function and is most commonly found in exonic sequences, rather 
than intronic sequences. 
 Although rs1344706 is described as a risk SNP for schizophrenia in 
ZNF804A, it is unknown whether this SNP is directly associated with 
schizophrenia and is therefore the functional allele conferring risk, or if the 
association is indirect and rs1344706 is a tagging SNP for the true causative 
locus.  To investigate this issue, Williams et al. (2011) re-sequenced this region 
and conducted fine-scale LD mapping. Almost all the known SNPs in this gene 
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were covered (96% with a minor allele frequency > 0.01) yet rs1344706 
remained the most strongly associated marker in the gene. Meta-analysis (21 
274 cases of schizophrenia and bipolar disorder and 38 675 controls) provided 
further support for the association of this SNP with both schizophrenia (p=2.5 x 
10-11) and schizophrenia and bipolar disorder combined (p=4.1 x 10-13), far 
surpassing the accepted threshold for genome-wide significance.  
 
1.5.2.8 ZNF804A gene function 
This strong statistical support doesn’t, however, provide us with any clues to 
the function of the protein product ZNF804A or, indeed, how it may confer risk 
to schizophrenia. As previously indicated, the structure of the ZNF804A protein 
is largely unknown with the only characterised region being a C2H2 domain 
occurring early on in the protein. Such domains are characteristic of the zinc 
finger protein family and suggest that the protein may have some DNA-binding 
function and therefore, a role in transcription of other genes; indeed, further 
bioinformatic analysis of the sequence flanking rs1344706 indicates there may 
be transcription-factor binding sites in this region (Donohoe et al. 2010). It is not 
unusual, however, for C2H2 domains to also have a role in RNA- and protein-
binding (Donohoe et al. 2010).  
There is evidence that rs1344706 may also influence expression of 
ZNF804A itself. Riley et al. (2010) showed in post-mortem brain tissue analysis 
using qPCR that the A-allele at rs1344706, the risk allele, shows higher levels 
of expression in dorsolateral pre-frontal cortex (DLPFC) in  controls (and also in 
patients with schizophrenia, although this increase is non-significant). 
Bioinformatic analysis predicted that the risk A-allele maintains binding sites for 
 35 
the brain-expressed transcription factors MYT1l and POU3G2/OCT-6. These 
transcription factors are known to be involved in oligodendrocyte differentiation 
and proliferation. Further clues connecting rs1344706 to expression of 
ZNF804A emerge from work by Williams et al. (2011) based on the GeneVar 
database, which again showed that the risk allele was significantly associated 
with higher levels of expression of ZNF804A mRNA; confirming this association 
with higher expression levels in post-mortem samples using a proxy SNP, 
inferring that this translated as a increase in ZNF804A expression 1.13-fold. 
A link between the mouse orthologue of the gene, Zfp804a and Hoxc8, a 
gene implicated in neurodevelopment has also been found (Chung et al., 
2010). Binding of Hoxc8 to an intronic region in the third intron of Zfp804a was 
reported. Hoxc8 upregulated Zfp804a mRNA levels. In the study, Zfp804a and 
Hoxc8 were coexpressed in E11.5 mouse embryos. Despite these hints at 
mechanism there is still a huge amount of work to be done to understand the 
basic brain function of ZNF804A; a crucial pre-requisite if we are to ever 
understand its involvement in schizophrenia pathogenesis.  
 
1.5.2.9 Neurocognitive function of ZNF804A 
In addition to work done at the molecular and cellular levels, there are a 
number of studies that have examined the neurocognitive phenotype 
associated with the risk allele at rs1344706. A study in Science by Esslinger 
and colleagues (2009) genotyped a cohort of 115 healthy participants for 
rs1344796 genotype. The authors examined performance on the n-back 
working memory task and a face-matching task to probe the link with the 
affective/bipolar disorder. Correlational regional brain activity in the DLPFC and 
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hippocampal formation (HF) using fMRI was also examined. In the study, 
regional brain activity was not significantly altered in relation to genotype 
although indices of connectivity were. The authors found connectivity within the 
DLPFC and to the contralateral DLPFC was reduced in risk allele carriers. 
Furthermore, the HF and DLPFC showed normal connectivity in people 
homozygous for the non-risk allele but there was a risk-allele dose-dependent 
decrease in DLPFC connectivity in heterozygous and homozygous risk allele 
carriers. Conversely a dose-dependent increase in HF-DLPFC coupling 
associated with the risk allele. Interestingly, the genotype at rs1344706 had no 
impact upon performance in the tasks.  
The same research group, following similar methodology, also looked at 
‘theory of mind’ measures in relation to rs1344706 genotype, finding a risk 
allele dose effect on levels of activity in parts of the mirror neuron system 
implicated in the theory of mind network (left inferior parietal cortex and left 
inferior frontal cortex) and also in the medial prefrontal cortex and left tempero-
parietal cortex. The authors additionally found evidence for aberrant functional 
connectivity between the frontal and temporo-parietal regions in risk allele 
carriers (Walter et al., 2010). ZNF804A therefore seems to have an impact on 
neural networks associated with aspects of cognition, and at least one aspect 
of social cognition. 
 Further work on the risk allele was conducted by Walters et al. (2010) in 
a large-scale study looking at the influence of rs1344706 genotype on a 
number of cognitive functions in both patients and controls. Interestingly, the 
authors found the risk allele to have a protective effect on cognition in patients 
but not in controls. An association between rs1344706 and IQ, episodic 
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memory, working memory, and attention was tested for in an Irish discovery 
sample. Significant results were then looked at in a German replication sample. 
In the Irish samples, genotype was associated with better performance on tests 
for episodic and working memory in patients but not in controls. These findings 
were replicated in the same direction in the German samples, leading the 
authors to hypothesise that perhaps the risk variant at the ZNF804A locus 
contributes to risk for a particular sub-type of schizophrenia that doesn’t 
encompass cognitive deficits.  
 
1.6 Animal models for schizophrenia 
One means of understanding gene function is by using an animal model. 
Genetic animal models most commonly exploit the mouse as an organism for 
several reasons. As with all mammals, there are high levels of genetic similarity 
between the mouse and the human genomes and extensive synteny 
(conserved gene order). Mutations that cause certain diseases in humans can 
cause similar diseases in mice (Beckers, Wurst & de Angelis, 2009). Mice have 
emerged as the model organism of choice in preference to other mammalian 
species due to their diminutive size (making them easier and cheaper to 
manage), the short breeding cycle and gestation period (a new generation can 
be produced every two to three months) and their amenability to genetic 
manipulations such as transgenesis and mutagenesis. There is also a large 
existing catalogue of mutant mice (e.g. The Jackson Laboratory, 
http://jaxmice.jax.org/query/f?p=205:1:12049464109724088944, MRC 
Mammalian Genetics Unit, Harwell, http://www.har.mrc.ac.uk/services) and a 
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compendium of well-validated phenotyping tests for ease of comparison of 
findings between studies.  
 Genetic animal models for psychiatric disorders are useful tools, 
especially since the advent of the GWAS. They allow us to examine functions 
of uncharacterised putative genes for the disorders including exploring the 
putative associated neurobiology and observing the effects of knocking 
out/altering the gene on the behavioural phenotype, gene expression of other 
genes and the effects of drug therapy (such as antipsychotics) on any deficits 
or abnormalities observed.  
 
1.6.1 Non-genetic animal models for schizophrenia 
Many different types of animal models for schizophrenia have emerged over 
the years. There are developmental models generally using environmental 
insults such as isolation rearing (e.g. Wilkinson, et al., 1994), influenza 
challenges (e.g. Fatemi et al.,1999; Shi, 2003; Fatemi et al., 2005;  Fatemi et 
al., 2008; Winter et al., 2008) and other various types of prenatal and neonatal 
immune challenge (e.g. Romero et al., 2007; 2008; Pletnikov et al., 2000). 
There are also pharmacological challenge models, most commonly, and 
successfully using NMDA receptor antagonists such as phencyclidine (PCP) 
and ketamine, which are known, in humans to cause a psychosis reminiscent of 
that observed in schizophrenia (e.g. Jentsch & Roth, 1999; Manahan-Vaughn 
et al., 2008; Zavitsanou et al., 2008; Karasawa et al., 2008). Animal lesion 
models of schizophrenia have also been popular and yielded some interesting 
findings, particularly in the regions strongly implicated in schizophrenia such as 
hippocampal lesions (e.g. Lipska & Weinberger, 2000; Lipska, 2004; Tseng et 
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al., 2006; 2007; 2008; Endo et al., 2007; Marquis et al., 2008a,b) frontal cortex 
lesions (e.g. Lazar et al., 2008) and prefrontal cortex lesions (e.g. Wilkinson et 
al., 1997; Lipska et al., 1998). 
 
1.6.2 Genetic animal models for schizophrenia 
Genetic animal models of schizophrenia are currently a big growth area in 
psychiatric research, in a large part due to the advent of the GWAS and the 
identification of numerous new putative candidate genes for disorders such as 
schizophrenia. Many genes identified in such association studies are largely 
uncharacterised, biologically and patho-physiologically and genetic animal 
models are invaluable in ascertaining their function, and equally importantly, 
how this might inform us about the disease mechanism.  
 
1.6.2.1 Creating and characterising genetic models 
Methods of creating genetic animal models include deleting (knockout) or 
inserting (knockin or transgenesis) individual genes. Some inbred strains have 
naturally occurring mutations or deletions in some genes that may be of 
interest. For example Clapcote and Roder (2006) discovered that the deletion 
found by Koike et al. (2006) in 129S6/SvEv mice from Taconic Farms is 
common to all 129 substrains. The mutation is homozygous and 25-bp in exon 
6 are deleted, inducing a frame shift in the reading frame of Disc1, resulting in 
the production of 13 novel amino acids, followed by a premature stop codon. 
Neither full-length Disc1 nor the predicted C-terminally truncated protein were 
detectable in 129S6 brain tissue (Koike et al., 2006), suggesting that the 
deletion is a null allele. Other mutations found include a deletion of the α-
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synuclein locus in a C57Bl/6J substrain in mice supplied by Harlan UK (Specht 
& Schoepfer, 2001).The creation of conditional mutants adds further to the 
inventory of methods available for creating genetic animal models by allowing 
the researcher to study the spatial and temporal effects of the gene affected. 
More subtle and varied mutations, as exploited in the current work, can also be 
achieved by using chemical mutagenesis (such as N-ethyl-N-nitrosourea, ENU) 
causing random point mutations in the genome which can be identified by 
phenotype- or genotype-driven screens of mice treated with mutagens. 
 Desbonnet, Waddington and O’Tuathaigh (2009) review mutant 
models for genes associated with schizophrenia. When conducting a 
phenotype screen of a mutant model for a gene of unknown function, it is 
important to adopt a hierarchical approach and screen at the levels of anatomy, 
physiology and behaviour. Endophenotypes are also very important (refer to 
Esslinger et al., 2009, discussed in 5.2.3 Neurocognitive phenotypes 
associated with ZNF804A) as the absence of a phenotype does not indicate the 
absence of an endophenotype. Desbonnet and colleagues additionally warn 
that when using an animal model for schizophrenia, the merits of ethologically-
based approaches must be considered compared with using more structured 
tasks that are perhaps better disease-validated in humans. Both approaches 
have their merits and the compendium of tests selected to characterise a 
mutant mouse model should reflect a consideration of what is known about the 
function of the gene on all levels to date. 
 Genetic animal models for schizophrenia can largely be divided into 
two categories: those implicated in putative disease-associated mechanisms 
(e.g. a focus on dopamine-related genes) and those implicated by clinical 
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association, discovered through methods such as linkage analysis and 
association methods. In terms of the former approach, it is important to note 
that the absence of strong genetic evidence does not necessarily exclude 
genes from an involvement in developing schizophrenia. A strong physiological 
story may produce features analogous to the disease in mouse models, 
providing an alternative means of investigating disease pathogenesis. Mohn et 
al. (1999) for example showed that mutant mice expressing only 5% of 
essential NR1 show hyperactivity that is ameliorated by haloperidol and 
clozapine in line with evidence that an NMDA receptor gene is altered in 
schizophrenia.    
 
1.6.2.2 Genetics mouse models for functional candidate genes 
Genetic animal models for putative disease-associated mechanisms have 
largely focused on the dopamine and glutamine hypotheses of schizophrenia 
and are interesting as they offer an alternative means of investigating genetic 
susceptibility to schizophrenia by offering a ‘bottom-up’ perspective and are a 
departure from traditional gene discovery methods. Kellendonk et al. (2006) for 
example, with their conditional knockout, implicated dopamine receptors (D2 
and D1) in cognitive symptoms associated with schizophrenia. In their model, 
striatal overexpression of D2 receptors resulted in a phenotype of impaired 
PFC-mediated working memory and marked perseverative behaviour. These 
effects interestingly persisted after the transgene was switched off which 
indicates that these observed effects were (at least in part) due to some 
secondary compensatory mechanism. The striatal overexpression of D2 
 42 
receptors also resulted in altered dopamine turnover and D1 receptor activation 
in PFC.  
 COMT (an enzyme that catabolises dopamine), has also been shown 
through mouse models to have an effect on cognitive behaviours that are 
associated with schizophrenia with a dissociation between homozygous and 
heterozygous knockouts/deletions respectively. Babovic et al. (2007) found that 
heterozygous deletion but not homozygous knockout resulted in disrupted 
exploration of and habituation to a novel environment. Babovic et al. (2008) and 
Papaleo et al. (2008) found that the knockout but not the heterozygous deletion 
resulted in improved spatial learning and working memory.  COMT is implicated 
in schizophrenia through both its pathophysiological influence (association with 
dopamine) and through association analysis (meta-analyses by Allen et al., 
2008). 
 The glutamate receptor (NMDA, N-methyl-D-aspartate) hypo-function 
hypothesis of schizophrenia is derived largely from observations of the effects 
of NMDA receptor antagonists (e.g. PCP and ketamine) and their effects on 
normal people and people with schizophrenia. Relevant animal models have 
generally supported the hypothesis. Mohn et al. (1999) for example created 
mutants with a 90% reduction in NMDA receptor 1 expression and 
demonstrated increased LMA and deficits in social and sexual behaviour. 
Hyperactivity (and to a lesser extent, the social deficits) were ameliorated by 
the antipsychotics haloperidol and clozapine. 
 
 
 
 43 
1.6.2.3 Genetics mouse models for candidate genes discovered through 
clinical samples 
The second main approach for genetic animal models, and the approach 
utilised in the present thesis, is based on manipulations of genes that have 
been implicated by traditional gene discovery approaches using clinical 
samples.  Animal models for the majority of putative schizophrenia 
susceptibility genes have been created and tested, some with more success 
than others. 
 
NRG1 
Neuregulin 1 (NRG1) has been frequently implicated in the development of 
schizophrenia, is expressed widely throughout the brain and influences key 
neurodevelopmental processes such as myelination and neuronal migration 
(Buonanno, 2010).  
 Mouse models for NRG1 are an interesting example and also serve to 
warn us of some of the difficulties inherent in characterising a mouse model for 
a complex disorder such as schizophrenia. The majority of NRG1 proteins are 
synthesised with a transmembrane (TM) domain. Mutant mice with a 
heterozygous mutation of the TM domain of NRG1 exhibited hyperactivity when 
examined in anxiety- and exploration-related tasks, facets which were reversed 
by clozapine. The mice also showed a PPI deficit, selective impairment in social 
novelty preference and altered patterns of social interaction (O’Tuathaigh et al., 
2007). Different types of NRG1 mutants show variance in the pattern of deficits 
observed. For example, type iii mutant mice (a mutant model of a different 
isoform) display more pronounced PPI deficits and WM impairment than the 
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mice described by O’Tuathaigh et al. (2007), suggesting the effects of specific 
mutation of NRG1 isoforms on behavioural phenotype may be masked by the 
compensatory activity of other genes or environment factors.  
 
DNTBP1 
Mutant mice for a schizophrenia candidate gene identified by positional cloning, 
DTNBP1, have also received substantial attention in the field. The Sandy (sdy) 
mouse (e.g. Murotani et al 2007, Bhardwaj et al 2008, Takao et al 2008, Feng 
et al 2008, Hattori et al 2008, Chen et al 2008) have a deletion mutation that 
arose spontaneously in the DBA/2J strain in the gene encoding dysbindin-1 
(Dtnbp1). This mutation (Dtnbp1(sdy)) leads to an absence of dysbindin-1 
protein in homozygotes, as well as reductions in protein levels of several direct 
and indirect binding partners of dysbindin-1. Neurobiological effects were also 
observed in the model with decreases in dopamine levels in the cortex, 
hippocampus and hypothalamus and some increases in dopamine metabolism 
(reviewed in Talbot, 2009). Behaviourally, the mice have shown delayed activity 
in novel environments, and reduced activity in the open field, suggestive of an 
increase in anxiety. Object recognition was also impaired as well social 
interaction and long-term and working memory.  
 
DISC1 
Various Disc1 mouse models have also been characterised. These are a good 
example of a mouse model for schizophrenia due to the heterogeneity of the 
models in terms of the genetic manipulation. The ‘natural’ model for the gene 
exploits the mutation occurring in the 129 strain previously discussed. The 
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model displays working memory deficits, decreased hippocampal short-term 
plasticity and altered organisation of neurons in dentate gyrus (Koike et al., 
2006, Kvajo et al., 2008). Clapcote et al. (2007) created two Disc1 ENU 
mutants (that both showed reduced binding to the known binding partner, 
Pde4b) and found that one showed depressive-like behaviour (indexed by the 
forced swim task) and the other showed PPI and latent inhibition (LI) deficits 
that were reversed by antipsychotic treatment. These mutations have not been 
biochemically characterised so it is difficult to draw conclusions from this study 
but the data nevertheless suggest that a reduction in Disc1 can produce some 
deficits akin (arguably) to psychiatric disorders.  
 Four groups have now produced DISC1 transgenic mice (expressing 
the human mutant form of the gene) Pletnikov et al. (2007), Li et al. (2007), 
Hikida et al. (2007) and Duan et al. (2007). Results between the groups are 
consistently supportive and all groups found that the mutation affects brain 
morphology (e.g. mutants have a mild enlargement of the lateral ventricles), as 
well as some cognitive deficits  such as enhanced LMA, disrupted PPI and 
impaired social interaction. Findings from mouse models for DISC1 are 
compatible with DISC1 playing a role in the pathogenesis of schizophrenia (and 
other major psychiatric illnesses).   
 
1.7 An ENU mouse model of Zfp804a gene function: strengths and 
cautions 
The main aim of this thesis was to create and begin to characterise ENU-based 
mouse mutants of Zfp804a, the mouse orthologue of ZNF804A. Details of the 
specific procedures used and experiments undertaken can be found in the 
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relevant methods and experimental chapters of the thesis. However, it is 
important, at the outset, to be aware of the advantages and, in particular, the 
limitations of modelling human disorders in another species, in this case the 
mouse. As noted earlier, genetic animal models for schizophrenia are 
potentially extremely useful in schizophrenia research as they allow us to 
create mutant gene isoforms and study these effects in vivo. There are 
however, difficulties with genetic animal models for the psychiatric disorders.  
           First, the major psychiatric disorders are acknowledged to be genetically 
complex disorders with numerous genes of different effect size interacting in a 
complex network with each other, and with the environment. In a genetic animal 
model, in the near future at least, we are only able to model specific genes and 
their effects, possibly with some informative environmental interactions rather 
than the actual disorder, in other words, any model is only ever going to be 
partial. This is before taking into account the fact that psychiatric disorders are 
essentially ‘human’ problems, involving distortions in perception, thought, 
language, emotion and behaviour. It is important to state therefore, that we 
cannot, with our current understanding, create an animal that has 
schizophrenia. Indeed, it may be better to say that, as was the case in the 
present work, most animal models involve determining the functions of a gene 
involved in some way in the pathogenesis of schizophrenia. 
           Limiting the ambition of any animal model will hopefully inhibit over-
interpretation of the clinical meaning of any experimentally-derived 
(endo)phenotypes. However, another problem with animal models for 
psychiatric disease is that processes and observable traits affected by 
disorders such as schizophrenia that we are able to observe in animals, such 
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as pre-pulse inhibition (PPI), are not specific to schizophrenia. People with 
bipolar disorder for example, also have PPI deficits (Thaker, 2008). 
Additionally, another problem with animal models for genes implicated in 
schizophrenia is that it is expected that (notwithstanding the above cautions) 
there will be at least some indications reminiscent of schizophrenia in the 
model. Given the genetic complexity of schizophrenia and the cascade nature 
of gene-gene interactions, gene-environment interactions and combinations of 
the two, a-priori it seems somewhat hopeful to expect that a mutant model of a 
single gene will have a significant deficit on a particular measure. Failing to find 
any deficits or abnormalities in a model does not necessarily provide evidence 
against the involvement of that particular gene in schizophrenia. It also does 
not mean that the gene being investigated has no impact upon the domains 
tested as there may be compensatory effects involved, for example, a paralog 
may take over function.  
 Despite the fundamental limitations noted above, it is possible to 
approach an understanding of the function(s) of a gene implicated in a complex 
disorder such as schizophrenia, and then make cautious connections with the 
disease condition itself. For example, by starting off with a gene that is 
definitively involved in schizophrenia – this was the logic in choosing to study 
ZNF804A/Zfp804a – and by using well-validated translatable assays, in 
particular at the psychological/behavioural levels of analysis. However, in 
addition to choosing informative genes and functional assays it is also 
necessary to be aware of a number of technical limitations and pitfalls inherent 
in using genetic animal models. These are considered in detail in the relevant 
sections of the thesis but one potential problem in the creation of mutant 
 48 
models is linkage. Through the principle of linkage, the effects of a closely 
linked gene may be attributed to the mutation when the mutation is crossed 
onto a different background strain (Crusio, 2004); although the chances of this 
happening are small, it remains a consideration.  
 Epistasis may also be a problem. The effects of other alleles at 
perhaps unlinked locations may change the effects of a mutation. An example 
of this is Le Roy et al. (2000). nNOS knockout mutants showed an aggressive 
phenotype on a mixed 129S4/SvJae – C57BL/6J background which vanished 
after five generations of backcrossing onto the C57BL/6J background. This led 
to the conclusion that the nNOS knockout may only cause aggression upon an 
interaction with some variant in the 129S4/SvJae genome that is not found in 
the C57BL/6J background.  The environment could also have a similar 
modifying effect to epistasis but it is rarely considered explicitly beyond 
controlling the environment so it is a homogenous as possible between 
experimental subjects. For example, Rampon et al. (2000) found that a null 
mutation in the gene for the NMDA receptor 1 subunit in area CA1 of the 
hippocampus caused learning deficits but no effect when the animals were 
raised in enriched environments. 
 
1.8 Specific aims 
The overall aim of the experimental work in the thesis was to create novel 
mouse mutants targeting Zfp804a, the mouse orthologue of human ZNF804A in 
order to be able to conduct basic functional studies examining the role of 
Zfp804a in brain and behaviour, and thereby gain information of potential 
relevance to how genetic variance in ZNF804A may contribute to risk for 
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schizophrenia. The main aim was to be achieved via the following practical 
objectives: 
 To identify ENU-induced mutations in Zfp804a, in the MRC Mammalian 
Genetics Unit’s archive of DNA from the offspring of ENU-mutagenised 
mice and select mutations of interest to be re-derived for investigation in 
vivo based upon the estimated impact on the structure and function of 
the Zfp804a protein. 
 To backcross the re-derived mutations onto a C57Bl/6J wild-type 
background to isolate the mutations of interest and reduce the possibility 
that any observed phenotypes are due to other residual mutations. 
 To assess the general viability of the mutant lines 
 To begin the specific functional assessment of the novel Zfp804a 
mutated lines, focusing on behavioural endophenotypes 
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CHAPTER 2: General Materials and Methods 
 
This chapter describes procedures performed throughout the course of work for 
this thesis including specific laboratory equipment and descriptions of any 
behavioural apparatus used. Further details are given in experimental chapters 
where appropriate. All procedures necessitating the use of live animals were 
performed in accordance with Animals (Scientific Procedures) Act (1986) and 
the Home Office Project Licence granted to Dr William Davies (PPL 30/2601). 
All animal work was performed under the Home Office Personal Licence 
granted to Tamara Al-Janabi (PIL 30/8107). 
 
2.1 DNA extraction and quantification  
A tail biopsy (following the protocol described in 2.7) was taken from 
experimental subjects for genotyping  
 
2.1.1 DNA extraction 
Tail samples (approximately 10mm) were lysed overnight in a solution of tail 
lysis buffer (0.2% SDS, 100mM Tris HCl pH8.8, 5mM EDTA pH8.0, 200mM 
NaCl) and 10μg/ml proteinase K in phosphate-buffered saline (10X, Sigma). 
For every 10ml tail lysis buffer, 50µl proteinase K was added, making enough 
solution to lyse 20 tail samples. This solution (500 µl/ 10mm tail) was added to 
tail samples and left in a waterbath overnight (14-18 hours) at 55C.  
The following day, samples were centrifuged for 10 mins at 13 000 RPM. 
Supernatant was removed and aliquoted into fresh tubes. The pellet of fur left 
at the bottom of the original tube was discarded.  500 µl per tail of isopropanol 
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were then added and samples were stored at 4-8C for 20 minutes. 
Precipitated DNA was then fished out of the solution using a pipette tip and put 
into 100 µl of TE buffer (10mM Tris-HCl pH 8.0, 1mM EDTA). If the DNA was 
not visible or was unable to be retrieved by this method, samples were 
centrifuged for 10 minutes at 4C at 13 000 RPM, the supernatant pipetted off 
(and discarded), and allowed to air dry until the DNA became ‘glassy’ in 
appearance and no obvious liquid could be seen. 100 µl of TE buffer was then 
added to dissolve the DNA. Genomic DNA was refrigerated (4-8C) until use. 
Once used for PCR genotyping, DNA was stored at -20C.  
 
2.1.2 DNA quantification 
DNA was quantified using a spectrophotometer (NanoDrop 2000, Thermo 
Scientific). The absorbance (A) of UV light at wavelengths () of 260nm and 
280nm was calculated. Assuming that an A (260nm) of 1 is equivalent to 50g 
of DNA, a ratio of A (260nm) to A (280nm) of above 1.8 indicated a suitable 
amount of clean DNA without contaminating RNA and protein. The 
spectrophotometer calculates a concentration (in ng/l) for the sample based 
on the UV absorbance. 
 
2.2 Mutation detection 
Mutation screening was performed on 5 856 samples of DNA obtained from 
MRC Harwell Mammalian Genetics Unit. DNA was received at a working 
dilution of 5ng/l and corresponded to the first 5 856 samples in the ENU 
mutagenesis DNA archive for genotype-driven screens. 
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2.2.1 Mutation detection PCR 
Standard PCRs were performed to screen for mutations in Zfp804a in 2 regions 
using 3 sets of primers. Primer sets 2 and 3 overlap to cover a larger region of 
exon 4 than is possible to reliably amplify in a single PCR. Oligonucleotide PCR 
primers used in this study were designed in silico using the online program 
Primer3 (http://frodo.wi.mit.edu/primer3/). PCR primers used in this thesis were 
synthesised by Metabion unless otherwise stated. The following primer pairs 
were used in this study (for PCR optimisation methods, see Chapter 3: 
Mutation detection in Zfp804a in ENU-mutagenised mouse DNA): 
Zfp804a C2H2 G2: tcatgttttcaaacttgttttgctg 
Zfp804a C2H2 R2: aaacttgattcatcatcacagaattac 
 
Zfp804a SZ 1A F: CAGCGATGAATCCTCTATGG 
Zfp804a SZ 1B R: TTGTGATGTTTTCCTCTGTGG 
 
Zfp804a SZ 2B F: CAAATATCATAGAAAAGAATCCCACTG 
Zfp804a SZ 2A R: CCTTCTGTTCAGAGAAAAGGTCA 
 
 
Figure 2.1 below shows the position of the amplimeres in Zfp804a in relation to 
the the gene and exons 2 and 4. Diagram b) also shows the position of the zinc 
finger binding domain in relation to exon 2. 
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(a)  
 
 
 
 
 
 
 
 
 
 
 
b) 
 
Figure 2.1: A schematic diagram to illustrate the location and coverage of genomic regions 
screened of Zfp804a for mutations. The gene has 4 exons, denoted by short, dark, blue lines 
with the exception of exon 4, a larger exon, indicated by a blue square. Exon 2 is magnified in 
the red box in image a) and exon 4 is magnified in the blue box in image b). (a) shows the 
region covered by PCR spanning the C2H2 domain of Zfp804a; (b) shows the coverage of the 
PCRs covering part of exon 4.  
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PCRs were performed in Framestar 96-well plates (black frame with white wells 
for imaging on the LightScanner) in a 12l reaction using 3l of genomic DNA 
(at 5ng/l), 0.28l of each primer (at 5pmol), 0.96l dNTPs (5mM) each, 1.2l 
LC Green (MgCl2) buffer, 1.2l LC Green dye, 0.1l HotStar Taq (Qiagen) and 
4.98l of water.  Framestar plates, LC Green and LC Green buffer were all 
purchased from Cadama Medical Ltd (recommended for use with the 
LightScanner). HotStar Taq was used as it has a chemically modified site that 
prevents activity until it has been heated for 15 minutes at 95C. This prevents 
non-specific elongation by primer binding as the temperature increases, 
therefore annealing will only occur at the correct temperature as the reaction 
cools.  
 
PCR: 
1. 94C for 15 minutes 
2. 95C for 20 seconds 
3. 60C for 30 seconds 
4. 72C for 45 seconds 
5. Repeat steps 2-4 for 44 cycles 
6. 72C for 3 minutes 
7. 4C for 10 minutes 
 
Following the PCR, 15l of Mineral Oil (Sigma) was added to overlay the 
reaction and prevent evaporation during LightScanner analysis. 
Plates were then analysed using High Resolution Melting Analysis (HRMA) on 
the LightScanner. This involved following the SOP of heating the reactions on a 
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gradient from 70C to 98C (to denature the synthesised DNA) whilst the 
fluorescence given off is measured. LightScanner analysis (including repeating 
the PCR) was repeated for samples showing a variant profile on initial analysis. 
Samples showing a variant profile on two separate LightScanner analyses were 
sequenced. 
 
2.2.2 Sequencing 
All sequencing was performed using the fluorescent Sanger sequencing 
method via Big Dye termination chemistry (Applied Biosystems) and analysed 
using the ABI3100 PRISM Genetic Analyser. The fluorescent sequencing 
reaction involves obtaining large amounts of template DNA (i.e. by PCR) and 
then the random incorporation of four fluorescently labelled ddNTPs (di-deoxy-
dinucleotide-triphosphates: ddATP, ddCTP, ddGTP and ddTTP) that terminate 
after extending one base during primer extension. This produces a series of 
DNA fragments where the chain growth has been terminated at each 
successive position. When electrophoresed in a capillary sequencer and 
detected by a laser, each base of the sequence will be fractioned by size and 
fluoresce according to the base at that size. Sequencing required a 12l PCR 
of the genomic region to be sequenced. PCRs performed for LightScanner 
analysis were used for this purpose. The method was automated using a 
Beckman-Coulter NX liquid handler (programs were written by Sarah Dwyer). 
 
2.2.2.1 PCR clean-up 
Clean-up removed unincorporated dNTPs, primers, DNA, polymerase and salts 
from the PCR. PCR product is mixed with 21.6 AMPure reagent (Agencourt) 
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per sample. The AMPure contains metallic beads which adhere to the 
amplimers. Solution and products that are not adhered to the magnetic beads 
are washed off and removed using successive 85% ethanol wash steps. PCR 
amplimers are then eluted in 195l of pure water into a new plate. 
 
2.2.2.2 Sequencing reaction 
The cleaned PCR product was added in a 5l volume to a 5l reagent mix 
consisting of 0.166l of Big Dye termination mix, 1.917l water, 1.917l  Big 
Dye sequencing buffer and 1l of either the forward or reverse orientation 
oligonucleotide primer used in the original PCR (3pmol/l). The sequencing 
reactions were performed on a thermocycler under the following conditions: 
 
1. 96C for 2 minutes 
2. 96C for 30 seconds 
3. 55C for 15 seconds 
4. 60C for 4 minutes 
5. Repeat steps 2-4 for 24 cycles 
6. 4C for 4 minutes 
7. 15C for ever 
2.2.2.3 Post-sequencing clean-up 
Post-sequencing clean-up employs a CleanSEQ chemistry protocol 
(Agencourt) that is semi-automated. The process removes unincorporated dye 
terminators and further contaminants. Sequencing reaction product (10l) is 
added to 10l CleanSEQ reagent and 41.59l of 85% ethanol and aspirated to 
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mix. The sequencing product binds to the magnetic beads contained in the 
CleanSEQ reagent. The non-bound sequencing reaction contaminants are 
washed off and removed in successive 85% ethanol wash steps. The cleaned 
sequencing product can then be eluted in pure water (75l) and is ready for 
analysis using a capillary sequencer. 
 
2.2.2.4 Sequencing analysis 
The raw data generated by the ABI3100 PRISM Genetic Analyser is 
automatically analysed by Sequence Analysis Software (Applied Biosystems). 
The software calls the fluorescence at each nucleotide as the corresponding 
base. Sequencher software (Gene Codes) was then used, which aligns multiple 
sequencing traces and allows comparison with a reference sequence. The 
software then highlights where differences occur between the traces, allowing 
the user to manually inspect these and judge whether a polymorphism exists. 
 
2.3 Generating the mutant lines 
Mice were re-derived by in vitro fertilisation (IVF) using frozen sperm from an 
archive corresponding to the DNA archive screened (see Appendix 8.2). All IVF 
was performed by the MRC Mammalian Genetics Unit at Harwell. Genotyping 
and sequencing was performed as in 2.2 above except LC Green omitted and 
standard 10X buffer was used. The LC Green was replaced with double-
distilled water.  
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2.3.1 Mouse LD Linkage Panel 
The extent to which the mutations had been successfully backcrossed onto 
C57BL/6J background was estimated using the Mouse LD Linkage Panel 
(Illumina). The Mouse LD Linkage Panel consists of 377 SNPs that are 
polymorphic between different strains. The Mouse LD Linkage Panel is 
designed to include approximately four SNPs per 27 Mb interval and covers the 
entire genome. At least one SNP in each interval was selected by Illumina to be 
informative in crosses involving the C57Bl/6J strain. On average, at least one 
SNP in each interval is informative for 85% of all possible strain combinations. 
The linkage panel uses the GoldenGate Genotyping Assay (Illumina), a pre-
optimised assay that uses a discriminatory DNA polymerase and ligase to 
interrogate multiple SNP loci simultaneously.  Figure 2.2 gives an overview of 
the methods employed for genotyping SNPs in the panel. Data analysis was 
conducted using Microsoft Excel to count alleles corresponding to parental 
strain genotypes. Further details of the genotyping and data analysis 
methodology are given in Chapter 6: ‘Generating the 59X and 417Y lines’. 
 Before embarking on the protocol for the Mouse LD Linkage Panel, DNA 
was normalised to 50ng/l using PicoGreen (Invitrogen) and a fluorimeter 
Fluoroskan Ascent (Thermo Labsystems) to quantify the DNA. The PicoGreen 
reagent interacts with double-stranded DNA specifically (and not single-
stranded DNA or RNA) and is therefore more accurate than DNA quantification 
by spectrophotometry. Samples were first diluted to less than 100ng/l in sterile 
water, based on the concentration calculated using the spectrophotometer. The 
sample was then diluted to 1% in a 1 x TE buffer in a white 96-well cliniplate 
(Thermo Labsystems). A working PicoGreen solution is produced by adding 5l 
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PicoGreen at 200x to 995l of 1 x TE buffer. The fluorimeter dispenses 100l 
PicoGreen working dilution into each sample and measures the DNA 
concentration using a UV excitation wavelength of 485nm and an emission 
wavelength of 538nm. The DNA is quantified by comparison to the gradient of a 
standard curve which can be generated each time by the user using the 
calibrant (100ng/μl) DNA standard provided, or compared to a standard curve 
generated recently using the same kit (by Liam Carroll).  
 
 
 
 
 
THIS IMAGE HAS BEEN REMOVED BY THE AUTHOR FOR COPYRIGHT 
REASONS 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: Overview of Mouse LD Linkage Panel genotyping protocol using GoldenGate 
Asssay (Reproduced from www.illumina.com) 
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2.4 Subjects, animal husbandry and general procedures 
Once created, subjects were bred in the Behavioural Neurosciences 
Laboratory, School of Psychology, Cardiff University. All experimental mice 
were group housed in cages of 2-5 subjects except where fighting or bullying 
necessitated single caging. Cages were environmentally enriched (with chew 
sticks and cardboard tubes) and standard laboratory food and water were 
available ad libitum unless otherwise stated. Home cages were cleaned weekly 
by laboratory staff (not prior to testing on that day however). The light-dark 
cycle of the holding room was 12 hours with lights on at 07:00 and lights off at 
19:00. 
 Experimental animals were regularly monitored for signs of ill health. Any 
mice showing signs of illness were immediately assessed by the Named Animal 
Care and Welfare Officer and, if necessary, the University’s vet. If necessary 
mice were withdrawn from the experiment and treated or sacrificed, depending 
upon the nature and deemed severity of the illness. 
 
2.4.1 Habituation to handling, test environment and procedures 
Subjects were accustomed to being handled daily for two weeks prior to 
behavioural testing (approximately 1 minute per mouse, per day). Body weight 
measurements were also taken during this time 
 
2.4.2 Body weight measurement 
Body weights were recorded regularly (once per week after initial 2 week period 
prior to behavioural testing). Weights were taken at the same time each day 
(approximately 17:00). 
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2.4.3 Vaginal smearing 
Vaginal smearing was performed with a dampened cotton wool swab, and 
smears were stained in a 0.1% cresyl violet solution for at least 10 minutes. 
The procedure was performed several times during the first two weeks of 
handling and immediately following a behavioural procedure thereafter.  The 
swabbing was extremely quick and as uninvasive as possible and did not 
appear to cause discomfort to the mice. Smears were classified into three 
types, indicating dioestrus, proestrus and oestrus stages of the oestrus cycle 
(Fig 2.3). 
 
THIS IMAGE HAS BEEN REMOVED BY THE AUTHOR FOR COPYRIGHT 
REASONS 
 
Figure 2.3: Left-Right: Dioestrus cells, characterised by their small, dense structure. Proestrus 
cells, characterised by their compacted nuclei. Oestrus cells, characterised by their large size, 
not compacted nuclei and straight edges. Figure adapted from Mettus and Rane (2003). 
 
 
 
2.4.4 Behavioural testing environment 
All behavioural testing took place in an air-conditioned testing room adapted 
solely for this purpose where lighting levels could be adapted to the 
requirements of the specific experiment. Although humidity and temperature 
were not strictly controlled as they were in the animal holding rooms, these 
parameters were generally maintained around 50% and 21C respectively. 
Disturbances created by background noise were kept to a minimum and entry 
to the testing rooms was prohibited whilst experiments were taking place. 
Testing rooms were cleaned at the end of each day. 
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2.4.5 Phenotypic testing: control measures 
Methods of production employed in generating the C59X and C417Y mice 
meant that each line had a different array of residual mutations due to the 
nature of ENU mutagenesis. We overcame this by breeding the C59X and 
C417Y mutations onto the C57Bl/6J strain (a strain not used in the ENU 
mutagenesis) where the possibility of any 2 mice in the same group (genotype, 
line and gender) harbouring the same residual ‘other’ mutation was no longer 
deemed to be likely (discussed further in Chapter 6). In addition to the breeding 
control measures described above, numerous other control measures were 
used to ensure consistency of the data. Behavioural testing always took place 
in the daytime (coinciding with the light phase of the holding room). If the 
experiment required more than a single test session per subject, subjects were 
tested at the same time each day, in order to minimise any ‘time of testing’ 
effects. ‘Order of running’ effects were negated through running experimental 
and control subjects in a pseudorandom order. In order to minimise possible 
cage/litter effects, experimental subjects were drawn from as large a number of 
cages/litters as possible. No single-caged animals were used in the production 
of data from behavioural experiments for this thesis and in every cage there 
were at least two different genotypes. In addition to these precautions, the data 
was routinely screened for any such effects; in no experiment in this thesis was 
there any evidence of systematic differences, which could be attributed to these 
general factors. 
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2.5 Behavioural apparatus 
 
 
 
2.5.1 RotaRod 
 
 
Mice were tested on a 5-lane 
accelerating RotaRod (Ugo Basile) with a 
ribbed rubber coating on the rotating rod. 
Each compartment was separated by a 
wheel and sensors detected when the 
mouse fell from the rod and stopped the 
time. Fixed-speed or accelerating 
sessions were programmable on the 
equipment 
 
 
2.5.2 Phenotyper cages 
 
 
The PhenoTypers (Noldus 
Instruments) consisted of a 
Perspex square-base home cage 
environment with an overhead 
camera and tracking device (in 
A). Cages were furnished with 
wood shaving bedding, a shelter 
(B), a food hopper (D), a running 
wheel (E) and a water bottle (C). 
Mice spent 12 hours in darkness 
and 12 hours in light in the cages. 
Cages were separated by a black 
opaque sheet of card placed 
between outside walls so mice 
were unable to see neighbouring 
mice. Image reproduced with 
permission from Trent et al. 
(2012) 
 
Plan view of the Phenotyper 
homecage showing the zones 
used for data analysis. (A) hidden 
shelter, (B) drinking zone, (C) 
feeding zone, (D) exercise wheel, 
(E) arena floor – general activity. 
All zones combined comprised 
the tracking arena. Image 
reproduced with permission from 
Trent et al. (2012) 
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Figure 2.4 Photographs and 
summaries of the behavioural 
apparatus used. Theschematic 
diagram (left) shows the division of 
the zones in the open field. 
 
 
2.5.3 Locomotor activity boxes 
Mice were tested in a set  of 12 clear 
perspex boxes (width x length x height = 
215mm x 350mm x 200 mm) with two 
infrared beams crossing each box 30mm 
from each end and 10mm from the floor of 
the cage. Beam breaks were recorded by a 
computer using custom-written programs 
run by ARACHNID (Cambridge Cognition 
Ltd., Cambridge, UK) 
2.5.4 Elevated plus maze 
The elevated plus maze comprised two 
open arms (length x width = 180mm x 80 
mm) and two enclosed arms (length x width 
x height = 180mm x 80mm x 160mm) with 
an open roof. The maze was coated in 
white Benchkote (Camlab) which could be 
wiped clean and enabled tracking of the 
contrasting (black or brown) mouse. The 
plus maze was elevated 500mm from the 
floor and illuminated by a 60 watt bulb. 
2.5.5 Open field apparatus 
The open field apparatus was a white 
perspex walled box (length x width x height 
= 750mm x 750mm x 470mm). The open 
field was subdivided into ‘centre’ (a circle, 
located centrally, diameter 120mm), ‘inner’ 
(a square surrounding the circle measuring 
450mm x 450mm) and ‘outer’, the 
remainder of the open field.  
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2.6 Tail biopsy 
A tail biopsy was taken from animals for DNA extraction. Animals were 
restrained and the tip of the tail was anaesthetised using a freezing anaesthetic 
spray. Approximately 10mm was removed from the tip of the tail using a sharp 
pair of scissors and the animals were returned to the home cage and later 
checked for excessive bleeding and general well-being. The procedure was 
extremely quick and did not appear to cause excessive stress or discomfort to 
the animal. Biopsies were taken in accordance with Animals (Scientific 
Procedures) Act (1986) and relevant Home Office licences. 
 
2.7 Culling protocol 
At the end of the breeding/experiment, or if persistent illness/injury occurred, 
subjects were culled through cervical dislocation or suffocation by CO2 in 
accordance with Schedule 1 of Animals (Scientific Procedures) Act (1986).  A 
tail biopsy of experimental animals was taken at death to confirm the genotype 
of the animal.  
 
2.8 Brain extraction 
Brains were obtained from sexually-naïve subjects previously used in 
behavioural experiments. Immediately after culling, the head was removed and 
the brain manually extracted. Brains were immediately weighed before being 
frozen in liquid nitrogen prior to storage at -80C. 
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2.9 Data presentation and statistical methods 
Behavioural data are presented either as mean values  standard error of the 
mean (SEM), calculated from the following formula: 
 
Standard error of the mean = standard deviation of values 
              number of values 
 
or as mean values together with an overall standard error of the differences of 
the mean (SED). The relevant formula for the calculation of the SED is given in 
Cochran and Cox (1957). As this parameter may be used as the denominator 
for post hoc statistical comparisons, it represents an appropriate comparator for 
the visual evaluation for the difference between two mean values. 
 Behavioural data were analysed using SPSS (SPSS for Windows, Rel. 
16.0 2007. Chicago: SPSS Inc.) Data were subject to ANOVA and ANCOVA 
and MANOVA. All genotype and gender comparisons were planned a priori. 
For all comparisons, p values of <0.05 were regarded as significant.  
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CHAPTER 3: Mutation detection in Zfp804a 
3.1 Introduction 
The general introduction discusses how O’Donovan et al. (2008) implicated 
ZNF804A in the pathogenesis of schizophrenia in their large-scale genome-
wide association study (p=1.61 x 10-7 in meta-analysis). The association of this 
gene has since received support from several independent studies (Riley et al., 
2010; Steinberg et al., 2010; Zhang et al., 2010, Williams et al., 2011),  with 
Williams et al. reporting more significant results at p=2.5 x 10-11. ZNF804A 
appears therefore, to be a true susceptibility locus for schizophrenia 
(O’Donovan et al., 2009); however, at present very little is known about the 
function of the gene, or how it may confer risk for schizophrenia. 
As noted previously, the structure of the ZNF804A protein is largely 
unknown with the only characterised region being a cysteine2-histidine2 (C2H2) 
zinc finger binding motif occurring early on in the protein (aa57-81 of 1200 in 
the mouse; discussed in 1.5.2.2).  This domain binds DNA (or less frequently 
RNA) and is the most common DNA-binding domain in transcription factors 
(Wolfe, Nekludova & Pabo, 2000). Some recent studies have been published 
investigating the biology and putative function(s) of ZNF804A (Donohoe et al., 
2010, Riley et al., 2010 and Chung et al., 2010, Williams et al. 2010) and gene 
variants has also been shown to have a role in human cognition (Esslinger et 
al., 2009, Walter et al., 2010, Walters et al. 2010).  
As discussed earlier, one way of investigating the function of a gene is 
using an animal model. Animal models are useful for studying gene function for 
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several reasons. They allow us to manipulate a gene and observe associated 
alterations in biology, biochemistry and behaviour in ways that we are not able 
to in human subjects. There are currently no in vivo animal models available for 
examining ZNF804A function. An animal model of the function of a given gene 
can only be created if that organism has an orthologue of the gene. 
Orthologues are equivalent genes (i.e. similar function and high similarity 
between sequences) between species.  
The mouse orthologue of ZNF804A, Zfp804a, is located on chromosome 
2 (2qD) and spans 206kb. The gene has one protein coding isoform 
(NM_175513.3 (81893815-82100036), ID: 241514, RefSeq) and 4.1kb of 
coding sequence from 4 exons. The Zfp804a protein is 1200 amino acids.  
Bioinformatic analysis of Zfp804a in silico has shown the protein to have a 
cysteine2-histidine2 (C2H2) zinc finger binding motif at approximately positions 
57-81 (positions vary ±2 depending on resource), encoded in exons 2 and 3 
(ProSite, PFam, EMBL-EBI, all programs available online).  No other domains 
or features in the protein are currently characterised.  
There are several different methods of creating a genetic mutant mouse 
model.  N-ethyl-N-nitrosourea (ENU) mutagenesis is one of the most efficient 
mutagens available; it induces point mutations at a rate far higher than any 
other chemical mutagen in a random, unbiased fashion (Hitotsumachi, 
Carpenter & Russell, 1985). As the mutations are random, this gives rise to a 
multiplicity of potential models including the loss of gene function (by the 
introduction of a null allele), partial loss of function (hypomorphic) or gain of 
function (hypermorphic). ENU can therefore produce more varied and subtle 
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genetic mutants than can be achieved by other methods of gene manipulation 
(such as knockouts and transgenics; Godinho & Nolan, 2006).  
ENU is a chemical mutagen, an alkylating agent that acts by transferring 
the ethyl group to individual nucleobases, with a preference for thymine 
(Cordes, 2005). During DNA replication, these alkylated nucleobases are mis-
read by the DNA polymerase, resulting in errors being incorporated into the 
DNA. The resultant mutant DNA may or may not result in a functional mutation, 
a mutant protein, depending on the position and nature of the point mutation 
(Bielas & Heddle, 2000, O’Neill, 2000, Acevedo-Arozena et al., 2008). ENU 
mainly targets the spermatogonial stem cells (which later become mature 
sperm), making the chemical an ideal agent to cause heritable point mutations 
(Cordes, 2005).  Russell et al. (1979) found ENU to be more effective than 
other mutagens such as x-rays and procarbazine producing a higher maximum 
number of mutations and being simpler to administer. Hitotsumachi et al. (1985) 
showed that repeated but lower (100 mg/kg, weekly for 3 to 4 weeks) doses of 
ENU yielded a higher rate of mutations than a single dose of 250mg/kg.  
The MRC Mary Lyon Centre, Harwell has compiled a DNA archive from 
mice treated with the ENU mutagen over the last decade (Coghill et al., 2002). 
The archive currently consists of over 12 000 DNA samples from ENU-
mutagenised male mice and is paralleled by a frozen sperm archive (Dr Pat 
Nolan, MRC Harwell, personal communication). Quwailid et al. (2004) 
estimated the mutation rate in the samples by performing a PCR-based screen 
of a gene covering 27.4mb of DNA. Using denaturing high-performance liquid 
chromatography (DHPLC, discussed later) to detect mutations, Quwailid and 
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colleagues found an overall mutation rate of 1 in 1.01 Mbp of which 1 in 1.82 
Mbp were non-synonymous. The study supports the idea asserted in Coghill et 
al. (2002) that if a sufficient length of DNA is screened in a sufficient number of 
samples, then the chances of finding a mutation that is likely to affect the 
structure and/or function of the protein that gene encodes is very high.  
 There are two different approaches to using ENU mutagenesis for 
investigating gene function. Godinho and Nolan (2005) describe the phenotype-
driven screening approach used at the MRC Harwell Mary Lyon Centre. Mice 
with unknown mutations are tested using standardised behavioural tasks. 
Those mice showing a phenotype in the tasks are backcrossed, selecting for 
the phenotype, onto a wild-type background to isolate mutations and positional 
cloning and candidate gene analysis are then used to identify the mutation that 
is believed to be causing the phenotype. The other type of approach is the 
genotype-driven approach. In this approach, a known candidate gene or 
genomic region is screened for potentially functional mutations. Once mutations 
have been selected mice can be re-derived carrying this/these mutation(s) and 
then phenotyped using behavioural tasks etc. Clapcote et al. (2007) created 
two Disc1 ENU mutants from mutations discovered in exon 2 of the gene using 
TGCE heteroduplex analysis. Mice carrying the mutations were bred for four 
generations onto a wild-type background and then intercrossed.  The cohort 
was then characterised for schizophrenia- and depression-like behaviours. 
 In the experiments described in this chapter, mutations were detected 
in Zfp804a using high resolution melting analysis (HRMA). HRMA is an 
effective means of mutation detection and can be used as part of a two-tier 
strategy to identify samples carrying putative mutations in the first instance. 
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These samples can then be sequenced (as sequencing all samples would be 
prohibitively expensive and time-consuming) (Dwyer et al. 2010).  HRMA is 
based upon the idea that melting temperature of DNA (i.e. the temperature at 
which the DNA denatures) depends, at least in part, upon the GC/AT ratio, 
length and sequence of the DNA (Ririe et al. 1997). In the presence of a 
fluorescent dye that binds specifically to dsDNA (such as LC Green), 
differences in melting temperature (Tm) between DNA samples can be detected 
by measuring the fluorescence given off as the samples are heated (and 
therefore denatured) on a temperature gradient.  Graham et al. (2005) 
demonstrate that not only can differences in Tm be produced by samples 
differing in sequence, but that these Tm differences also produce difference size 
and shape melting curves when plotting, allowing quick visual examination of 
data.  
 The LightScanner™ (Idaho Technology, Utah) operates on the 
principles described above. A temperature-controlled platform and fluorescent-
sensitive camera are combined with Call-IT™ software (Idaho Technology) that 
automatically plots a graphical representation of the fluorescence given off by a 
sample as the DNA is melted, a “melting curve”. The software also calculates 
“difference curves” showing the differences between samples in melting 
temperature (Figure 3.1). The LightScanner™ platform has been successfully 
used for mutation detection previously (e.g. Kennerson et al., 2007, Chen et al., 
2009, De Leeneer et al., 2009, Li et al., 2009, Dwyer et al. 2010).  
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Figure 3.1. Diagram to show melting curves and difference curves output from LightScanner 
Call-It software. (a) indicates the diagram generated by the software showing the position of all 
the variants in a 96-well plate layout; (b) points to the sample coloured in red, identified as a 
‘variant’ and shows the position of this variant in the 96-well plate, the melting curves and the 
difference curves; (c) shows a graphical representation of the temperature-normalised 
fluorescence given off over a temperature gradient by all samples (variant in D2 in red); (d) 
shows the difference between the melting curves in fluorescence given off over a temperature 
gradient and (e) indicates options for grouping, analysis and sample identification manual 
options. 
 
This chapter describes the screening of an ENU-treated DNA library for 
mutations in the mouse orthologue Zfp804a of the human gene ZNF804A, and 
the selection of two mutations to carry forward for functional characterisation. 
 
 
(d) Difference-
curves:fluorescen
ce over 
temperature 
gradient 
(e) Grouping, 
analysis and 
sample 
identification 
options 
(a) Diagram 
of position of 
variants in 
96-well plate 
(c) Temperature-
normalised 
fluorescence 
given off over a 
temperature 
gradient 
(b) Red “variant” corresponds to 
position D2 
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3.2 Materials and methods  
3.2.1 Samples 
All (5, 856) DNA samples involved in the screen described in this chapter were 
obtained from MRC Mammalian Genetics Unit, Harwell. The DNA was 
extracted (using a DNeasy Blood & Tissue Extraction kit, Qiagen)  from liver 
taken from animals which were male C3H/HeH x BALB/c offspring of mice 
injected with the ENU mutagen. At the MRC Centre in Harwell, three weekly 
doses of 100mg/kg of ENU were injected intraperitoneally into both BALB/c 
male mice from 10 weeks of age. Following a period of sterility these mice were 
mated to C3H/HeH females. The male progeny were used to provide DNA and 
sperm for the archive. DNA was at a working concentration of 5ng/µl. (Quwailid, 
et al. 2004). All DNA samples (and corresponding sperm samples) were frozen 
between 17-10-2001 and 20-01-2004. 
 
3.2.2 Regions selected for screening 
Two areas of Zfp804a were selected for mutation screening: exon 2 encoding 
the only characterised domain of the Zfp804a protein and a region of exon 4 
that is highly conserved that several non-synonymous SNPs were found in by 
Dwyer et al. (2010). Figure 3.2, below, shows a diagram of the Zfp804a protein 
with the C2H2 domain highlighted in pink. The Zfp804a (and ZNF804A) protein 
is largely uncharacterised. The only characterised domain is the C2H2 zinc 
finger binding motif, one of the most common DNA-binding domains found in 
transcription factors (Wolfe, Nekludova & Pabo, 2000). These proteins typically 
consist of several fingers that make parallel contacts along the DNA. Each 
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finger has a  structure where the -helix is the point of contact with the 
major groove of the DNA. Each of these fingers has a single zinc ion that is 
coordinated by two cysteine residues at one end of the two anti-parallel -
sheets and two histidine residues at the C-terminal of the -helix. A C2H2 zinc 
finger spans approximately thirty amino acids: (F/Y)-X-C-X2-5-C-X3-(F/Y)-X5--
X2-H-X3-5-H where X represents any amino acid and  is one of the 
hydrophobic residues (Wolfe, Nekludova & Pabo, 2000).  Bioinformatic analysis 
(using PFam, ProSite, UniProt and EMBL-EBI) has shown the zinc finger 
binding domain to span exons 2 and 3. The cysteine and histidine residues that 
bind the zinc ion are both coded for in exon 2 of the gene so screening was 
commenced in this region. 
 
MECYYIVISSTHLSNGHFRNIKGVFRGPLSKNGNKTLDYAEKENTIAKALEDLKANFYCELCDKQYYKHQ
EFDNHINSYDHAHKQRLKELKQREFARNVASKSRKDERKQEKALQRLHKLAELRKETVCAPGSGPMFKST
TVTVRENLNDVSQRESVDPINNQQDLIPSEEKERDGTTALAETETASNCTANNCQIGDQSQAVHRHRIGF
SFAFPKKATVKLESCSAAAFSEYSDESSMEKEFSRKTRFVPSTSHLQLPPPTCELLSSEEKGNSPPPEAM
CTDKATAQTEERKITSNENNTLLTSSFCQLQHYIPTCSEADTCQNLAPFEDQLPMEAVIVNEDGPVSKSN
PNIIEKNPTVPNDRTSAQMTTEENITINDVTKMETRNKIDHEPLTPSSTIEESIRLQKRPDLCKRQCDPF
VPVLNKLGSTVLQWPSEMLAYTTTEPSISYSCNPLCFDFKSTKLNNNQDKNKLTLNDLFSEQKEDCCKGA
HADCKDVPIARVTNDETGHSKNDYPQVTTLSPVHVLSNGCDLGQNENVGQRYKHISCTNRQTNKYKFTRC
QIKRDMLNEKYDKMRLKETREHWFHKSRRKKKRRKLCRYHPGKSSKEPEGSGKTERSRQRTDEARKNPRE
PVLEKHPRSPERASDLHQLPDERPKAASTHLGEKETMNTTVNTESNDAAPGSQNCGGKNATVVNEQAKPL
VIHSVKQNLTYVRTYCCWKARTSRYQEDDGSLASQSNVKGPTQNQPVKRGYSSLTNDSERIHRKRRQHSC
SYSSDESLNQQHHLGEYLKPLSTSLISCQPKKKRRRKRSRLHIGDGTTKMKGNSNYPMKCSSLSQPDELA
KDCIKED 
INPQENVSIEKNSEQTEQTEIKGMLHPYNPLLSEPSGEGEHSVTETTPCDSSQTSNDLATPVNVTRDPSN
STTDNTLLEHNQRSQTTNSNEKQTPFKVTNPERNFRHSQAKSYICRYELAETIPQGKTNEASTEWLCYNS
GILNTQPPLQFKEAHVSGHAFVTTEQILAPLPLPEQALLIPLENHDKLKHLPCEVYQHIIQPNMLTNKVK
FTFPPPPLPPPSTPVQPLPLQRPFCSTSVTTIHHTVLQHHAAAAAAAAAAAAAGTFKVLQPHQQFLPQVP
ALARTSIPQISVGTVGPRLCPGGQPALVASPQMPIIPASVLHPSPLAFPPLPHSFFPSLLSPHPTVIPLQ
PLF 
 
Identity between mouse and human, whole protein: 66.5% identity in 
1212 residues overlap 
 
Identity between mouse and human, C2H2 domain: 100% 
 
Figure 3.2. Mouse Zfp804a protein sequence. C2H2 zinc finger domain in Zfp804a (highlighted 
in pink). Percentage identity between the mouse and human for the whole protein sequence of 
Zfp804a/ZNF804A and for the zinc finger domain is also given  
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The second region selected for screening was identified as a particularly 
well-conserved region of the protein and to potentially provide a contrasting 
model to an exon 2 mutant line. This region of exon 4 of the gene was identified 
as rich in non-synonymous SNPs with variants found in both cases and controls 
(Dwyer et al., 2010). It was not practical to screen the entire gene although a 
comprehensive screen would have been optimal. Figure 3.3 below shows a 
schematic diagram of the genomic regions amplified by PCR. 
 (a)  
(b)  
 
 
Figure 3.3. A schematic diagram to illustrate the location and coverage of regions screened of 
Zfp804a for mutations. The gene has 4 exons, denoted by short, dark, blue lines with the 
exception of exon 4, a larger exon, indicated by a blue square. Exon 2 is magnified in the red 
box in image a) and exon 4 is magnified in the blue box in image b). (a) shows the region 
covered by PCR spanning the C2H2 domain of Zfp804a; (b) shows the coverage of the PCRs 
covering part of exon 4.  
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3.2.3 Primer Design 
Oligonucleotide primers were designed using software available online, Primer3 
(http://frodo.wi.mit.edu/primer3/). Primers were all designed to have an 
annealing temperature of 55 to 65C and a length of 18 to 22 nucleotides. 
Primers were checked against catalogued SNPs in the region to ensure the 
oligonucleotides did not overlap with any known SNPs using the Mouse 
Genome Informatics database (Blake, Bult et al., 2011). All oligonucleotides 
were synthesised by Metabion and are listed  in 2.2.1. 
 
3.2.4 PCR Optimisation 
PCRs were optimised for use with the LightScanner with and without the 
addition of dimethyl sulfoxide (DMSO, 1.2µl water substituted for DMSO where 
appropriate), over an annealing temperature gradient of 55-65°C, using 
different primer combinations for each region.  
 
3.2.5 Mutation Detection 
See 2.2.1 for details of PCRs performed. PCRs were analysed on the 
LightScanner following the protocol described in Dwyer et al. (2010). Melting 
curves generated automatically by the Call-It software were normalised by 
defining ‘0%’ and ‘100%’ fluorescence manually either side of the prominent 
change in fluorescence, where the DNA is denatured. For consistency these 
lower and upper temperature intervals were always normalised to -2°C to -1°C 
and +1°C to +2°C respectively. Samples were then analysed using the “normal” 
sensitivity setting of the Call-It software which groups samples by melt curve. 
All samples were then inspected manually and re-grouped if deemed 
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necessary. PCRs were repeated for samples showing a different melt curve 
and re-analysed using the LightScanner. Samples showing an unusual profile 
on both occasions were sequenced across the region covered by the PCR to 
identify any mutations present. Details of sequencing methods can be found in 
2.2.2.  
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3.3 Results 
 
3.3.1 Mutations discovered 
Mutation detection was carried out in a total of 5,856 putative mutation-carrying 
DNA samples. Approximately 1200bp were screened in each sample (therefore 
5856x1200 = 7 272 000bp were screened for mutations in this study). A 
summary of results (mutations found) from the screen are shown in table 3.1. 
Twelve mutations were found with two of these mutations being synonymous 
and excluded from further analysis. The mutation discovery rate was therefore 
1 in 0.61Mb with a non-synonymous mutation rate of 1 in 0.73Mb. Table 3.1 
shows the mutations discovered in the 7 272 000bp screened by sample ID, 
genomic position, Zfp804a region, substitution, type of mutation and amino acid 
change if relevant. 
 The raw sequencing data is shown for non-synonymous mutations, i.e. 
those mutations predicted to result in an amino acid substitution (or the 
introduction of a premature stop codon in the case of the mutation in sample 
X23, E5) in figures 3.4 to 3.14. Raw data is not shown for the synonymous 
mutations in X33, E8 and X15, E8 as the mutations were not considered any 
further.   
 The quality of the sequencing varies and is in some cases poor. This 
was particularly the case with output near the 5’ or 3’ end of the amplified 
sequences. Nonetheless, it is deemed sufficient quality to infer the presence of 
a mutation (Liam Carroll, personal communication, 2009). The mutations that 
were carried forward for re-derivation were confirmed in separate PCRs and 
sequencing reactions. 
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DNA 
sample ID 
 
Genomic 
position 
REGION Base 
change 
Mutation Amino acid 
change 
X14,E1 82076010 
 
EXON 2 AAT>AGT 
 
Non-synonymous 
(Missense) 
Asparagine > 
serine (N>S) 
 
X23,E5 82076020 
 
EXON 2 TGT>TAA
†
 
 
Non-synonymous 
(Nonsense) 
Cysteine > 
terminator (C>*) 
 
X33,E8 82076065 
 
EXON 2 AAT>AAC 
 
Synonymous N/A 
 
X32,E3 82096730 
 
EXON 4 TTT>ATT 
 
Non-synonymous 
(Missense) 
Phenylalanine > 
Isoleucine (F>I) 
X13,A5 82096776 
 
EXON 4 GAG>GGG 
 
Non-synonymous 
(Missense) 
Glutamic > glycine 
(E>G) 
 
X13,A5 82097042 
 
EXON 4 ATC>ACC 
 
Non-synonymous 
(Missense) 
Isoleucine > 
threonine (I>T) 
 
X13,D5 82097056 
 
EXON 4 AAT>AAA 
 
Non-synonymous 
(Missense) 
Asparagine > lysine 
(N>K) 
 
X13,E2 82097138 
 
EXON 4 ACT>GCT 
 
Non-synonymous 
(Missense) 
Threonine > 
alanine (T>A) 
 
X42,G9 82097223 
 
EXON 4 TGT>TAT 
 
Non-synonymous 
(Missense) 
Cysteine > tyrosine 
(C>Y) 
 
X9,G1 82097246 
 
EXON 4 GTA>GCA 
 
Non-synonymous 
(Missense) 
Valine > alanine 
(V>A) 
 
X29,A12 82097262 
 
EXON 4 AAA>AGA 
 
Non-synonymous 
(Missense) 
Lysine > arginine 
(K>R) 
 
X15,E8 82097269 
 
EXON 4 GGA>GGG 
 
Synonymous N/A 
 
† double adjacent mutation 
Table 3.1: Summary of results from the mutation screen of Zfp804a 
 
Figure 3.4 overleaf additionally shows the output from the LightScanner CallIt 
software showing how mutations with a varying melt profile were identified 
initially. None of the mutations discovered were strain polymorphisms. This was 
confirmed using the Jackson Laboratory’s Mouse Genome Informatics Strains, 
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SNPs and Polymorphisms database 
(http://www.informatics.jax.org/strains_SNPs.shtml) accessed November 2008.  
 
a) 
 
 
b) 
c) 
 
 
 
 
Output from the LightScanner (see 
Figure 3.1 for a more detailed 
explanation of the images generated). 
Diagram a) shows the 96-well plate and 
the location of the identified variant (E1, 
red). b) shows the melt curve of this 
sample and c) shows the difference 
curves. d) shows the sequencing trace 
demonstrating that the red sample, E1, 
was a true variant where wild-type 
sequence is the top row and mutant 
sequence (A>G, complement is 
shown)is shown below. 
     For the remainder of the mutations 
discovered, the sequencing traces only 
(d) are shown 
     The blue variant was a false positive. 
 
d) 
 
Figure 3.4: Mutation X14,E1 
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LightScanner traces for this 
and the remainder of the 
mutations discovered are 
shown in Appendix 8.1. 
Figure showing sequencing 
trace of sample X23, E5  - 
the wild-type (top) and 
mutant (bottom). Codon 
TGT>TAA, complement is 
shown).  
Figure 3.5: Mutation X23, E5 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure showing sequencing 
trace of sample X33, E8 - the 
wild-type (top) and mutant 
(bottom) (T>C, complement 
is shown). 
Figure 3.6: Mutation X33, E8 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure showing sequencing 
trace of sample X32, E3 and 
the wild-type (top) and 
mutant (T>A) (bottom) 
sequencing trace (b).  
Figure 3.7: Mutation X32, E3 
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a) 
 
 
 
 
 
Figure showing 
sequencing traces of 
sample X13, A5 - the 
wild-type (top row a 
and b) and mutant 
(bottom row, a and 
b). a) shows the A>G 
mutation. The T>C 
mutation is shown in 
(b). 
b) 
 
 
 
Figure 3.8: Mutations in X13, A5 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure showing 
sequencing trace 
of sample X13, D5  
- the wild-type 
(top) and mutant 
(T>A) (bottom) are 
shown. 
Figure 3.9: Mutation X13, D5 
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Figure showing 
sequencing trace of 
sample X13, E2 -  the 
wild-type (top) and mutant 
(A>G)(bottom) are shown.  
Figure 3.10: Mutation X13, E2 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure showing 
sequencing trace of 
sample X42, G9 -  the 
wild-type (top) and mutant 
(G>A)(bottom) are shown.  
Figure 3.11: Mutation X42, G9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure showing 
sequencing trace of 
sample X9, G1 - the wild-
type (top) and mutant 
(T>C)(bottom) are shown. 
Figure 3.12: Mutation X9,G1 
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Figure showing sequencing 
trace of sample X29, A12 - 
the wild-type (top) and 
mutant (A>G)(bottom) traces 
are shown.   
Figure 3.13: Mutation X29,A12 
 
 
 
 
 
 
 
 
 
  
 
 
Figure showing sequencing 
trace of sample X15, E8 - the 
wild-type (top) and mutant 
(A>G)(bottom) traces are 
shown.  
Figure 3.14: Mutation X15, E8 
 
Figure 3.15: Summary of mutations discovered on a schematic diagram of the Zfp804a protein. 
Mutations depicted by pink lines were the mutations selected for phenotypic analysis (see 
below). The green lines depict mutations that were not pursued.  
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3.3.2 Mutation analysis 
Synonymous mutations were excluded from further analysis as they do not 
affect protein structure. For each mutation, the predicted magnitude of the 
substitution was considered by taking into account the chemical properties of 
the amino acids substituted and the extent of conservation (by phylogenetic 
protein sequence alignment done in silico, see below) both at that particular 
residue and if the residue was within a block of conservation. Orthologous and 
paralogous protein sequences were compared using Malign (a multiple 
alignment program available online) to assess conservation. The yeast GIS1  
SPECIES GENE HOMOLOGY 
Mouse Zfp804a N/A 
Human ZNF804A Orthologous 
Human ZNF804B Paralogous 
Mouse Gpatch8 Paralogous 
Human GPATCH8 Paralogous 
Rat Znf804a Orthologous 
Chicken Znf804a Orthologous 
Horse ZNF804A Orthologous 
Chimpanzee ZNF804A Orthologous 
Rhesus monkey LOC707018 Orthologous 
Zebrafish LOC561947 Orthologous 
Yeast GIS1 A zinc finger protein 
containing a C2H2 
domain 
Table 3.2: Listof the proteins aligned with Zfp804a. Orthologous sequences in humans, other 
mammals, and the zebrafish were used. Paralogous sequences in the mouse and human were 
also selected. 
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was added as the gene contained a C2H2 zinc finger binding domain. Proteins 
aligned are shown in the table above (table 3.2). 
 Table 3.3, below, shows a summary of results from the mutation screen 
(non-synonymous mutations only), with the amino acid substitution, chemical 
nature of the substitution and conservation between similar proteins aligned 
(see table 3.2) around that residue. 
 
Sample 
ID 
Type of 
mutation 
& position 
Substitution Nature of change Conservation 
X14E1 
 
 
 
Missense 
aa56 
Asparagine> 
serine 
(N>S) 
 
 
Within zinc finger domain 
and both the original and 
substituted aa are polar 
and uncharged N slightly 
larger than S. 
Within a highly conserved 
block but not conserved in 
the paralog Gpatch8 or the 
yeast GIS1 
X23A5 Nonsense 
aa59 
Cysteine> 
terminator 
(C>*) 
 
Truncates 1200aa protein 
prematurely at 59aa (aa 6 
of 28 comprising zinc finger 
domain). The mutated 
cysteine is the first of two 
vital cysteine residues. 
Substituting one of these is 
predicted to have a 
destructive effect on the 
zinc finger binding domain. 
This cysteine residue is 
involved in binding the zinc 
ion of the finger and its 
substitution is predicted to 
disrupt the binding of the 
zinc ion (Wolfe et al. 2000). 
Within a highly conserved 
block but not conserved in 
the paralog Gpatch8 or the 
yeast GIS1 
 
 
X32E3 Missense 
aa249 
Phenylalanine
> isoleucine 
(F>I) 
Both are hydrophobic, not 
charged. F has a phenyl 
ring. Both amino acids are 
similar in size. 
F is conserved in 6 of 7 
orthologous sequences (not 
in LOC561947, zebrafish) 
but not in paralogous 
sequences. Residue is F in 
GIS1 (yeast). In a fairly well 
conserved region of the 
protein. All mutations found 
in exon 4 are within this 
block. 
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X13A5 MIssense 
aa264 
Glutamate> 
glycine (E>G) 
Glutatmate is negatively 
charged and highly polar. It 
is a much bigger amino 
acid than glycine which is 
amphiphilic and not 
charged. G is smaller than 
E. 
The glutamate residue is 
shared only by the mouse 
and rat orthologous 
sequences and the majority 
residue is valine (rhesus 
monkey, chimp, horse and 
human orthologs). Valine 
has different properties from 
glutamate. It is nonpolar and 
not charged and is smaller 
and differs in shape from 
glutamate. 
X13A5 Missense 
aa353 
Isoleucine> 
threonine (I>T) 
I is non-polar, T is polar, 
more reactive and slightly 
smaller 
The isoleucine residue is 
shared only by the mouse 
and rat orthologous 
sequences and the majority 
residue is leucine (rhesus 
monkey, chimp, horse and 
human orthologs), although 
leucine is very similar to 
isoleucine. 
X13D5 Missense 
aa357  
Asparagine> 
lysine (N>K) 
Both are polar although 
lysine is positively charged. 
N and K are different 
shapes and N is slightly 
bigger 
Residue is K in human, 
chimp, rhesus monkey & 
horse orthologs and also in 
yeast GIS1. 
X13E2 Missense 
aa385 
Threonine> 
alanine (T>A) 
No charge difference 
between the amino acids 
although A is non-polar and 
T is polar and a bigger 
amino acid. 
The locus is not particularly 
well-conserved. The majority 
residue (found in human, 
horse and chimp) is valine. 
Valine is non-polar and so 
differs from threonine and 
therefore suggests a 
substantial variability at this 
locus. 
X42G9 Missense 
aa417 
Cysteine> 
tyrosine (C>Y) 
The loss of a cysteine 
residue may disrupt the 3D 
structure of Zfp804a. Y is 
also polar (C is non-polar) 
and bigger than C. 
C is found at this locus in 5 
of 6 orthologous sequences 
(zebrafish doesn’t align here 
and residue is serine (polar) 
in the horse. Paralogs are 
leucine (ZNF804B human) 
which is nonpolar, and 
threonine in the human and 
mouse forms of GPATCH8 
(polar).  The residue is well 
conserved amongst 
orthologs but not in paralogs. 
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X9G1 Missense 
aa421 
Valine> 
alanine (V>A) 
Amino acids are smaller, 
both non-polar, except 
valine has a slightly larger 
hydrocarbon side chain. 
Residue is valine in the 
majority of orthologs and not 
conserved in paralogous 
sequences.  
X29A12 Missense 
aa426   
Lysine> 
arginine (K>R) 
Both are hydrophilic and 
positively charged. They 
are similar in size. 
 
Residue is lysine in all genes 
compared other than 
LOC561947 in zebrafish and 
GIS1 in yeast. 
Table 3.3: Summary of non-synonymous mutations, chemical nature of the substitution 
and conservation at that position between sequences aligned (see table 3.2). 
 
From comparison of the mutations, two were considered to have a greater 
predicted functional effect than the others and so were taken for further in silico 
analysis: 
 
 The nonsense mutation C59X (genomic position 82076020) prematurely 
truncates the protein in the zinc finger domain, and it is predicted that the 
mutant mRNA transcript will not be fully translated and will be destroyed 
by nonsense mediated decay. 
 The cysteine to tyrosine missense mutation C417Y (genomic position 
82097223) is predicted to disrupt the structure of the protein. This 
residue is well conserved in orthologs. From the exon 4 mutations 
discovered, this mutation was deemed to be the most severe due to the 
nature of the substitution. Cysteine is known to be important in 
determining protein structure (Berg et al., 2002) and the loss of the 
residue may damage the 3D protein structure. Tyrosine is also polar 
(cysteine is non-polar), and bigger than cysteine. 
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3.3.2.1 In silico analysis of the functional impact of the chosen mutations 
The C59X mutation is predicted to result in nonsense-mediated decay of the 
mRNA transcript. The effect of the C417Y substitution is however more 
uncertain. There are several bioinformatic resources available online that use 
algorithms to predict the effect of amino acid substitutions on structure and 
function. The C417Y substitution in Zfp804a lies in an area of the protein that is 
uncharacterised which makes prediction of the effects of mutations in this 
region more difficult, as obviously the function of this part of the protein is 
unknown. However, programs such as Align GVGD (where GV is the Grantham 
Variation and GD is the Grantham Deviation) and PolyPhen are nevertheless 
useful and use other factors to predict the magnitude of mutations. 
 Align GVGD uses an algorithm based on the Grantham Difference 
(Grantham, 1974), a formulaic means of analysing amino acid substitutions. 
Similarly to Grantham (1974), Align GVGD uses the composition, polarity and 
molecular volume information to estimate difference between amino acids. The 
program uses two variables to estimate differences, both of which are based on 
the original Grantham Difference. GV refers to the range of variation observed 
at a position in a protein multiple sequence alignment and GD is a measure of 
the magnitude of the difference between the substitution and the range (if any) 
of variation observed at this position Tavtigian et al. (2008) provides further 
details. Align GVGD generates a prediction of the severity of the substitution 
based upon the multiple protein sequence alignments entered.  Figure 3.16 
below shows the output from the program. 
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Figure 3.16: Output from Align GVGD on the predicted impact of the C417Y mutation 
 
Align GVGD predicted the mutation to be in class C65. This is the most severe 
class of mutations. 
PolyPhen (http://genetics.bwh.harvard.edu/pph/) predicts the functional 
effects of human non-synonymous SNPs (nsSNPs) but it is also used for 
predicting the effect of non-synonymous mutations in the mouse (Reuveni, 
Ramensky & Gross, 2007). After entering a protein sequence and the 
substitution, PolyPhen searches the UniProt database for specific features in 
the sequence such as binding sites. It then calculates a score for the likelihood 
of the substitution, based upon the amino acid change and information 
retrieved from database searches. The programme then attempts to map the 
substitution onto the known 3D structure of the protein to predict the magnitude 
of the change for example whether or not it interferes with the hydrophobic core 
or not. Figure 3.17 illustrates the output from PolyPhen for the C417Y mutation. 
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Figure 3.17: Output from PolyPhen on the predicted impact of the C417Y mutation 
 
The mutation in exon 4 of Zfp804a using this algorithm was predicted to be 
‘probably damaging’. Although the programme was unable to map the 3D 
structure of the protein (as the region of the protein in which the C417Y 
substitution falls is currently uncharacterised), the mutation was predicted to 
have a damaging effect based on protein sequence alignments entered. 
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3.4 Discussion 
Mutation detection was carried out in a total of 5,856 putative mutation-carrying 
DNA samples. Approximately 1200bp were screened in each sample (therefore 
5856x1200 = 7 272 000bp were screened for mutations in this study). Twelve 
mutations were found with two of these mutations being synonymous and 
excluded from further analysis. In this study, the mutation discovery rate was 
significantly higher than expected (χ2 = 23.01, 1df, p<0.0001), compared with 
the rate of mutations found by Quwailid and colleagues (2004). Whilst Quwailid 
et al. discovered 1 mutation in 1.01Mb (in exonic sequence of which 1 in 
1.82Mb was functional), mutations were discovered (in the same DNA archive) 
at a rate of 1 in 0.61Mb (of which 1 in 0.73Mb was functional). Three 
suggestions of possible explanations for this difference are provided. Nolan, 
Hugill and Cox (2002) state that AT-rich genes are more likely to be targeted by 
ENU mutagenesis (as 82% of sequenced mutations discovered by Justice et al. 
(1999) involved transitions/transversions of AT pairs). However, in a large 
screen of 9.48Mb, Coghill et al. (2002) found more GC than AT transitions 
(although 40% were AT transitions).. In the present study, 10 out of the 12 
mutations, or 83% were AT rather than GC transitions, in agreement with the 
rate discovered by Justice et al. (1999). Detailed analysis of the sequences 
analysed in this chapter compared with the sequences analysed by Quwailid et 
al. (2004) would be useful to investigate the possibility of sequence differences 
being responsible for the difference in mutation discovery rate further. Another 
possible reason for the difference in discovery rate is that different mutation 
detection techniques were used. As discussed in 3.1, the LightScanner has a 
very low false negative rate (although consequently a high false positive rate). 
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Quwailid et al. (2004), on the other hand, used denaturing high performance 
liquid chromatography (DHPLC) which has a higher false negative rate and 
could lead to mutations being missed (Coghill et al., 2002). A third reason for 
the higher mutation rate discovered in the present study could be that the 
Zfp804a locus is particularly susceptible to ENU-induced mutations, a so-called 
‘ENU hotspot’ (e.g. Kiernan et al., 2002). Of the ten non-synonymous mutations 
considered, two mutations stood out as potentially more severe from in silico 
analysis, the C59X and C417Y mutations. These mutations were selected to be 
investigated further in a mouse model.  
 
3.4.1 C59X 
It is assumed that the introduction of the premature stop codon in Zfp804a in 
this model will cause the mutant mRNA transcript to be destroyed due to 
nonsense-mediated decay, resulting in no detectable Zfp804a protein in mice 
homozygous for the C59X substitution. Nonsense mediated decay (NMD) is a 
highly-conserved function that destroys transcripts encoding premature stop 
codons (see figure 3.18). A mutant or truncated version of the protein can be 
more harmful than the complete absence of the protein due to potentially 
deleterious gain-of-function or dominant-negative effects (Chang et al., 2007). 
NMD is vital to the survival of a healthy organism. Medghalchi et al. (2001) 
show that mice lacking the up-frameshift 1 (Upf1) protein die at day 7.5 of 
gestation. Upf1 is a protein heavily involved in NMD and promotes translation 
and histone mRNA decay. 
Nonsense mediated decay occurs when a premature termination codon 
(PTC) is encountered in the mRNA transcript during translation. The main 
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method believed to indicate whether a stop codon is premature or not is the 
presence of an exon junction complex (EJC, a protein complex deposited about 
20-24 nucleotides upstream of exon-exon boundaries) downstream from the 
PTC. As the ribosome passes along the mRNA transcript, EJCs are removed. 
Translations ends when eukaryotic release factors (eRG2 and eRG3, which 
also interact with UPG2), attached to the ribosome, recognise a stop codon. 
When a stop codon is encountered that isn’t in the last exon of a gene, EJCs 
remain on the mRNA. Any remaining EJCs bind to the eRFs and UPG2, 
initiating nonsense-mediated decay by dissociating the ribosome and causing 
the cap-binding complex to be removed, which protects the mRNA transcript. 
This leaves the mRNA transcript susceptible to rapid decay by exonucleases. 
NMD is believed to happen during the ‘pioneer’ round of translation (see figure 
3.19). Chang et al. (2007) review the topic.  
 
 
 
 
THIS IMAGE HAS BEEN REMOVED BY THE AUTHOR FOR COPYRIGHT 
REASONS 
 
 
 
Figure 3.18: Diagram taken from Chang et al. (2007) to illustrate the NMD process. NMD 
occurs when up-frameshift protein 1 (UPG2, labelled 1) interacts with UPG3 (2), and UPG4b 
(3b). This interaction does not normally occur as the ribosome (purple) does not ordinarily meet 
a stop codon until all the EJCs have been removed. PTCs in the last exon of a gene normally 
escape destruction by NMD.  
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Figure 3.19: Diagram taken from Chang et al. (2007) shows the removal of the cap-binding 
complex and destruction of the mRNA by exonucleases.   
 
It is predicted that NMD will occur with the C59X mutant. The nonsense 
mutation is not in the last exon of the gene nor is it less than 50 nucleotides 
upstream of the final splice junction of the gene, two factors which can cause a 
transcript containing a PTC to escape NMD (Strachan & Read, 2010). There is 
currently no Zfp804a antibody however to verify the decay of the transcript. 
There are exceptions to NMD, where there may be ‘read-through’ in the 
transcription phase, or the stub may not be decayed depending on the position 
of the premature stop codon in the transcript. Matsuda, Sato & Maquat (2008) 
review the topic. Whether or not NMD indeed occurs, the loss of the cysteine 
residue is predicted to have a large effect on the structure of Zfp804a 
(predicted by both literature and bioninformatic analysis of the protein).The 
mutated cysteine is the first of two vital cysteine residues. Substituting one of 
these is predicted to have a destructive effect on the zinc finger binding 
domain. This cysteine residue is involved in binding the zinc ion of the finger 
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and its substitution is predicted to disrupt the binding of the zinc ion (Wolfe et 
al. 2000). Thus even if the mutated protein were to escape NMD it is likely that 
the mutation would disrupt the function of Zfp804a.   
 
3.4.2 C417Y 
This mutation was selected to take forward for phenotyping as the cysteine to 
tyrosine substitution was predicted to have a damaging effect on the protein, 
the mutation occurred in a highly conserved genomic region and several non-
synonymous SNPs were found in this region by work in this laboratory (Dwyer 
et al., 2010). The substitution occurs in a part of the protein that has not yet 
been characterised and it is unknown what function this part of the protein may 
fulfil. It is therefore difficult to predict the effect the mutation will have on the 
protein. Nonetheless cysteine and tyrosine residues are different in size and 
polarity and the loss of a cysteine residue may disrupt the 3D structure of 
Zfp804a which may result in a loss or gain of function. Differently folded 
proteins can dramatically affect protein-protein interactions and consequently 
their functions. Such effects may be seen in both homozygous and 
heterozygous mutants (if there is haploinsufficiency of the protein product) 
which necessitates investigation of phenotypes in wild-types and homozygous 
and heterozygous mutants to explore the phenotypic effects of the mutation. 
Cysteine has a sulfhydryl group which makes cysteine highly reactive and gives 
cysteine an important role in the structure of proteins by forming disulfide links. 
These bonds enable cross-links between polypeptide chains and are formed by 
the oxidation of the cysteine residue.  
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3.4.3 Summary 
The selected mutations are predicted to have differing effects on the protein 
and comparison of the two models will provide more insight into the potential 
function of Zfp804a than a single model. Another benefit of using two parallel 
models is the reduction of the risk that one (or both) mutant(s) may not be 
viable, i.e. the mutation may be embryonic lethal in the homozygous form. This 
is potentially a problem with mutant Zfp804a models as Ramensky et al. (2002) 
found that proteins involved in transcription regulation display the highest 
selective pressure against deleterious non-synonymous SNPs when compared 
with other classes of proteins such as enzymes.  
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CHAPTER 4: Creating the mutant Zfp804a models 
 
4.1 Introduction 
To recapitulate chapter 3, we selected two mutations to re-derive for 
behavioural characterisation. The first, a nonsense mutation in exon 2 of 
Zfp804a, is predicted to prematurely truncate the protein at the beginning of the 
zinc finger domain with the transcript predicted to be destroyed by nonsense 
mediated decay. The other mutation, in exon 4 occurs 417 amino acids 
downstream from the N-terminal of the protein and is a cysteine to tyrosine 
substitution, which is predicted to influence the 3-D structure of the protein, 
given the involvement of cysteine in maintaining protein structure (e.g. Wolfe, 
Nekludova & Pabo, 1999). Both mutations are expected to disrupt the function 
of Zfp804a by causing aberrant protein-protein interactions. Comparison of the 
two models will provide more insight into the potential function of Zfp804a than 
a single model and provides an alternative model should one of the two be 
embryonic lethal.  
 Having identified mutations of interest, the next stage is to create mice 
carrying these mutations. The MRC Mary Lyon Centre, Harwell, hosts a large 
resource described in Chapter 3 (3.1) containing DNA and corresponding 
sperm for re-derivation by in vitro fertilisation (IVF) of wild-type surrogate 
mothers. IVF following such methods has been shown to be an effective means 
of re-deriving ENU mutants (Coghill et al., 2002).  However, once mice have 
been created or ‘re-derived’ carrying the mutations of interest, a cohort must be 
bred suitable for behavioural testing in number, age, genotype, gender etc.  
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Breeding a cohort of mice carrying mutations selected from ENU 
mutagenesis can be time-consuming and problematic. ENU is a mutagen that 
causes multiple mutations in the genome, meaning that these mutations may 
also be inherited, along with the mutation selected. Just how many mutations 
are caused by ENU mutagenesis is a matter of some debate although a 
consensus is now gradually being reached.  
The rate of mutations is affected primarily by the dosage of ENU that is 
administered (subject to a threshold level, Russell and Montgomery, 1982; 
Hitotsumachi et al., 1985; Lewis et al., 1991). Keays et al. (2006) review 
mutation rates over several studies. Of the four studies reported, the rates of 
coding (missense) mutations varied from 1 in 0.42Mb (Wienholds et al., 2003) 
to 1 in 1.82Mb (Quwailid et al., 2004). Quwailid and colleagues has been taken 
as a more reliable estimate as the mutation rate is based upon a larger 
sequence. The mouse haploid genome is estimated to be 2.6 billion bases (or 
2600Mb, Mouse Genome Sequencing Consortium, 2002). 2.3% of this is 
coding (Keays et al., 2006). This gives 59.8Mb of coding bases. Mutation rate 
of 1 in 1.82Mb of coding DNA gives an estimated mutation rate of 32.86 
mutations, or 33 corrected to the nearest integer. 
It is important to be able to estimate the number of mutations a mouse 
may carry in order to calculate how many backcrosses (breeding the mutant to 
a wild-type background, selecting for the chosen mutation, with the ultimate 
goal of congenicity) would be required to be confident of studying the mutation 
of interest in isolation and to estimate the likelihood of other mutations being 
responsible for any phenotypes observed. Backcrossing is the easiest method 
of isolating the mutation of interest (Coghill et al., 2002) and is relatively simple 
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(genotyping for the mutation of interest and selectively breeding that mutant 
with a wild-type). Keays, Clark and Flint (2006) discuss backcrossing and 
demonstrate that backcrossing is an efficient means of eliminating potentially 
confounding mutations. Mice in the Harwell DNA archive (G1) are the product 
of one parent (male) who was exposed to the ENU mutagen (and heterozygous 
for the selected mutation) and one wild-type mother. This G1 mouse will carry 
two copies of each chromosome, one copy carrying mutations from the father 
and one wild-type chromosome from the mother. Assuming 54.89Mb (figure 
used by Keays et al., 2006, taken from Ensembl) of the genome is coding in a 
male mouse, and using the rate of mutation of 1 in 1.82Mb (given in Quwailid et 
al., 2004, used as this study represents the largest [in bases] screen of all 
published screens), this estimates that the G1 mouse would have 30.16 (given 
as 31 in Keays et al.) potentially functional mutations. With each backcross 
onto a wild-type background, the number of mutations will decrease on average 
by 50%. Following this, G2 mice are likely to have 15.5 potentially functional 
mutations, G3 mice, 7.75 and and G4 3.88. So, after five backcrosses, a mouse 
(G6) is likely to harbour just one mutation (the mutation of interest selectively 
bred for). In this thesis it was decided to examine the G4 generation in order to 
gain some functional data in the time available. Although individuals in this 
generation are likely to harbour mutations other than the selected Zfp804a 
mutation, studying the G4 generation is justifiable (as the mice in any one 
genotype, line or gender group are unlikely to share the same set of additional 
mutations), especially as a means of preliminary screening for gross 
abnormalities or indicators of further areas to investigate. If necessary, tests 
can be repeated on purer animals. 
 101 
 Although estimates of additional mutations harboured are extremely 
helpful to the researcher, they give a deceptively simplistic picture of 
confidence in isolating the selected mutation. A major obstacle with residual 
mutations and backcrossing comes from linkage. Linkage occurs due to the 
way in which chromosomes recombine during germline cell division (see 
description of linkage in general introduction, section 1.5.2.2.). Keays et al. 
(2006) estimate the likelihood of another linked mutation being inherited along 
with the selected mutation for each chromosome. Zfp804a is found on 
chromosome 2 and mice were bred 3 generations from the founder mouse and 
then intercrossed. For mutations on chromosome 2 and 4th generation 
mutants, there is estimated to be a 32.8% probability that another mutation is 
linked (from estimations given by Keays et al., 2006). The chance that this 
mutation is missense is 64% (Keays et al., 2006) of this, resulting in a 21.0% 
chance that a missense mutation is linked to either of the mutations selected on 
Zfp804a. The potential for a linked mutations is another reason why it was 
thought prudent to follow up two mutations of interest, rather than a single 
model as there is a far lower (21.0% x 21.0% = 4.4%) chance that both 
selected mutations will be linked to another (which can only reliably be 
ascertained by sequencing around the mutation of interest) and it is extremely 
unlikely that both the selected  mutations in Zfp804a will be linked to the same 
‘other’ mutation. 
 It is important to note that although G4 mice are predicted to have 3.88 
potentially functional mutations (2.88 being residual, unwanted mutations) and 
there is a 21.0% chance that a missense mutation will be linked to the mutation 
of interest, these residual mutations do not pose as much of a problem as it 
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may appear. Individual mice will have different sets of residual mutations and 
the chances of any one mutation occurring more frequently in any one 
genotype and gender group are extremeley low. These residual mutations also 
may not interact with Zfp804a, affect brain function and may not have an 
influence on the performance of the mouse in behavioural tests administered. 
These issues are discussed in more detail in the Discussion of this chapter. 
Backcrossing - although an effective means of isolating the mutation of 
interest - can be time consuming. For example, backcrossing the mutation onto 
a wild-type background for five generations (assuming a gestation period of 3 
weeks, a further 5 weeks to reach sexual maturity and a further week to 
conceive, 9 weeks per generation) and then performing an intercross 
(heterozygous to heterozygous breeding to generate heterozygous and 
homozygous mutant and wild type littermate controls) would take upwards of a 
year, assuming no problems are encountered with fertility and breeding. One 
way to speed this up is through ‘speed congenics’. Speed congenics allows 
individual mice to be screened (through linkage analysis) for the relative 
contribution of each parental strain and uses data from mouse genomic 
analysis for marker-assisted selection of breeders.  The mouse/mice with the 
highest proportion of markers corresponding to the recipient strain genome 
(and therefore the lowest corresponding to the mutagenised strain genome) 
can then be selected for breeding at each generation. The method traditionally 
uses microsatellites as markers (e.g. Markel et al., 1997, reviewed in Wong, 
2002), although SNP panels are also readily available and are perhaps more 
suited for comparison to a reference genome as microsatellites are mutationally 
less stable than SNPs. Marker-assisted selection can be used on mice either 
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as pre-selected carriers of a mutation or the mice may have a phenotype of 
interest such as epilepsy (Legare et al., 2000) that the researchers wish to 
pinpoint. A search on PubMed yielded only one publication using marker-
assisted selection to speed up congenicity in the case of ENU mutants 
(Ogonuki et al., 2009). Wong (2002) estimates that using the speed congenics 
approach, full congenicity may be achieved in 5 generations (where the ‘best’ 
male could consist of 100% recipient genome but for the mutation of interest). 
Using the traditional backcrossing method, F5 mice would have 97% recipient 
genome. Similarly at G4, using speed congenics, mice could be 94% ‘pure’, as 
opposed to 87.5% by chance using the traditional method. Although it does 
speed up breeding, speed congenics can be problematic if sufficient numbers 
of mice to produce the full range of congenicity (in order to select the purest 
possible males) are not bred. It is also fairly resource intensive. The C57Bl/6J 
strain was chosen to be the recipient genome in this study for a number of 
reasons. 
C57Bl/6J is well-characterised genetically and was the first mouse strain 
to have the genome sequenced (Mouse Genome Sequencing Consortium et 
al., 2002). The strain is also frequently used for behavioural testing and so 
using this strain allows greater validity of results when comparing to other 
findings. The strain also breeds well which is especially important for ENU 
mutants due to the amount of breeding needing to be done to isolate the 
mutation of interest on a wild-type background. Mice are also long-lived, 
genetically tractable and have low comparative susceptibility to tumours. 
(Mouse Mutant Resource website, The Jackson Laboratory obtained July, 
2011).  
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4.2 Methods 
 
4.2.1 In vitro fertilisation 
IVF was performed by MRC Mammalian Genetics Unit (Harwell, Oxfordshire). 
Full details are provided in the Appendix (8.2). In brief, young sexually mature 
female mice were superovulated (ovulation was induced by administration of 
gonadotropin). Oocyte harvest, fertilisation and sperm dispersal dishes were 
prepared. Sperm was rapidly thawed and oocytes harvested from the 
superovulated females. Sperm and oocytes were added to the prepared 
fertilisation dish and incubated at 37C to allow fertilisation to occur. IVF 
success was scored and 2-cell embryos were transferred into pseudopregnant 
females to mature.  
 
4.2.2 Subjects and animal husbandry  
Subjects obtained from the MRC Mammalian Genetics Unit, Harwell were 
housed and bred in the Behavioural Neurosciences Laboratory, School of 
Psychology, Cardiff University. Mice were group housed in cages of 2-5 
subjects except where fighting or bullying necessitated single caging. Cages 
were environmentally enriched (with chew sticks and cardboard tubes) and 
standard laboratory food and water were available ad libitum. The light-dark 
cycle of the holding room was 12 hours with lights on at 07:00 and lights off at 
19:00. 
 Experimental animals were regularly monitored for signs of ill health. Any 
mice showing signs of illness were immediately assessed by the Named Animal 
Care and Welfare Officer and, if necessary, the University’s vet. Only mice 
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showing no signs of ill health were used for breeding. If necessary, mice were 
withdrawn from breeding and treated or sacrificed, dependent upon the nature 
and presumed severity of the illness. 
 
4.2.3 Breeding 
Mice were used for breeding from approximately one to three months of age. 
Females were introduced to the male’s home cage. If this was not possible then 
both male and female animals were introduced to a new cage. Tubing was 
removed from cages to facilitate breeding. Breeding cages ranged from one to 
four females with one male and breeding pairs/ harems were left undisturbed 
for one week. After this period females were checked for signs of pregnancy or 
a semen plug and left with the male for a further week if required. If any 
females were not pregnant following two weeks exposure to the male, they 
were removed from the breeding programme. If the male (by process of 
elimination) was not thought to be fertile, it was removed from the breeding 
programme.  
 
4.2.4 Tail biopsy 
See 2.7; Tail biopsy in General Materials and Methods 
 
4.2.5 Genotyping 
Genotyping methods followed those described in 2.2 used for mutation 
discovery but for substituting LC Green in the PCR master mix for double 
distilled H20. The LightScanner stage was also not performed as it was not 
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necessary. PCRs were cleaned as per protocol and sequencing was 
performed.  
 
4.2.6 Culling  
Mice no longer required for the breeding programme were culled according to 
the protocol outlined in 2.8 Culling protocol in General Materials and Methods.  
 
4.2.7 Linkage panel 
The Mouse LD (low density) Linkage Panel (Illumina, Inc) was used to 
genotype 377 SNPs in mice carrying the Zfp804a mutations (see 2.3.1 and 
figure 2.2 for methods). The SNPs were pre-selected by Illumina as they are 
known to be polymorphic between the 10 most common strains of mouse. 
Coverage is approximately four SNPs every 27Mb, with at least one of these 
four SNPs being informative for crosses involving the C57Bl/6J strain. The 
Panel uses the GoldenGate Gentoyping Assay protocol (Illumina, Inc). Full 
details of the protocol are provided on Illumina’s website (www.illumina.com).  
 Genomic DNA (gDNA) was normalised to 50 – 60 ng/µl (250ng minimum 
in total required). DNA was then ‘activated’ by treating it with streptavidin-biotin 
to prepare the gDNA for binding to paramagnetic particles. Assay 
oligonucleotides, hybridisation buffer and the paramagnetic particles were then 
added to the DNA for the hybridisation stage. Three oligonucleotides are 
provided for each SNP: two oligos are allele-specific and the third is designed 
to anneal several bases downstream from the allele that ligates to the extended 
allele-specific oligos in the next phase following several wash steps to remove 
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excess and mis-hybridised oligos. Following this, PCR is performed on the 
samples using three universal PCR primers. Single-stranded DNAs are 
hybridised to their complement bead. These products were then hybridised 
onto the BeadChip and dried to isolate the assay products for individual 
analysis. After the products were hybridised, the SNPs were analysed using the 
BeadArray Reader (which analyses fluorescence signal). This is then analysed 
by software for automated genotype clustering and calling. The GenomeStudio 
Genotyping Module uses a clustering algorithm to call genotypes, depending on 
the threshold set by the user. Further details of the software are contained in 
the Technical Note available online (www.illumina.com). Further analysis was 
performed in Microsoft Excel. 
 Figures 4.1 and 4.2 below show the layout of the results from the Mouse 
LD Linkage Panel. Figure 4.1 shows the SNP, the C57Bl/6J genotype, the 
chromosome, genomic position and quality score (1 is the highest). Columns J 
to P shown represent individual mice. Figure 4.2 is a different view of the same 
spreadsheet demonstrating how the estimated percentage C57Bl/6J was 
calculated (for the formula used, see figure 4.3). 
 
 
 
 
 
 
 108 
Figure 4.1 (above): Layout of results from G4i linkage panel showing the SNP, chromosome, 
position, C57Bl/6J genotype and genotypes of individual mice (per column). Each row 
represents a SNP and each column represents a mouse (J-P). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: Screenshot of the spreadsheet used to calculate % C57Bl/6J of the mice, 
demonstrating how the % congenicity was arrived at. 
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The percent congenicity of the mice (or % C57Bl/6J) was estimated by the 
proportion of successfully genotyped alleles that were of C57Bl/6J origin (see 
Figure 4.3). The equation below illustrates how the percent C57Bl/6J 
congenicity for each mouse was then calculated, where N=number of SNPs 
successfully genotyped, het= number of SNPs heterozygous (1 allele C57Bl/6J, 
1 allele BALB/c or C3H/HeJ), hom=number of SNPs homozygous (both alleles 
non-C57Bl/6J),  
 
 
Figure 4.3: Equation to demonstrate the calculation of percentage congenicity for C57Bl/6J 
Due to comparatively low numbers of markers used, the data were not suitable 
to be analysed by programs such as PLINK (a whole-genome data analysis 
toolset). 
 
 
 
 
 
 
 
 
100
(hom))5.0(
/657% 


N
hetN
JBlC
 110 
4.3 Results  
4.3.1 IVF 
In vitro fertilisation attempts for both the C59X and the C417Y lines were 
successful. One hundred embryos for each line were transferred into 
pseudopregnant female mice. IVF for the C417Y line was more successful than 
for the C59X line although there was no significant difference. The proportion of 
male to female pups was fairly equal for both lines. Table 4.1, below, 
summarises the results of the IVF. 
Mutation Number of 
embryos 
transferred 
Number of 
pups received 
Males  Females 
C59X 100 44 22 22 
C417Y 100 61 26 35 
Table 4.1: Summary of IVF results for C59X and C417Y lines  
4.3.2 Breeding the C59X and C417Y lines 
Generation Line Males Females 
G2 C59X 5  Zfp804a
C59X/+
 10 Zfp804a
+/+ 
G2 C417Y 9 Zfp804a
C417Y/+
 18 Zfp804a
+/+
 
G3 C59X 6  Zfp804a
 C59X/+
 24 Zfp804a
+/+
 
G3 C59X 2 Zfp804a
+/+
 2  Zfp804a
 C59X/+
 
G3 C417Y 4  Zfp804a
C417Y/+
 16 Zfp804a
+/+
 
G3 C417Y 2 Zfp804a
+/+
 2 Zfp804a
C417Y/+
 
G4 C59X 11  Zfp804a
C417Y/+
 13  Zfp804a
 C59X/+
 
G4 C417Y 9 Zfp804a
C417Y/+
 10  Zfp804a
C417Y/+
 
Table 4.2 Summary of mutant breeding for generations G2 to G4 by line and gender 
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The table above (Table 4.2) shows the numbers of mutants at each generation 
used for breeding. Of the 44 mice (G2) of the C59X line received from MRC 
Mary Lyon Centre, only 5 of these mice were heterozygous mutant males and 9 
of the 61 mice received for the C417Y line were heterozygous mutant males 
carrying the C417Y mutation. These figures are surprising as it would be 
expected by Mendelian inheritance that 11 of the 22 males received from the 
C59X line would be homozygous for the mutation and 13 of the 26 males 
received for the C417Y line would be homozygous for that mutation. These 
differences were not however significant in a chi-squared test. These mice 
received from the MRC Mammalian Genetics Unit were used to breed the G3 
with C57Bl/6J wild-type females and so forth as detailed in the table. The 
diagram below (Figure 4.4), outlines the breeding programme used to generate 
the experimental cohort, the G4i (intercross) generation.  
 All G2 progeny received from the MRC Mammalian Genetics Unit, Harwell 
were genotyped and sexed. All females and any male wild-types were culled 
and homozygous mutant males were bred with wild-type C57Bl/6J females. 
The resultant G3 offspring were again genotyped and all wild-types killed. 
Heterozygous mutants were crossed with C57Bl/6J wild-types. G4 offspring 
were again genotyped and heterozygous intercrosses (within the same line) 
were set up to produce the experimental cohort containing heterozygous and 
homozygous mutants and wild-type littermate controls. 
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Figure 4.4: Flow diagram to show breeding programme for the generation of the G4i 
 
 
 
C59X and C417Y 
thawed sperm ♂  
G2 ♂ progeny 
sent from Harwell 
G3 ♂ Zfp804amut/+  
and ♀ Zfp804amut/+   
Killed 
Zfp804a+/+  
and all 
females 
Zfp804a+/+  
♀ 
(C57Bl/6J) 
X 
X 
X 
X 
Killed 
Zfp804a+/+  
G1 
G2 
G3 
G4 
G4i 
Zfp804a+/+  
♀ 
(C57Bl/6J) 
Zfp804a+/+  
♀ 
(C57Bl/6J) 
G3 ♂ Zfp804amut/+  
and ♀ Zfp804amut/+   
G4 ♂ Zfp804amut/+  
and ♀ Zfp804amut/+   
  
G4i ♂ Zfp804amut/+ , Zfp804amut/mut  , 
Zfp804a+/+   and ♀Zfp804amut/+ , 
Zfp804amut/mut  , Zfp804a+/+    
Killed 
Zfp804a+/+  
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4.3.3 Speed congenics 
Two linkage panels were used in this chapter, one on the G3 generation to 
assist selection of breeders and one on the G4i generation to confirm estimates 
of percentage congenicity. The rate of successful SNPs genotyped by 
generation (Table 4.3) and the results from each linkage panel are provided 
(Tables 4.4 and 4.5). 
Number of SNPs 
genotyped 
Generation Number SNPs 
successful 
% SNPs successful 
377 G3 337 89.3 
377 G4i 117 31 
Table 4.3: Summary of SNPs successfully genotyped in the linkage panel by generation 
In the G4i linkage panel, far fewer SNPs were successfully genotyped than in 
the G3 linkage panel, thought to be due to reagent degradation as reagents 
were used after nine months of the receipt of the reagents. However, the 
successful SNPs (in both linkage panels) all were rated with a Gentrain score 
(a score of confidence of the genotyping score) of >0.64 (where 1 is the 
maximum). This confidence threshold is used by others in the laboratory (Kiran 
Mantripragada, personal communication, 2009), indicating that the successful 
SNPs in this linkage panel were reliable. 
 Tables 4.4 – 4.6 show the results of the linkage panels for G3, G4i and 
C57Bl/6J controls respectively. The average percentage of SNPs conforming to 
the Illumina C57Bl/6J genotype at that locus is given and is used to infer an 
estimate of C57Bl/6J congenicity. 
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Generation Mouse 
ID 
Estimated %         
C57Bl/6J 
Generation Mouse ID Estimated %         
C57Bl/6J 
G3 F3.2 88.18 G3 F15.1 80.03 
G3 F5.3 88.98 G3 F19.7 84.35 
G3 F11.4 86.42 G3 F4.3 86.74 
G3 F15.6 81.15 G3 F7.4 85.30 
G3 
F1.6 88.34 G3 F21.5 
 
84.35 
G3 
F5.6 88.98 G3 F19.9 85.94 
G3 F12.1 85.30 G3 F4.5 87.86 
G3 F18.2 84.50 G3 F3.5 84.03 
G3 F1.7 77.96 G3 F20.3 87.86 
G3 F5.7 84.66 G3 F7.2 87.54 
G3 F12.4 
F18.5 
83.87 
86.42 
G3 
F14.5 86.42 
G3 F1.8 82.75 G3 
F19.6 90.58 
G3 F6.2 83.55 G3 F3.7 83.87 
G3 F12.5 82.75 G3 F7.3 89.14 
G3 F18.6 86.26 G3 AVERAGE 85.45 
G3 F3.6 84.98 
Table 4.4: Summary of results by mouse for G3 linkage panel  
Generation Mouse 
ID 
Estimated %         
C57Bl/6J 
Generation Mouse ID Estimated %         
C57Bl/6J 
G4i Z6B 96.12 G4i Z9C 96.85 
G4i S5B 96.12 G4i S16A 98.25 
G4i Z18B 94.4 G4i S17A 94.78 
G4i S10D 94.78 G4i Z2E 97.81 
G4i S8D 96.88 G4i S14B 94.30 
G4i S4C 96.05 G4i S5C 89.38 
G4i S5A 97.83 G4i Z17D 94.2 
G4i S9A 97.83 G4i Z15B 98.67 
G4i S2B 97.41 G4i S4D 89.47 
G4i S14A 97.39 G4i AVERAGE 96.13 
 
G4i Z16A 97.39 
      Table 4.5: Summary of results by mouse for G4i linkage panel 
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Generation Mouse ID Estimated %         
C57Bl/6J 
C57Bl/6J  
control 
BL627 99.57 
C57Bl/6J 
control 
BL628 100 
C57Bl/6J 
control 
BL629 100 
C57Bl/6J 
control 
BL630 100 
C57Bl/6J 
control 
BL631 100 
C57Bl/6J 
control 
BL632 100 
      Table 4.6 Summary of results by mouse for C57Bl/6J controls 
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4.4 Discussion 
This chapter provides further evidence that mutant mice can be successfully 
created from ENU mutagenesis, and that the procedures adopted in this 
protocol for mutation detection and re-derivation were successful. Mice for both 
mutant lines were successfully created and bred to third generation, and an 
estimate made of congenicity. G4, although some argue is not ideal to study, is 
valid, especially as a means of preliminary screening for gross abnormalities or 
indicators of further areas to investigate. If necessary, tests can be repeated on 
purer animals. 
4.4.1 Residual mutations 
As previously mentioned (4.1), the chances of any two mice in the same group 
having the same residual mutation are extremely low. Using the mutation rate 
adopted by Keays et al. (2006) assuming the founder mouse had 31 mutations, 
there is therefore a ‘pool’ of 31 mutations which any offspring from that mouse 
may have. On average, a G4 mouse will have approximately 4 mutations (3 of 
which are unwanted; see the introduction of this chapter for an explanation). 
This gives a probability of a specific mouse having any specific unwanted 
mutation of 0.1 (3/30=0.1). This gives a probability of any two specific mice 
having the same specific unwanted mutation of 0.01 (0.1x0.1=0.01). This figure 
becomes smaller with the addition of the likelihood that the mice are in the 
same experimental group (by gender, genotype and line). It can be seen 
therefore that the issue of potential confounding residual mutations is minimal. 
This however, is not taking into account the potential problem of other linked 
mutations. The issue of how likely mice are to have the same residual 
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mutations is further complicated by other issues such as gender, parentage, 
and the chances of any one mutation. However, the chance of recurring 
residual mutations in groups is extremely unlikely. Standard errors obtained 
from behavioural tasks and whether or not the wild-type mice can be grouped 
statistically will give an idea of whether or not the other residual mutations are 
causing problems. It is important to state that this issue of other mutations is 
not unique to ENU-derived models and other approaches to a genetic mouse 
model are equally likely to have confounding factors. Background variation is 
apparent in the creation of all genetic mouse models as all strains of mice have 
variation at SNPs and many strains carry a mutation such as the 129 strain’s 
Disc1 deletion or Harlan’s deletion in the α-synuclein locus in a C57Bl/6J 
substrain (discussed in 1.6.2.1). Moreover, any crossing of a mutation onto a 
different background strain will result in some variance in genetic background 
between subjects in the same experimental group. Backcrossing, as well as a 
means of isolating the mutation of interest, is also a strategy to minimise 
differences in genetic background between subjects, making the background as 
homogeneous as possible. With ENU mutants, because of the residual 
mutations,  researchers are often more cautious with background genetics and 
so tend to backcross for more generations than perhaps researchers looking at 
other models such as knockout models who may only backcross for two 
generations (Pat Nolan, personal communication, 2012). 
One point to note is that mice, and all wild species,  have naturally 
occurring mutations and it could be argued that it is more ecologically valid ( i.e. 
more akin to the human population) to have some genetic differences between 
the subjects (although these populations are not suited to studying in small 
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groups, such as this study). Additionally, not every gene is expressed in the 
brain (although the majority are). It was recently found that a minimum of 82% 
of genes are expressed in the brain and so therefore may influence brain 
function (Human Brain Map, Allen Brain Atlas, 2009).   
As previously stated, there is a 20.1% chance that there will be a linked 
mutation that is inherited along with the C59X or C417Y mutations, or a 4.4% 
chance that there will be a mutation linked to both the C59X and C417Y 
mutations. Additionally, the chances that the mutation linked to the C59X and 
C417Y mutations is the same are extremely small. With the little currently 
known about ZNF804A and Zfp804a, it is extremely difficult and not useful to 
speculate on what we might observe (behaviourally) if there is indeed a linked 
mutation. Until we are able to characterise the lines molecularly with the use of 
a reliable antibody, it is a consideration not easily excluded short of sequencing 
large regions either side of the mutations.  
 Searching for genes surrounding Zfp804a (UCSC Genome Browser, 
http://genome.ucsc.edu/) revealed many genes and did not prove particularly 
helpful in terms of guessing the influence of potential linked mutations as it is 
not known what region of chromosome 2 is likely to be inherited through linkage 
in the G4i generation.    
 
4.4.2 Speed congenics  
This chapter presents the development of the Zfp804a mutant lines with a trial 
of the ‘speed congenics’ approach described in Ogonuki et al. (2009) although 
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the protocol was not followed. The approach used in this thesis had both 
successes and failures as a means of effectively speeding up congenicity.  
The speed congenics approach used in this chapter provided scientific 
assessment of and confidence in the level of congenicity of the mice as 
opposed to the conventional probabilistic assessment of congenicity used in 
simple backcrossing. It has demonstrated that a novel method could work, 
provided sufficient numbers of mice are bred to make the approach work well, 
i.e. sufficient numbers of mice to generate a spread of levels of inheritance of 
the C57Bl/6J parental genome so the ‘best’ mice can be selected. 
 Ogonuki et al. (2009) bred to 100% congenicity in 5 generations using 
microsatellite marker-assisted selection, whereas 96.13% was achieved in this 
chapter with 4 generations. However, due to the numbers of mice the linkage 
panel was carried out on, the most C57Bl/6J-congenic  mice were not able to 
be selected in the breeding program, instead the lowest congenicity were 
excluded. As well as increased numbers of mice, confidence in estimates of 
congenicity would have been improved with a higher density linkage panel, i.e. 
a linkage panel containing upwards of 1000 SNPs rather than a 377 SNP 
panel, especially if there is not a high success rate of successfully genotyped 
SNPs. 
To conclude, this chapter has successfully created 2 parallel Zfp804a 
mutant lines harbouring the C59X and C417Y mutations described in Chapter 
3. There are some potential problems with the models but characterisation and 
investigation of these models will provide some insight into whether these are in 
fact issues.  
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CHAPTER 5: Initial characterisation of Zfp804a mutants; 
assessment of general viability and preliminary behavioural 
screen 
5.1 Introduction  
In Chapter 4, the creation of two novel mouse lines carrying mutations in 
Zfp804a was described. This chapter is concerned with the initial physiological 
and behavioural characterisation of the mutants. These mutant lines are the 
first available animal models for human ZNF804A, a largely unknown gene in 
terms of function. Preliminary investigations with any novel mouse model are 
important in several ways. They give an indication of the viability of the model 
including any physical deficits the model may have which could confound future 
analyses, in particular with respect to behavioural tasks. The screen can also 
provide indications of phenotypes that warrant further investigation per se. 
These were the primary goals of Chapters 5 and 6. Once the presence of 
confounding deficits are excluded or noted however, it will be of further interest 
to examine the differences between the genotypes and between the two lines, 
C59X and C417Y. The latter will be of especial interest as there is, at the time 
of writing, no biochemical analysis of the mutations so it will give us some initial 
pointers as to whether or not the two mutations are impacting on function 
differently.  
Characterisation of the mutants at an early stage is also important to 
assess the validity of one of the potential criticisms of this work, inherent in 
using ENU-derived animal models in the first few generations of backcrossing 
(as noted in Chapter 4, in order to gain some functional data in the thesis it was 
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decided to analyse mice from the G4i  generation). Measures of standard 
deviation in behavioural tasks for animals within groups and the similarity 
between wild-types from the two separate lines (as wild-types should carry the 
same amount of residual mutations as the ‘mutants’ but not the Zfp804a 
mutations) might be informative. 
 There has been mixed evidence regarding the interaction between 
biological sex and ZNF804A. Sex does not appear to affect association with 
rs1344706 (O’Donovan, personal communication) whereas another SNP, 
rs7597593, shows association with schizophrenia in females, but not in males 
(Zhang et al., 2011). As both males and females were investigated in the 
present work, the analysis of the data obtained in these preliminary studies may 
also give us an idea of whether or not sex interacts with the mutations selected 
for study. With female mice, it is important to be aware of the potential effects of 
the stage of oestrus cycle on behaviour (e.g. Marcondes et al., 2001; Sousa, 
Almeida & Wotjak, 2006) and to conduct analyses to investigate whether or not 
this has an impact on results, and could explain any differences observed 
amongst the female mice. In order to do this, it is necessary to obtain vaginal 
cells at the time of each test, which can be done with a simple and relatively 
non-invasive smearing procedure. 
This chapter assessed the initial viability and some preliminary 
behaviour of the G4i generation. As discussed in Chapter 4, this generation is 
not ideal due to the possibility of residual, potentially confounding ‘non-specific’ 
ENU mutations. However, it was considered valid to exploit this early 
generation in order to get advance notice of the general viability of the mutant 
lines and provide some indications of possible behavioural phenotypes for 
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further investigation. Necessarily, most of the G4 generation (used to breed the 
G4i line) were needed for further backcross breeding. Additionally, even a 
‘preliminary’ analysis of the type reported here required substantial numbers of 
experimental animals; 12 groups (2 lines, 3 genotypes [wild type, heterozygous 
mutants and homozygous mutants], male and female). Together with time 
constraints, these practical issues dictated that some of the group sizes in this 
section were relatively small.  
Throughout this chapter, all 12 groups of mice were treated identically 
with the exception, that females underwent vaginal smearing on the day of 
testing, post-experiment.  For clarity, the data are described in terms of the 
main experimental groups (i.e. C59X and C417Y, genotype, males and 
females). Wild-types for both lines were treated as separate groups. The 
groupings were planned a priori.  
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5.2 Materials and methods 
 
5.2.1 Subjects and animal husbandry 
An experimental cohort of G4i   (G4, heterozygous x heterozygous intercross) 
C59X and C417Y mice (aged 3-9 months) and littermate wildtype controls were 
subjected to general observation and a number of discrete physiological and 
behavioural tests. General housing, handling and behavioural testing conditions 
were as described in chapter 2, General Materials and Methods (2.5). The 
number of mice (n) used in each assay is summarised in the tables below 
(table 5.1 and 5.2 for the C59X and C417Y lines respectively): 
 
C59X Genotype and n 
Test ♂  
Zfp804a+/+ 
♂  
Zfp804a 
+/C59X 
♂ 
Zfp804a 
C59X/C59X 
♀  
Zfp804a +/+ 
♀ 
Zfp804a 
+/C59X 
♀  
Zfp804a 
C59X/C59X 
Weights 
from birth 
6 5 1 1 5 2 
Brain 
weights 
(adult) 
5 4 4 5 5 5 
Body 
weights 
(adult) 
8 9 4 10 10 10 
PhenoTyper 
cages 
8 - 4 - - - 
Rotarod 8 9 4 10 10 10 
Table 5.1: Number of mice, byexperimental group (genotype [wild-type, heterozygous mutant, 
homozygous mutant] and sex [male, female]) used in each measure in the C59X line 
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C417Y Genotype and n 
Test ♂  
Zfp804a +/+ 
♂ 
Zfp804a 
+/C417Y 
♂ 
Zfp804a 
C417Y/C417Y 
♀ 
Zfp804a 
+/+ 
♀ 
Zfp804a 
+/C417Y 
♀  
Zfp804a 
C417Y/C417Y 
Weights 
from birth 
6 6 2 1 4 3 
Brain 
weights 
(adult) 
5 5 5 5 5 5 
Body 
weights 
(adult) 
7 14 8 8 12 9 
PhenoTyper 
cages 
7 - 8 - - - 
Rotarod 7 14 8 8 12 9 
Table 5.2: Number of mice, byexperimental group (genotype [wild-type, heterozygous mutant, 
homozygous mutant] and sex [male, female]) used in each measure in the C417Y line 
 
Physiological measures: 
5.2.2. Body weight assessments 
A subset of mice was weighed daily for the first 6 weeks of life and identified by 
a coloured spot on the abdomen, back or the base of the tail (dependent on 
stage of development). Final body weight was measured at death for all mice. 
Mice had access to ad libitum water and standard laboratory chow throughout 
their life course. 
  
5.2.3 Brain weight assessment 
Brains were extracted as described in chapter 2.9 and weighed immediately 
following death, with the olfactory bulbs removed.  
 
5.2.4 Oestrus cycle status 
Oestrus status was determined by vaginal smearing immediately following a 
behavioural procedure (as described in the General Methods, 2.5.3). The data 
from the behavioural tests was then analysed to assess whether or not there 
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was a correlation between the behavioural data and the stage of oestrus of a 
particular mouse.  
 
Behavioural measures: 
5.2.5 ‘PhenoTyper’ homecage environment 
A subset of subjects was observed in PhenoTyper cages (Noldus, described in 
chapter 2.6.2) for 24 hours from between 07:00 and 09:00 with 12 hours of light 
and 12 hours of darkness. These cages are designed to replicate a temporary 
home cage environment and can provide a useful initial behavioural screen 
across a wide variety of measures, including general activity, consumatory 
behaviour, bouts of activity on an exercise wheel and general indices of 
circadian function and sleep. Data was recorded by automated software and 
the mouse was tracked for the duration using a heat-sensitive camera.  
 
5.2.6 Rotarod 
Subjects were tested on the Rotarod apparatus (as described in chapter 2.6.1) 
to assess motor learning, motor function, balance and coordination. Subjects 
underwent 3 trials separated by at least 30 minutes (to allow for recovery). In 
the trial, the rotating rod constantly accelerated over 5 minutes, up to a 
maximum of 48rpm. The latency to fall off the apparatus was noted up to a 
maximum of 500 seconds. 
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5.2.7 Statistical analyses 
Experimental data were analysed using SPSS PASW Statistics, release 18.0 
(IBM SPSS Inc., 2009, Chicago). Data were subjected to One Way, Two Way 
or multivariate AN(C)OVA (if normal or One Way Kruskal-Wallis ANOVA if data 
did not conform to normality estimates, Levene’s test, p>0.05). All comparisons 
were planned a priori and corrections for multiple testing were not made.  
Significance was defined as p<0.05.  
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5.3 Results 
 
5.3.1 Generation of experimental cohort 
Table 5.3 shows the number of animals paired to generate the G4i cohort. 
There were no significant differences observed in the birth ratios for males and 
females or by genotype. From the animals paired, 3 Zfp804a+/C59X and 2 
Zfp804a+/C417Y mice failed to conceive. Additionally, 2 of the C417Y litters were 
killed by their mothers. Thus the average litter size for the C59X line was 10.9 
and 11.3 for the C417Y line. Not all of the animals born were used in the 
experimental cohort.  
Line Pairings (n) Offspring: genotype (n) 
 G4 ♂ 
+/mut 
G4 ♀ +/mut ♂ +/+ ♂ +/mut ♂ mut/mut ♀ +/+ ♀ +/mut ♀ mut/mut
 
C59X 11 13 15 25 4 21 27 17 
C417Y 9 10 8 14 9 8 16 13 
Table 5.3: Number of (G4) heterozygous mutant animals paired to breed the G4i (experimental)  
cohort for each line and consequent births observed. Mut is used to denote the mutation, C59X 
or C417Y. 
 
5.3.2 Early development of mutant lines  
Weight gain from birth until 6 weeks post-natal was used as a general proxy of 
early development (see Figures 5.1 and 5.2). Statistical analyses was not 
performed on these data as group sizes in some instances were too small to 
analyse (i.e male Zfp804aC59X/C59X and female Zfp804a +/+ for both lines had 
n=1), however, from simple by eye observations, males seem to be heavier 
than females, which would be expected. This sex difference in weight seems to 
emerge at about 3 weeks. 
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Males (both lines): growth from birth
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Figure 5.1: Mean average body weight gain from P1 to P45 in males (C59X and C417Y lines) 
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Females (both lines): growth from birth
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Figure 5.2: Mean average body weight gain from P1 to P45 in females (C59X and C417Y lines) 
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5.3.3. Gross physical appearance of adult mutants and general 
observation 
The photos in figure 5.3 show the gross physical appearance of the mutant 
lines, (males only shown), when adult. There were no gross observable 
physical deficits found in the mutant mice and on general observation the 
mutants appeared identical to their wild-type littermate controls. As the mutation 
was bred from a Balb/c x C3H/HeJ cross onto a C57Bl/6J background, there is 
some variation between the mice in terms of coat colour. The majority of the 
mice were black with the remaining mice having agouti coats. 
  
a) Zfp804aC59X/C59X ♂  b) Zfp804a+/+ ♂ (C59X line) 
 
 
 
 
 
 
c) Zfp804aC417Y/C417Y ♂ d) Zfp804a+/+ ♂ (C417Y line) 
Figure 5.3: The physical appearance of the mutants, from left to right, top to 
bottom: a) Zfp804aC59X/C59X male b) Zfp804a+/+male(C59X line) c) 
Zfp804aC417Y/C417Y male d) Zfp804a+/+ male(C417Y line) 
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Continuous monitoring of health and welfare of the animals by the experimenter 
and animal technicians throughout the periods of both development and 
experimentation revealed no abnormal health problems segregating with any 
particular group. During the testing period the mortality rate of the mutant lines 
did not differ from that of WT littermate controls (1 female mouse was found 
dead, Zfp804aC59X/C59X). As the mice were not allowed to age to the point of 
natural death (subjects were culled at c. 8 months of age average) the effects 
of the mutations on frank ageing remain unknown to date. Animals were 
excluded from further testing if they became sick and did not show signs of 
improving after two days of illness (2 males, Zfp804aC417Y/+ and Zfp804aC59X/+and 
1 female, Zfp804a+/+ from the C417Y line). Mice which were bullied to the point 
of detrimental health effects were also removed from further testing (1 male 
mouse, Zfp804a+/+) as were any pregnant mice (1 female mouse, 
Zfp804aC417Y/+). Few mice were excluded in practice and, overall, exclusions 
did not segregate with any line, genotype or sex. 
 
5.3.4. Adult body and brain weights 
Differences in adult body and brain weights taken at death, around 8 months on 
average, were observed (see figure 5.4 for mean average body weights at 
death, by experimental group). A 2-way ANOVA with factors sex (male/female) 
and genotype (wild-type, heterozygous mutant, homozygous mutant) for each 
line, revealed significant differences between the experimental groups in terms 
of body weight. As would be expected, there was a main effect of sex in both 
lines. Males (C59X mean [M] = 36.10g, standard deviation [SD ]= 3.89, C417Y 
M=34.63, SD=3.52) were significantly heavier than females (C59X M = 29.07g, 
 132 
Body weights at death
G
ra
m
s
10
20
30
40
SD = 4.26, C417Y M=27.66, SD=3.82), F(1,51) = 41.43, p<0.0001 for the C59X 
line and F(1,57) = 47.59, p<0.0001 for the C417Y line. There was also a main 
effect of genotype on body weight in the C59X line, F(2,51) = 16.32, p<0.0001. 
The homozygous mutants independent of sex (M = 26.74g, SD = 3.66) were 
significantly lighter than both the heterozygous mutants (M = 34.3g, SD = 4.13) 
and the wild-type mutants (M = 33.67g, SD = 5.04). There were no differences 
observed between the heterozygous and wild-type mutants in this line. In the 
C417Y line, there was no impact of genotype on body weight (F(2,57) = 3.013, 
p>0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4: Graph (above) showing mean average body weights at death, by experimental 
group (sex, line and genotype), with key (right of figure). Standard error of the mean bars are 
shown 
 
From looking at the graph overleaf (figure 5.5), it would appear that the 
homozygous male mutants in the C59X line had lighter brain weights than their 
heterozygous mutant and wild-type littermate controls. However, an ANCOVA, 
with factors sex (male/female) and genotype (wild-type, heterozygous mutant, 
homozygous mutant) for each line, co-varying for body weight revealed that this 
was not the case (F(2,28)=0.96, p>0.05). Although body weight had no 
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significant impact on brain weight (not reported) in the C59X line, in the C417Y 
line it did (F(1,30)=4.86, p=0.037). Additionally, in the C417Y line, there was a 
main effect of gender which revealed that females had heavier brains than the 
males, independent of body weight (F(1,30)=10.20, p=0.004, females M=0.43, 
SD=0.02, males M=0.41, SD=0.02). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5: Graph (above) showing mean average brain weights at death, by experimental 
group (sex, line and genotype), with key (right of figure). Standard error of the mean bars are 
shown 
 
5.3.5. Reactivity of the mutant lines to general handling 
All subjects were handled from weaning age, at least weekly. Most animals 
showed some signs of distress during initial handling (including vocalisation, 
fecal deposition, urination and struggling). There were no apparent sex, line or 
genotype effects on these behaviours with all subjects reacting to careful 
handling in a similar way.  Only one mouse from the experimental cohort 
showed particular signs of aggression or anomalous behaviour, taking the 
opportunity to bite the experimenter whenever possible. This mouse was a 
male heterozygous for the C59X mutation and was the only mouse from the 
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group of 10 mice of the same sex, line or genotype, meaning any systematic 
relation of the aggression to genotype was likely to be spurious. Prior to 
behavioural testing mice were handled daily for at least two weeks. Testing 
began at approximately 8 weeks and mice were well accustomed to handling in 
general by this point. All female mice responded with signs of distress 
(unsurprisingly) to the vaginal smearing procedure with some habituation to the 
procedure over time. Habituation to the procedure did not appear to segregate 
with any particular line or genotype.  
 
5.3.6 Behaviour monitored in the PhenoTyper cages 
Due to time constraints, only a subset of mice was examined in the 
PhenoTyper homecage environment. Details of animals examined are provided 
in tables 5.1 and 5.2. In brief, up to 8 homozygous male mutants and wild-types 
of each line were tested and behaviour was recorded.  
 
5.3.6.1 General activity      
Following an initial spurt of activity in the first 3-hour bin measured in the 
Phenotyper Home Cage Environment (due to exploration of a novel 
environment), mice habituated somewhat and the level of activity reduced (see 
figure 5.6). There was another increase in activity after the lights went out after 
12 hours in the cages. A significant difference in activity during this 3-hour 
period in the C417Y line was discovered using MANOVA (factor: genotype) to 
examine distance travelled in each of the 8 3-hour bins in the 24 hours between 
the genotypes.Homozygous mutant mice were more active than wild-types 
(indexed by cm travelled on the cage floor, M=25 657.73cm, SD=8364.37, 
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M=16 293.08cm, SD=7870.46 respectively, F(1,26)=8.93, p=0.006. There were 
no other differences between the two genotypes examined in the C417Y line 
and none in the C59X line in the 24 hours spent in the phenotypers in general 
activity in the cages, data not reported. 
 
General activity in the Phenotyper cages (total distance moved)
Time periods
Start - 3hrs 3-6hrs 6-9hrs 9-12hrs 12-15hrs 15-18hrs 18-21hrs 21-24hrs
D
is
ta
n
c
e
 t
ra
v
e
lle
d
 (
c
m
)
0
10000
20000
30000
40000
50000
Zfp804a+/+(C59X) 
Zfp804aC59X/C59X 
Zfp804a+/+(C417Y line) 
Zfp804a(C417Y/C417Y) 
 
Figure 5.6: Graph (above) showing general activity (indexed by distance travelled on the cage 
floor in cm) in the PhenoTyper cages over 24 hours by line and genotype. Dashed line indicates 
when lights were turned off, after 12 hours in the phenotyper cages. Mean averages of the 
experimental group and SEM (error bar) are shown. 
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5.3.6.2 Exercise wheel 
In each of the lines, bouts of activity, measured by time spent on the exercise 
wheel, were measured in homozygous mutants and wildtypes using MANOVA 
(factor: genotype) to look at total time spent on the exercise wheel in each of 
the 8 3-hour bins. There were no significant differences in bouts of activity 
between the genotypes for either of the lines in any of the 3-hour bins (data not 
reported). From examination of the graph (figure 5.7) showing the mean 
average time (seconds) spent on the activity wheel with standard error of the 
mean marked, this lack of difference between the genotypes is likely due to 
fairly large size of the standard errors. 
Bouts of activity: total time spent on exercise wheel
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Figure 5.7: Graph (above) showing time (s) spent on the exercise wheel in the PhenoTyper 
cages over 24 hours by line and genotype. Dashed line indicates when lights were turned off, 
after 12 hours in the cages. Mean averages of the experimental group and SEM (error bar) are 
shown. 
Time spent in the phenotyper cages in hours, 
by 3-hour bin 
 137 
5.3.6.3 Feeding and drinking behaviour 
Figure 5.8 shows the total amount of food and water consumed in the 
phenotyper cages during the 24 hours for both genotypes of both lines. As is 
apparent in the graph, there were no differences in food or water consumed 
between the genotypes for either the C59X line (food: F(1,11)=0.164, p>0.05, 
water: F(1,11) = 0.118, p>0.05) or the C417Y line (food: F(1,26)=0.142, p>0.05, 
water: F(1,26) = 0.361, p>0.05), mean grams consumed and standard 
deviations are given in the table below (table 5.4).Data analysed by MANOVA 
(factor: genotype x total amount of food consumed and total amount fo water 
consumed). It is interesting to note that the homozygous mutants in the C59X 
line did not consume less food than their wild-type counterparts as their body 
weights were significantly lower (see 5.3.4).Data are shown in figure 5.8. 
 
 
 C59X line C417Y line 
Zfp804a+/+ Zfp804aC59X/C59X Zfp804a+/+ Zfp804aC417Y/C417
Y 
M 
(grams) 
SD M 
(grams) 
SD M 
(grams) 
SD M  
(grams) 
SD 
Food 5.88 2.47 5.25 2.63 5.6 3.33 5.08 3.78 
Water 5.63 1.92 6 1.41 5.27 1.94 4.83 1.75 
Table 5.4: Table showing mean grams and standard deviations of food and water consumed by 
homozygous mutants and wild-types in 24 hours in the phenotyper cages, by line and 
genotype. 
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Figure 5.8: Graph (above) showing mean average food and water consumed in the 
PhenoTyper cages over 24 hours by line and genotype. SEMs (error bars) are shown. 
 
 
5.3.6.4 Time spent in the hidden shelter 
Figure 5.9 shows a striking picture of results of total time spent in the hidden 
shelter (presumed to be sleeping) by genotype and line in the phenotyper 
cages in 24 hours. MANOVA (factor: genotype x total time spent in the hidden 
shelter in each of the 8 3-hour bins) revealed that there were however, no 
differences between the homozygous mutants and the wild-type mice in time 
spent in the hidden shelter for either line (statistics not reported). The most 
striking observation is the time spent in the shelter by C417Y line wild-types, 
apparently almost three times more time than their homozygous mutant 
counterparts. However, this result was largely produced by 2 outliers (out of 8 
subjects in this experimental group). For example, in bin 2, representing 3-
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6hours in the phenotyper cages, the mean average for the wild-types of the 
C417Y line was 1248.42 seconds spent in the hidden shelter over 3 hours 
(SD=2985.91), whereas if the 2 outliers were removed, the mean average time 
spent in the shelter was reduced dramatically to 123.22 seconds (SD=71.31), 
mirroring the trend shown by the C417Y homozygous mutants and both 
genotypes in the C59X line. This finding would be interesting to investigate 
further in the two outlier mice. 
Total time spent in hidden shelter (duration)
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Figure 5.9: Graph (above) showing mean average time spent in the hidden shelter zone in the 
PhenoTyper cages over 24 hours by line and genotype. Dashed line indicates when lights were 
turned off, at 12 hours. SEM error bars are also shown.  
Time spent in the phenotyper cages in hours, 
by 3-hour bin 
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5.3.7 Behaviour monitored on the RotaRod 
 
Time stayed on the RotaRod by session, line and genotype (males only) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10: Mean average time stayed on the RotaRod (males) over sessions  
A1, A2 and A3 and combined sessions. SEM error bars are shown 
 
 
Time stayed on  the RotaRod by session, line and genotype (females only) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11: Mean average time stayed on the RotaRod (females) over sessions  
A1, A2 and A3 and combined sessions. SEM error bars are shown 
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The RotaRod task revealed some interesting differences between the subjects. 
There were no differences between the male and female (homozygous and 
heterozygous) mutants and wild-types in the C417Y line (see figure 5.10 for 
performance of the male mice and figure 5.11 for performance of the female 
mice), although several differences were revealed by MANOVA (factors: 
genotype and sex x seconds stayed on the RotaRod in conditions A1, A2, and 
A3) in the C59X line (stage of oestrus was taken into account in both analyses). 
Means and standard deviations for this line across the sessions are given in 
table 5.5. Not surprisingly, there was a main effect of session (F(3,105)=19.66, 
p<0.0001) with mice performing better (staying on the RotaRod for a longer 
time) with practice, which is to be expected (although there was no effect of 
session in the C417Y line [F{3,75}=1.76, p=0.161]). Interestingly, homozygous 
C59X mutant mice stayed on the RotaRod longer than their heterozygous 
mutant and wild-type cage mates with a main effect of genotype (F(2,45)=8.36, 
p=0.001). Homozygous mutant mice in this line also improved more in ability to 
stay on the RotaRod with practice than did their cage mates with a session x 
genotype interaction (F(6,135)=4.22, p=0.001). 
 Although from looking at figures 5.10 and 5.11, it seems that the male 
C59X homozygous mice performed better than the female C59X homozygous 
mice and improved more with practice, this was not apparent in the analysis. 
There was no effect of gender (F(1,45)=2.62, p=0.112) in the C59X line on 
performance in the RotaRod task. No influence of stage of oestrus was seen on 
seconds on the RotaRod in either line. 
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 A1 A2 A3 
Mean 
(s) 
SD Mean 
(s) 
SD Mean 
(s) 
SD 
Male Zfp804a
+/+ 75.38 58.63 93.88 48.03 106.25 47.60 
 Zfp804a
+/mut 65.00 31.68 96.70 51.31 108.10 50.85 
 Zfp804a
mut/mut 162.75 78.06 234.00 134.02 331.50 213.39 
 Total 86.55 61.82 120.64 86.35 148.05 127.30 
Female Zfp804a
+/+ 80.00 70.65 142.30 112.47 137.60 71.43 
 Zfp804a
+/mut 55.10 55.36 83.60 74.99 122.40 64.82 
 Zfp804a
mut/mut 115.10 80.02 115.50 74.51 191.40 101.51 
 Total 83.40 71.51 113.80 89.39 150.4 83.62 
Total Zfp804a
+/+ 77.94 63.75 120.78 90.89 123.67 62.38 
 Zfp804a
+/mut 60.05 44.19 90.15 62.89 115.2 57.18 
 Zfp804a
mut/mut 128.71 79.61 149.36 105.24 231.43 148.17 
 Total 84.73 66.96 116.69 87.32 149.44 103.20 
Table 5.5: Means and standard deviations (SD) of seconds stayed on the RotaRod in the 3 
accelarating conditions in the C59X line 
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5.4 Discussion 
This chapter was intended as an initial preliminary characterisation of the novel 
Zfp804a mutant mice using an experimental group G4i (third generation, 
intercross), focusing on possible effects of genetic background and sex. The 
preliminary assessment was also designed to pick up, at an early stage, any 
gross deficits that may interfere with further, more complex behavioural and 
neurobiological testing in future work exploiting the mutant lines. 
 
5.4.1 The effects of background genetics and sex  
All groups of mice were bred onto the C57Bl/6J background (~97% C57Bl/6J 
average in the experimental cohort). The cohort is therefore not inbred but a 
mixed inbred strain, carrying a proportion (albeit a minimal amount) of the 
ancestry from the founder parents (BALB/c and C3H/HeH) as well as the 
selected ENU mutation (in mutants, and likely another one or two residual 
random [i.e. non-selected] mutations in all the mice, as discussed in chapter 4). 
The mice are therefore unlikely to be genetically homogeneous at all individual 
loci (as they are not 100% C57Bl/6J), which may have given rise to a degree of 
variability within the data. This level of ‘impurity’ is however small, given the low 
estimated number of residual ENU mutations in the first place, and additionally  
the chances of these mutations being functional, and furthermore affecting 
brain function. This degree of genetic variation between subjects in an 
experimental cohort of animals is common to all forms of genetic mutants and 
is not unique to ENU models. Moreover, these models are intended to help 
characterise a human disease gene; humans are not inbred and it could 
therefore be argued that inbred mouse models looking at human disease genes 
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have limited ecological validity. Additionally, it is worth noting the data 
generated by the wild-type control mice in these experiments do not show 
excessive degrees of variation and are not excessive when compared with 
mice on a ‘purer’ C57Bl/6J background (Eddy, personal communication). It is 
unlikely therefore, that any group differences were either observed or obscured 
due to lack of genetic homogeneity.   
 Female mice are generally avoided in studies due to potential effects of 
the stage of oestrus cycle on behaviour (particularly emotional-related 
behaviours) (Gray and Cooney, 1982). Some evidence was found in these 
experiments that such a correlation existed, with stage of oestrus having an 
impact upon performance in the RotaRod task. Such differences are easily 
taken into account in the analysis of data however. Female mutant mice 
showed normal oestrus cycling patterns (described by Parkes, 1928), when 
compared with wild-types. Determining (and accounting for, where appropriate) 
the stage of oestrus in female mice, controls for the possibility that any effects 
observed in females may be influenced by this factor.  
 
5.4.2 Comparability of the lines 
By comparing the two lines, C59X and C417Y, it could be argued that any 
differences observed between the two lines were not directly due to genotype 
per se, but due to differences in maternal behaviour between the mothers of the 
different genotypes. The optimal counter to this criticism would be to cross-
foster the litters between the different lines. The data at this early stage of 
testing shows that, there is little, if any difference between the wild-type groups 
of the two lines, allowing them to be combined in analysis, suggesting that 
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there are no persistent differences between the lines in terms of mothering 
behaviour. Additionally, to minimise the effect of the genotype of the mother, 
the G3 crosses to C57Bl/6J to produce the G4 cohort were alternated so that 
some litters in the cohort had a wild-type mother and a heterozygous father and 
other litters had a heterozygous mutant father and a wild-type mother.  
 
5.4.3 Behavioural comparison of the lines 
All the groups tested showed intact motor and neurologic competence and no 
obvious deficits on physical examination nor in more specific assessments 
(PhenoTyper cages and the RotaRod apparatus). Sensory abilities were not 
formally assessed although mice handled normally and appeared to behave 
normally in their home cage environments. Pre-pulse inhibition (Eddy, personal 
communication) suggested the mice are able to hear and in the RotaRod 
showed no deficits in strength, co-ordination, grip or fatigue. Anecdotal 
evidence from casual observation of the animals in their home cage 
environment indicated that social interaction appeared to be fairly normal. 
There was no excessive barbering (where a dominant mouse plucks out hairs 
from the face of a more submissive mouse) of any one genotype group for 
example, and no excessive fighting going on in any of the cages.  
Two formal methods of assessment of behaviour were used in the preliminary 
characterisation of the Zfp804a mutant lines: the PhenoTyper ‘homecage’ 
environment and the RotaRod. No differences were observed between the lines 
or genotypes (wild-types and homozygous mutants only were tested) in the 
PhenoTyper homecage environment. However, for this task, due to 
practicalities and time constraints, a sub-sample only of the mice was used. 
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This reduced the power of the analysis and consequently could mean 
differences were missed (false negatives). However, even the limited analysis 
possible gave some indication that there are unlikely to be any large differences 
between the mice in terms of activity, sleeping behaviour, or feeding and 
drinking behaviour. There have been no other published data in behaviour in 
the Phenotyper Home Cage Environment in a mouse model for schizophrenia. 
However, the circadian rhythm disturbances in schizophrenia have long been 
known about (reviewed in Pritchett, 2012) with an estimated 30-50% of people 
with schizophrenia experiencing some disturbances in sleep and/or circadian 
rhythms (Cohrs, 2008). In genetic mouse models for schizophrenia, few 
researchers have investigated sleep and circadian rhythms in mutant models. 
However, there are four schizophrenia-relevant genetic models that have: 
Snap-25 (Oliver et al. 2012), Vipr2 (Hughes and Piggins 2008), Nrg1 (Johnson 
et al. 2002) and Cckar (Shimazoe et al. 2008). In all of these models, significant 
disturbance in sleep and circadian rhythms was observed, providing a case for 
further investigation with the phenotyper cages and other methods in the 
Zfp804a mutants. 
Measuring motor agility and balance, the RotaRod data gave rise to 
reliable differences between the experimental groups. Homozygous mutant 
mice from the C59X line (males and females) performed ‘better’, i.e. stayed on 
for longer, than did the C59X heterozygous mutants and wild-types and the 
C417Y line. A search on PubMed revealed that this finding of improved 
performance may be the first in genetic mouse models for schizophrenia as no 
other studies reported better performance in mutants than wild-types on the 
RotaRod task, although Benoit et al. (2010), reported enhanced RotaRod 
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performance in a quinone reductase 2 (QR2) knockout model. QR2 
overexpression in this study was also associated with learning deficits.  Several 
studies looking at well-characterised schizophrenia genes have assessed 
performance on the RotaRod. Takao et al (2008) for example looked at the Sdy 
mouse with a deletion in Dtnbp1 and found that the mutants had impaired 
motor learning capabilities on the RotaRod, compare with wild-types. Deakin et 
al. (2009) found that mice over-expressing Nrg1 were impaired on the 
accelerating RotaRod. Pharmacological studies have also reported deficits in 
the RotaRod with the NMDA receptor antagonist, phencyclidine (PCP) being 
demonstrated to impair performance (Beraki et al., 2008) and the partial D2 
receptor agonist aripiprazole impairing performance on the RotaRod in more 
challenging accelerating conditions (Nordquist et al, 2008). Very few studies 
have shown substances to enhance RotaRod performance. Shiotsuki et al. 
(2010) however demonstrate the dopamine-uptake inhibitor nomifensine to 
improve learning on the RotaRod. Further investigation of the mechanism(s) by 
which the Zfp804aC59X/C59X mutants show enhanced RotaRod performance 
could prove to yield very interesting findings about the gene and it’s 
neurochemical and behavioural influences. 
 
5.4.4 Body and brain weight phenotypes 
There were no obvious differences between the groups in early development as 
indexed by initial body weight gain from birth, although sample sizes were small 
and could lack power to detect differences. Later on in the adult though, there 
were differences between groups in body weight. Homozygous mutant mice of 
both lines tended to be lighter than the others, more notably so in the C59X 
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line, despite assumed equal access to ad libitum food and water. This is an 
observation commonly seen in mutant models (Wilkinson, personal 
communication).  
Despite there being an apparent trend of a reduced brain weight in male 
Zfp804aC59X/C59X mutants, the finding was non-significant. Further investigation 
of brain weight differences with larger cohorts would help to elucidate whether 
this trend exists or not. There is substantial post mortem evidence from human 
studies showing reduced brain weight in people diagnosed with schizophrenia 
(as discussed in the General Introduction, 1.5.3). Moreover, it is not unknown 
for variations in a putative schizophrenia susceptibility gene to lead to 
alterations in brain weight in both humans (e.g. Hashimoto et al., 2010, 
alterations in DTNBP1) and in mice (e.g. in study looking at both an SREB2 
over-expressing model and an SREB2 knockout, Matsumoto et al., 2008 found 
that brain volumes were reduced and increased respectively).   
More specifically to ZNF804A, Donohoe et al., (2011) compared 
rs1344706 risk allele carriers with non-carriers (both schizophrenia patients and 
controls). They found that for patients, but not for controls, the homozygous risk 
carriers had relatively larger grey matter volumes than heterozygous and 
homozygous non-carriers, particularly for hippocampal volumes. Cousijns et 
al.’s (2012) findings were not incompatible with this result, demonstrating no 
differences in brain volume in healthy participants between ZNF804A risk and 
non-risk allele carriers. Clearly, more work, confirming differences in brain 
weight in the Zfp804a mutant lines, and extending the analysis into morphology 
might be of use.   
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5.4.5 Genetic explanation for the findings 
Genetic explanations for these initial functional data are speculative, as there 
is, at present, no biochemical characterisation available for the models. It is 
unknown at the time of writing whether the C59X mutation does indeed cause 
nonsense mediated decay of the transcript, if it truncates the protein at 59aa, or 
if something else occurs. The effect of the C417Y mutation on the protein is 
also unknown and merely predicted to be ‘probably damaging’ to the protein 
and disrupt the normal functioning of the Zfp804a protein in some way.  It would 
be premature therefore, on the basis of the data in this chapter to conclude that 
the behavioural differences observed were definitely related to distinct, 
dissociable effects of the two mutations. More analyses, both of the behavioural 
and the biochemical consequences of the mutations are required.  
 
5.4.6 Summary  
In summary the work in this chapter has provided important information on the 
utility of the models created in this thesis and has provided some important 
indications of areas for further work and investigation.  
 There was no excessive variation observed in the animals (due to other, 
residual mutations). 
 There were no differences observed with regard to mortality and general  
health, in the young and in adults 
 There were no differences amongst the mice in activity in the PhenoTyper 
home cage environment 
 C59X homozygous male mutants performed better on the RotaRod 
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 C59X homozygous mutants were also lighter in body weight 
 C59X homozygous mutants (females only) had heavier brains than the 
heterozygous mice but not the wild-types, although a trend in the other 
direction in the C59X males makes the picture somewhat unclear. 
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CHAPTER 6: Further behavioural phenotyping of the 
Zfp804a mutant lines: emotion-related behaviours 
 
6.1 Introduction  
Chapter 5 involved the first ever characterisation of two novel mutant mouse 
lines carrying non-synonymous mutations predicted to affect the structure and 
therefore function of the Zfp804a protein, the mouse orthologue of the human 
ZNF804A protein. From an initial screening we have seen that the mutant lines 
breed, the mutations are not embryonic-lethal and nor do they lead to any 
grossly observable physical abnormalities in post-natal life. We have therefore 
confirmed the basic utility of the mutant lines for further functional analysis. 
Additionally, from an initial analysis of behaviour we have gained preliminary 
evidence of changes in the behaviour of the mutants.      
This chapter extends the basic functional screen with a focus on 
behaviour that indexes emotionality. As previously noted, ZNF804A is a 
robustly replicated candidate gene for schizophrenia, and also for bipolar 
disorder (Williams et al., 2011).  Research to date, in terms of influence of the 
gene at a phenotypic level, has focused on altered cognition. Schizophrenia 
and bipolar disorder (as discussed in the General Introduction, 1.2) are 
syndromic disorders, which can have many symptoms that overlap and so the 
diagnosis can be complex. There is a growing school of thought, especially with 
the generation of increasing genetic evidence for an overlap between the 
disorders, or the existence of the disorders on a spectrum (e.g. Owen et al., 
2007).  
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Given this evidence, it is conceivable that ZNF804A may influence 
shared domains known to be aberrant in schizophrenia and bipolar disorder 
other than cognition, such as emotion. Consequently, this chapter assays 
differences in emotional-type behaviour between the experimental groups. 
Three behavioural assays were used, (i) activity in and habituation to a novel 
environment, locomotor activity (LMA); (ii) the ‘Open Field’ (OF) test and (iii) the 
‘Elevated Plus Maze’ (EPM). All three assays are well established (reviewed in 
Sousa, Almeida & Wotjak, 2006; Ramos, 2008; Sartori, Landgraf & Singewald, 
2011) means of assessing components of emotional functioning, in particular 
anxiety, as they all make use of the conflict between the natural instinct to 
explore new environments and the fear of exposure. As before, female mice 
were smeared after testing in order to be able to take account of any effects of 
oestrus cycle on behaviour.   
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6.2 Methods 
 
6.2.1 Subjects and animal husbandry 
The same experimental cohort of G4i   (third generation, intercross) C59X and 
C417Y mice as described in Chapter 5 (see 5.2.1) were used in the 
experiments. General housing, handling and behavioural testing conditions 
were as described in chapter 2, General Materials and Methods (2.5). The 
number of mice (n) used in each behavioural task is summarised in the tables 
below (tables 6.1 and 6.2). 
C59X Genotype and n 
Test ♂  
Zfp804a+/+ 
♂  
Zfp804a 
+/C59X 
♂ 
Zfp804a 
C59X/C59X 
♀  
Zfp804a 
+/+ 
♀ 
Zfp804a 
+/C59X 
♀  
Zfp804a 
C59X/C59X 
Locomotor 
activity 
8 8 4 11 10 11 
Open field 9 9 4 10 12 11 
Elevated 
plus maze 
8 9 4 9 8 12 
Table 6.1: Number of mice, by experimental group, used in each task: C59X line 
C417Y Genotype and n 
Test ♂  
Zfp804a 
+/+ 
♂ 
Zfp804a 
+/C417Y 
♂ Zfp804a 
C417Y/C417Y 
♀ 
Zfp804a 
+/+ 
♀ 
Zfp804a 
+/C417Y 
♀  
Zfp804a 
C417Y/C417Y 
Locomotor 
activity 
7 14 8 7 11 12 
Open field 7 14 9 8 16 11 
Elevated 
plus maze 
8 13 8 7 12 13 
Table 6.2: Number of mice, by experimental group, used in each task: C417Y line 
 
6.2.2 Oestrus cycle status 
Oestrus status was determined by vaginal smearing immediately following a 
behavioural procedure (see General Materials and Methods, 2.5.3 for a 
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description). The data from the behavioural tests was then analysed to assess 
whether or not there was a correlation between the behavioural data and the 
stage of oestrus of a particular mouse.  
 
6.2.3 Locomotor activity 
The apparatus used to assess locomotor activity is described in Chapter 2 
(2.6.3). Locomotor activity throughout a specified period was used as an index 
of general movement ability/volition, willingness to explore a novel environment 
and the degree to which mice habituated to this novel environment (both during 
the session and over subsequent sessions the following days, as indexed by 
the difference in performance upon repeated exposure to the test apparatus). 
There are two infra-red beams in the cages one crossing either end of the 
cage. The total number of infra-red beam breaks made by each mouse, every 5 
minutes was recorded by a computer running custom-written BBC BASIC V6 
programmes with additional interfacing by ARACHNID (Cambridge Cognition, 
Cambridge, UK) over a 2-hour sessions (i.e. 24 bins in total). Breaking one of 
the beams by moving through it resulted in a beam break and breaking each of 
the beams in succession resulted in a ’run’. Cages were cleaned thoroughly 
with 1% acetic acid to mask the scent of the previous animal. All animals were 
run in darkness between the hours of 07:00 and 18:00 on three consecutive 
days, with each animal run at a similar time each day.  
 
6.2.4 Elevated plus maze (EPM)  
In a further test for fear responses, subjects were tested in an elevated plus 
maze apparatus (described in Chapter 2, 2.6.4). At the time of testing, subjects 
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were habituated to the testing room environment (dimly lit with some low-level 
noise from background ventilation) for a minimum of 20 minutes prior to the 
experiment.  To conduct the test, subjects were transferred to the centre of the 
plus maze where they were placed facing an open arm. The experimenter 
stood back approximately 2 metres and the mice were allowed to freely explore 
the maze for 5 minutes. Between subjects, the maze was cleaned thoroughly 
with 1% acetic acid and all faecal boli removed to mask the smell of the subject 
for the next mouse. All subjects were run between the hours of 09:00 and 
18:00. From automated Ethovision analysis, the following parameters were 
recorded: time spent in the open and closed arms of the maze, entries into the 
open and closed arms of the maze, distance moved in the zones and overall 
movement. Time and entries into the arms were recorded according to where 
the greatest proportion of the subject’s body was positioned. Traces depicting 
the total journey of the mouse in the maze were also recorded. In the EPM, 
anxiolytic behaviour indicating lower levels of anxiety in the mice is indexed by 
exploring the open, more fear-inducing arms of the maze and anxiogenic 
behaviour indicating higher levels of anxiety in the mice is judged as staying in 
the closed, more secure arms of the EPM. 
 
6.2.5 Open field  
Subjects were investigated for fear reactivity in an open field paradigm 
(described in General Materials and Methods, 2.6.5). After habituation to the 
general testing environment (i.e. the room, dimly lit with some low-level noise 
from background ventiliation) for a minimum of 20 minutes, subjects were 
placed in the corner of the open field arena and allowed to explore freely for 10 
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minutes. Between subjects, the open field was cleaned thoroughly with 1% 
acetic acid and all fecal boli removed. All mice were tested between 08:00 and 
18:00. For analysis, the arena was subdivided into 4 quadrants, and 2 
concentric circles corresponding to radii of 200 and 275mm respectively. A 
number of parameters were recorded: the time spent in each circle, the number 
of quadrants entered. Increased entries into and time spent in the centre part of 
the apparatus is usually interpreted as behavioural evidence of anxiolysis, 
reduced anxiety in the mice, whilst increased levels of thigmotaxis (running 
round the perimeter of the apparatus close to the walls) is usually interpreted as 
the opposite.  
 
6.2.6 Statistical analyses  
Experimental data were analysed using SPSS PASW Statistics, release 18.0 
(IBM SPSS Inc., 2009, Chicago). Data were subjected to One Way, Two Way 
or multivariate AN(C)OVA (if normal or One Way Kruskal-Wallis ANOVA if data 
did not conform to normality estimates, Levene’s test, p>0.05). All comparisons 
were planned a prioriI and corrections for multiple comparisons were therefore 
not made. Significance was defined as p<0.05. 
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6.3 Results 
 
6.3.1 Oestrus cycle and behaviour 
Data were analysed using ANCOVA for any effects of stage of oestrus on 
behaviour and any significant findings in relation to stage of oestrus are 
reported in the results for individual tasks. 
 
6.3.2 Locomotor Activity 
 
Total beam breaks per session across the three successive 
            test days by line and genotype (males only) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1: Graph (above) to show mean average total beam breaks made in the 2-hour test 
sessions across the three successive test days (x axis) in males, both lines, by genotype and 
line. SEM error bars are shown 
  
To look at locomotor activity and habituation to a novel environment, 2 
measures were examined in the locomotor activity task: beam breaks (breaking 
one of two beams at either end of the activity box) and runs (breaking the two 
beam breaks consecutively). Figures 6.1 (males) and 6.2 (females) show the 
mean average total beam breaks per session by line and genotype.   
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Total beam breaks per session across the three successive 
            test days by line and genotype (females only) 
 
 
 
 
 
 
 
 
 
 
Figure 6.2: Graph (above) to show mean average total beam breaks made in the 2-hour test 
sessions across the three successive test days (x axis) in females, both lines, by genotype and 
line. SEM error bars are shown 
 
 
MANOVA (factors genotype and sex x total beam breaks per session for days 
1, 2 and 3 and total runs per session for days 1, 2 and 3), co-varying for stage 
of oestrus for the female mice was performed on the total beam breaks and 
runs per 2-hour session (i.e. day) for each line. The beam breaks of the 
females in neither line was influenced by stage of oestrus (C59X line: 
F(1,25)=0.59, p=0.45; C417Y line: F(1,19)=0.003, p=0.960). Findings for stage 
of oestrus and runs were similar with no effect of oestrus (data not reported). 
There were no significant differences between the sexes for either line, or 
between the genotypes (data not reported) in total beam breaks or total runs, 
indicating that the mutations have little effect on locomotor activity in such a 
situation. In the C59X line, there was an effect of day on runs (F(1,50)=4.26, 
p=0.035) whereby the mice became increasingly inactive over the three days, 
indicating habituation to the locomotor activity boxes. There was no effect of 
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day on beam breaks in this line or on runs or beam breaks in the C417Y line 
(data not reported).  
 
6.3.3 Elevated plus maze 
As would be expected,  both lines spent more time in the more secure closed 
arms of the EPM than they did in the more fear-inducing open arms (duration in 
closed arm:C59X, M=204.73s, SD=38.72, C417Y M=205.87s, SD=33.79, 
duration in open arm: C59X M=120.35s, SD=43.77, C417Y M=98.35s, 
SD=36.71).   
 There were no differences in behaviour in the C417Y line on the 
elevated plus maze with both sexes and all genotypes behaving similarly (data 
not reported). There were however, more varied results with the C59X line, 
revealed by MANOVA (factors sex, genotype x time spent on the open arms, 
frequency of entry to the open arms, total distance moved on the open arms, 
duration on the closed arms, latency to enter the open arms, latency to enter 
the closed arms, percentage of time moving in open zone, maximum distance 
moved in open zone, maximum distance moved in closed zone). There was a 
main effect of gender on several parameters in the elevated plus maze shown 
in table 6.3. On all the parameters, the females demonstrated more anxiogenic 
behaviour than the males by tending to stay in the closed arms of the maze and 
explore the open arms less. 
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Measure Degrees of 
freedom 
F 
statistic 
p  value Male Female 
M SD M SD 
Frequency in 
open zone 
1,48 8.84 0.005 21.64 9.04 16.81 5.86 
Total 
distance 
moved in 
open zone 
(cm) 
1,48 7.22 0.010 526.94 167.20 449.49 116.09 
Duration in 
closed zone 
(s) 
1,48 13.69 0.001 189.03 39.92 217.53 33.20 
Latency in 
closed zone 
(s) 
1,48 12.01 0.001 3.36 7.37 1.16 3.73 
Percentage 
of time 
moving in 
closed zone 
1,48 4.55 0.039 43.64 7.04 47.26 7.60 
Table 6.3: Statistics derived from MANOVA relating to parameters in the elevated plus maze 
where males and females showed a difference in behaviour in the C59X line 
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Measure 
Degrees of 
freedom F statistic p  value 
Zfp804a
+/+
 Zfp804a
+/C59X
 Zfp804a
C59X/C59X
  
M SD M SD M SD 
Frequency in open 
zone 2,48 3.49 0.039 17.71 4.21 17.94 9.52 21.86 8.05 
Total distance 
moved in open 
zone (cm) 2,48 3.78 0.031 475.32 86.97 450.85 180.82 538.10 144.48 
Percentage of time 
moving in open 
zone 2,48 3.64 0.035 27.58 4.64 26.64 9.44 31.75 6.52 
Frequency of entry 
to closed zone 2,48 4.90 0.012 23.53 5.04 18.89 6.18 18.29 3.56 
Duration in closed 
zone (s) 2,48 6.00 0.005 216.17 31.82 209.22 42.52 185.07 36.19 
Latency in closed 
zone (s) 2,48 16.86 <0.0001 0 0 1.06 2.49 6.16 9.32 
Total distance 
moved in closed 
zone (cm) 2,48 5.78 0.006 916.33 
113.0
9 801.52 131.51 758.80 144.85 
Maximum distance 
moved in closed 
zone (cm) 2,48 3.44 0.041 5.43 0.96 4.96 0.48 4.71 0.66 
Percentage of time 
moving in closed 
zone 2,48 4.93 0.012 49.48 4.84 44.49 7.59 42.42 8.44 
Table 6.4: Statistics derived from MANOVA relating to parameters in the elevated plus maze 
where males and females showed a difference in behaviour in the C417Y line 
 
 
Table 6.4, above, shows the parameters where there was a main effect of 
genotype in the elevated plus maze in the C59X line. In fact, there was a main 
effect of genotype in this line in 9 out of the 12 parameters measured in the 
maze. All of the effects were in the same direction, with the Zfp804aC59X/C59X 
mice showing more anxiolytic behaviour than the more timid wild-types.  
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   Figure 6.3: Graph to show mean average time spent in the open arms of the EPM, by line, 
sex and genotype. SEM error bars are shown 
 
 
Figures 6.3 – 6.6 illustrate the data (mean averages and standard error) for the 
experimental groups on time spent in the open arms (figure 6.3), frequency of 
entry to the open arm (figure 6.4), total duration spent in the closed arms (figure 
6.5) and total distance moved in the open arms (figure 6.6).  
 
 
 
. 
 
 
 
 
      
 
 
 
 
  Figure 6.4: Graph to show mean average number of entries to the open arms of the EPM by 
line, sex and genotype. SEM error bars are shown 
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Figure 6.5: Graph (above, left) showing mean average total time spent in the closed arms of the 
EPM by genotype (C59X males only).SEM error bars are shown.  Figure 6.6: Graph (above, 
right) to show mean average total distance moved in the open arms in the EPM by genotype (x 
axis) in the C59X line, males only. SEM error bars are shown 
 
 
6.3.4 Open field 
In the Open Field (OF), it is expected that mice will spend longer in the ‘safer’ 
edges of the field, close to the walls than they spend in the middle of the field 
which is more fear-inducing.  This general effect was observed here with mice 
spending almost 10 times as long on the edges (outer zone) as in the centre 
(outer zone: C59X M=527.88s, SD=57.05, C417Y M=485.66s, SD=48.36; 
centre zone: C59X M=59.74s, SD=33.00, C417Y M=60.52s, SD=38.81).   
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Total duration in the centre of the open field by line, sex and genotype
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Figure 6.7: Graph (above) to show the mean average total duration in the centre, most 
aversive, area of the field by line, sex and genotype. SEM error bars are shown 
 
Both lines showed differences in behaviour in some of the parameters between 
the sexes and the genotypes, revealed by MANOVA (factors: sex and genotype 
x frequency of entry to zone, total duration in zone, latency to enter zone and 
maximum distance moved in zone for each of the four zones [outer, inner, 
middle and centre], for each line). For example, figure 6.7, above, shows an 
overview of behaviour in the central, most anxiogenic zone of the field, indexed 
by total duration in the zone, across the genotypes, genders and lines 
examined. Due to the number of effects seen, it is not practical to discuss all 
the findings here. Instead, the main trends will be discussed. Tables 6.5 – 6.10, 
below, list the statistics for all the main effects and interactions seen by line. 
In the C59X line, there were several parameters showing a main effect 
of sex (listed in table 6.5). The data however, present a complex picture as the 
effects are not all in the same direction with females showing a more 
anxiogenic phenotype on some parameters (e.g.moving shorter distances in 
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the zones) than males and a more anxiolytic phenotype (e.g. remaining in the 
centre and inner zones for longer) than others. 
 
Zone Measure Degrees 
of 
freedom 
F 
statistic 
p  value Male Female 
M SD M SD 
Outer Frequency 
of entry 
1,52 72.17 <0.0001 90.55 26.06 35.10 16.77 
Outer Latency to 
first entry (s) 
1,52 5.46 0.024 0.17 0.73 0 0 
Outer Maximum 
distance 
moved  (cm) 
1,52 18.41 <0.0001 13.68 14.07 7.92 1.36 
Middle Total 
duration (s) 
1,52 6.50 0.014 37.94 22.77 59.29 30.29 
Middle Maximum 
distance 
moved  (cm) 
1,52 11.61 0.001 12.47 11.47 9.26 1.99 
Inner Total 
duration (s) 
1,52 8.27 0.006 3.58 3.66 6.89 4.42 
Inner  Maximum 
distance 
moved (cm) 
1,52 53.23 <0.0001 10.00 3.63 5.77 1.55 
Centre Total 
duration (s) 
1,52 7.00 0.011 41.52 25.59 66.18 34.28 
Centre  Maximum 
distance 
moved (cm) 
1,52 19.00 <0.0001 13.79 11.04 9.27 1.97 
Table 6.5: Statistics summary of parameters showing a main effect of sex in the C59X line, data 
analysed by MANOVA co-varying for stage of oestrus 
 
 
As these differences in anxiety were not observed in the EPM and the data are 
inconsistent in the OF, it is possible that these measures could be assaying sex 
differences in anxiety-related behaviour rather than anxiety per se. Further 
investigation on anxiety with the sexes would be warranted.  
Table 6.6 lists measures that showed a main effect of sex in the C417Y 
line in the open field. The table presents a similar picture of results to the C59X 
line. Females spent longer in the outer (‘safer’) zone than males but also longer 
in the central, most anxiety-provoking zone. Again, further investigation of these 
findings would be interesting. 
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Zone Measure Degrees 
of 
freedom 
F 
statistic 
p  value Male Female 
M SD M SD 
Outer Frequency 
of entry 
1,56 74.70 <0.0001 93.93 25.24 41.04 19.29 
Outer Total 
duration (s) 
1,56 31.47 <0.0001 459.99 37.62 513.24 38.68 
Outer Maximum 
distance 
moved  (cm) 
1,56 7.20 0.010 13.98 14.02 7.48 1.12 
Middle Frequency 
of entry 
1,56 11.68 0.001 26.10 15.01 45.89 24.03 
Middle Total 
duration (s) 
1,56 25.28 <0.0001 35.97 20.37 75.76 34.24 
Middle Latency in 
zone (s) 
1,56 6.60 0.013 90.67 109.82 27.28 28.15 
Middle Maximum 
distance 
moved (cm) 
1,56 6.66 0.013 8.50 2.28 9.87 1.69 
Inner Frequency 
of entry 
1,56 8.85 0.004 5.90 4.10 10.04 5.28 
Inner  Total 
duration (s) 
1,56 17.03 <0.0001 3.04 2.01 8.61 6.37 
Inner Maximum 
distance 
moved  (cm) 
1,56 28.00 <0.0001 27.31 20.56 6.34 1.01 
Centre Frequency 
of entry 
1,56 8.77 0.005 21.97 12.24 35.96 19.31 
Centre  Total 
duration (s) 
1,56 27.01 <0.0001 38.32 21.92 84.37 39.10 
Centre Latency in 
zone (s) 
1,56 6.61 0.013 85.36 96.47 27.28 28.15 
Centre  Maximum 
distance 
moved (cm) 
1,56 21.79 <0.0001 27.82 20.03 9.87 1.69 
Table 6.6: Statistics summary of parameters showing a main effect of sex in the C417Y line, 
data analysed by MANOVA co-varying for stage of oestrus 
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Zone 
Measure 
Degrees of 
freedom F statistic p  value 
Zfp804a
+/+
 Zfp804a
+/C59X
 Zfp804a
C59X/C59X
  
M SD M SD M SD 
Outer Latency in 
zone (s) 2,52 3.93 0.027 0.02 0.94 0 0 0.24 0.91 
Outer Maximum 
distance 
moved  (cm) 
2,52 
10.39 <0.0001 8.99 2.84 8.46 2.27 14.80 17.58 
Middle Maximum 
distance 
moved  (cm) 
2,52 
11.44 <0.0001 8.95 2.14 9.11 1.88 14.93 13.90 
Inner Maximum 
distance 
moved  (cm) 
2,52 
8.17 0.001 6.61 2.95 7.68 2.94 8.60 4.21 
Centre Maximum 
distance 
moved  (cm) 
2,52 
12.42 <0.0001 9.64 2.17 9.73 1.99 15.25 13.76 
Table 6.7: Statistics summary of parameters showing a main effect of genotype in the C59X 
line, data analysed by MANOVA co-varying for stage of oestrus 
 
Several differences were also seen between the genotypes in the C59X line in 
behaviour (listed in table 6.7, above). The most striking difference here 
between the genotypes is the difference in maximum distance moved at ony 
one time in all of the zones. Zfp804aC59X/C59X  mice moved significantly further 
than counterparts, suggestive of anxiolytic behaviour (consistent with findings 
from the EPM, see 6.3.3). Figure 6.8, below illustrates this finding in males, in 
the centre zone. 
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Figure 6.8: Graph to show the mean average maximum distance moved (cm) in the centre zone 
(x axis) in the C59X line, males only. SEM error bars are shown 
 
In the C417Y line, there were fewer main effects of genotype (see table 6.8), 
with mutants spending less time in the outer zone, and homozygous mutants 
moving more (at any one time) in the outer zone. Both main effects are 
suggestive of lower anxiety in the mutant groups than the wild-type groups but 
there were no significant findings suggestive of the same trend in the more 
anxiogenic, middle, inner and central zones. 
 
Zone 
Measure 
Degrees of 
freedom F statistic p  value 
Zfp804a
+/+
 Zfp804a
+/C59X
 Zfp804a
C59X/C59X
  
M SD M SD M SD 
Outer Total 
duration in 
zone (s) 2,56 3.77 0.030 510.08 44.94 475.93 41.12 478.11 50.27 
Outer Maximum 
distance 
moved  (cm) 2,56 3.27 0.046 7.40 1.14 9.72 7.95 16.23 16.65 
Table 6.8: Statistics summary of parameters showing a main effect of genotype in the C417Y 
line, data analysed by MANOVA co-varying for stage of oestrus 
 
Mean average maximum distance moved (at 
any one time) in the centre zone, by genotype 
(C59X males only) 
M
a
x
im
u
m
 d
is
ta
n
c
e
 m
o
v
e
d
 (
c
m
) 
 169 
The main effects of sex and genotype described above in the C59X line were 
found by MANOVA to interact on the maximum distance moved measure in all 
the zones. All interactions were in the same direction, with male 
Zfp804aC59X/C59X   mice showing a more anxiolytic phenotype (by moving further 
in the open field at any one time, e.g. see figure 6.9). These interactions 
support findings from the EPM (see 6.3.3). 
 
 
 
 
 
Zone Measure 
Degrees 
of 
freedom F statistic p  value 
Outer Latency in 
zone (s) 2,52 3.93 0.027 
Outer Maximum 
distance 
moved  (cm) 2,52 10.77 <0.0001 
Middle Maximum 
distance 
moved  (cm) 2,52 9.96 <0.0001 
Inner Maximum 
distance 
moved  (cm) 2,52 3.93 0.027 
Centre Maximum 
distance 
moved (cm) 2,52 10.82 <0.0001 
Table 6.9: Statistics summary of parameters showing an interaction of sex x genotype in the 
C59X line, data analysed by MANOVA co-varying for stage of oestrus.For means and standard 
deviations, see tables 6.5-6.8. 
 
 
There was a different set of results in the C417Y line. Genotype interacted with 
sex in the maxium distance moved in the outer zone parameter, with male 
Zfp804aC471Y/C417Y   mice moving more in this zone and no difference between 
the genotypes in females. For the total duration in the middle and centre zone 
parameters, genotype interacted with sex differently, particularly in the centre 
zone with male Zfp804aC471Y/C417Y   mice spending longer in the centre zone 
than their counterparts, whereas female Zfp804aC471Y/C417Y   mice spent less 
time in the centre zone than their coutnerparts. Statistics are shown in table 
6.10. 
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Zone Measure 
Degrees 
of 
freedom F statistic p  value 
Outer Maximum 
distance 
moved  (cm) 2,56 3.59 0.035 
Middle Total duration 
in zone (s) 2,56 3.29 0.045 
Centre Total duration 
in zone (s) 2,56 3.22 0.048 
Table 6.10: Statistics summary of parameters showing an interaction of sex x genotype in the 
C417Y line, data analysed by MANOVA co-varying for stage of oestrus.For means and 
standard deviations, see tables 6.5-6.8. 
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6.4 Discussion  
 
6.4.1 Main findings 
The experiments gave rise to complex data. The analysis of locomotor activity 
revealed a difference between the lines with the C59X line emerging as less 
active than the C417Y line. Additionally, the homozygous mutants were more 
active than the wild-type mice (independent of line). In the elevated plus maze 
(EPM), there were behavioural differences influenced by sex and line with the 
C59X males exploring the open (and more anxiety-provoking) arms more than 
the C417Y males. Homozygous mutants were also different between the lines, 
again with those in the C59X line more willing to explore than those in the 
C417Y line. Interestingly this effect did not persist in differences between the 
lines in terms of male homozygous mutants but perhaps this is due to the 
samples being underpowered (male homozygous mutants in the C59X line 
were only n=4). There were no effects of line in the open field, although there 
were genotype differences independent of line with mutants (both heterozygous 
and homozygous) being more active in the inner (and more exposed, therefore 
more anxiety-provoking) zones of the open field than wild-type mice. Females 
also explored the open field (inner zones) in general more than males.  
 
6.4.2 Activity 
It was interesting that the C59X homozygous mutants performed better on the 
RotaRod (Chapter 5) yet they were not more active in the locomotor activity 
cages. This finding sheds doubt to some extent on the proposal put forward in 
Chapter 5 that perhaps C59X homozygous mutants performed better on the 
 172 
RotaRod as they had a lower body weight, were more nimble, and therefore 
found activity easier. The similarity of the genotypes in locomotor activity (which 
is in agreement with the findings in terms of general activity in the phenotyper 
cages) makes the anxiety tasks simpler to interpret. It is less likely that any 
differences seen between animals in those tasks are due to differences in 
activity rather than anxiety per se. As with the other behavioural tasks reported, 
it is likely the investigation was under-powered, by having small sample sizes. 
Nonetheless, false negatives are far more likely than false positives.  
There were no group differences between sessions on days 1, 2, and 3 
on activity measures and no interactions involving day and line or genotype. 
That is, the anticipated general reductions in activity over the three days of 
testing as the mice habituated to the novel surroundings of the activity cages 
(Leussis & Bolivar, 2006) occurred but was common to all groups.  
LMA in mice has been used by many investigations as a proxy for 
positive symptoms in schizophrenia and is has a well-documented positive 
correlation with dopaminergic activity (described in van den Buuse, 2010). 
Interestingly, given the well known association of hyperactivity with bipolar 
disorder (psychomotor agitation can contribute to a diagnosis of a manic 
episode in bipolar using DSM-IV guidelines) LMA has been used as a simple 
way of assessing behaviour in mouse models of manic conditions (Young, et 
al., 2011).  
 Due to its simplicity and informativeness, many genetic mouse 
models for schizophrenia have assayed LMA. With Dtnbp1 mutants, there have 
been mixed findings with several reports of no change in LMA (reviewed in van 
den Buuse, 2010) but one recent report of hyperactivity in the Sdy mouse (Cox 
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et al., 2009). Findings with Nrg1 mutant mice are more consistent with several 
authors finding Nrg1 transmembrane mutants mildly hyperactive in the open 
field (Stefansson et al., 2002; O’Tuathaigh et al., 2006; Karl et al., 2007; van 
den Buuse et al., 2009), which could be partially reversed by clozapine 
(Stefansson et al., 2002).  
 The literature presents positive, negative and mixed findings in terms of 
LMA. Koike et al.(2006) for example, found no differences in LMA between 
mice with an endogenous Disc1 deletion in the 129 strain, nor when the 
deletion was crossed onto the C57Bl/6J strain. Another group (Yee et al., 2005) 
only saw differences in activity when the mutants (with a deletion in Comt which 
increased endogenous dopamine levels 2-3 fold) were given amphetamines 
(when compared with the wild-type response to amphetamine). 
One way of investigating LMA in Zfp804a mutants further would be to 
see if a differential response to pharmacological interventions LMA is known to 
be affected by such as amphetamine, PCP and some antipsychotics (van den 
Buuse, 2010). 
 
6.4.3 Anxiety 
The data from the behavioural assays of anxiety were similarly complex and 
again have to be considered in the light of the preliminary nature of the 
experiments. Nonetheless, in the EPM there was a clear difference in 
behaviour in the open (and more anxiety-provoking) arms of the apparatus. The 
findings are consistent with the view that, the C59X mutation in Zfp804a affects 
some anxiety-mediated behaviours, and acts differently between the sexes, the 
mutations and the mutation dosages. The interactions with sex are worthy of 
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comment, insofar as females are under-researched in animal models of 
psychiatric disorders, despite mood disorders being more common in females 
than males (Palanza, 2001). This is mainly due to perceived problems due to 
stage of oestrus effects on behaviour and physiology. We controlled for this 
factor by routine smearing of the mice. As it was, we found no effect of stage of 
oestrus in the data. 
  It is important to note at this point that neither the EPM nor the open 
field can be described as monolithic ‘tests of anxiety’; rather, they assay 
aspects of anxiety-mediated behaviour (e.g. see Turri et al., 2001). This is 
relevant to the increased activity of the mutants (both heterozygous and 
homozygous, both lines) in the inner zones of the open field. These data are 
congruous to some extent with the findings from the EPM; however this means 
that C417Y mutants were also more active (in addition to the C59X mutants) in 
the open field, indicating more willingness by all the mutants to go into an 
anxiety-provoking environment. In similar circumstances in the EPM however, 
the C417Y line were not as willing as their C59X counterparts. 
There are several possible explanations for the apparently divergent 
effects seen across the tasks. Beyond the group samples being too small to 
elucidate reliable effects, there is the possibility that the tasks are in fact 
measuring different things. Indeed, all we have truly measured is the 
exploration of an elevated plus maze apparatus and the middle of a large open 
–topped box. Neither task is directly or solely measuring anxiety so it could be 
suggested that it is not unexpected to achieve different results on the different 
tasks. In fact, order effects could have an influence on the results. Holmes 
(2001) in his review of anxiety-relevant phenotypes in genetic mouse models, 
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suggests that prior exposure to any anxiety-provoking task can make 
subsequent anxiety tasks less fearsome and produce an apparently more 
anxolytic phenotype. Much literature demonstrates that it is not uncommon to 
yield different, even contradictory findings from the elevated plus maze and the 
open field (e.g. Carola et al., 2002). In previous work by others, the two tasks 
have been shown, using principle component analysis  to measure different 
dimensions and components of anxiety in mice, with only some of these in 
common (Carola et al., 2002). Archer (1973), File (1985); and more recently, 
Turri et al., (2001) warn that open field alone is not a robust test for anxiety-
related behaviours, this task reflecting changes in activity and exploration as 
well as in anxiety. An additional possible explanation for the apparent 
inconsistency of the findings could be technical reasons. The open field or the 
EPM may not have been set up as a sufficiently fear-inducing environment for 
the mice (unlikely from the data) or they may have differed in the amount of 
anxiety they induced in the animals. Experiment effects (such as the distance of 
the experimenter from the test, background noise in the lab etc) could also 
have influenced the results (discussed in Holmes (2001). 
Other genetic mouse models of schizophrenia have also had some 
inconsistent anxiety-related phenotypes. In the Dtnbp1 Sdy mouse for example, 
although researchers generally report no alteration in anxiety with the Sdy 
model (reviewed in Talbot, 2009), other research (e.g. Hattori et al., 2008) has 
found heightened anxiety-like responses in the model with mutants spending 
less time in the centre of the open field, which was thought to be due to 
reductions in forebrain dopamine transmission. Earlier research tended to focus 
on neurotransmitter receptors and produced mixed findings with some positive, 
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negative and neutral reports. For example, researchers looking at the 5-HT1B 
receptor knockout found both anxiolysis on the elevated plus maze (Brunner et 
al., 1999) and no anxiety-related phenotype on the elevated plus maze 
(Malleret et al., 1999) or the open field (Malleret et al., 1999, Zhuang et al., 
1999), demonstrating the delicate and perhaps volatile nature of laboratory 
anxiety assays. 
Aside from replicating the results in an experiment, one way in which 
reliability of results from anxiety-related assays in mouse models for 
schizophrenia can be improved is through congruency with human findings. 
Due to the early stage of research into ZNF804A/Zfp804a function, it is difficult 
to draw parallels. However, it is worth noting that ZNF804A may be involved in 
anxiety behaviour as Steinberg’s association study of risk variants in ZNF804A 
revealed a CNV in the gene in an anxiety patient (Steinberg et al., 2011). 
Recent work in the Institute of Psychological Medicine and Clinical 
Neurosciences in Cardiff with the Zfp804a has shown promise as the 
phenotypes described in this study, of reduced anxiety in male Zfp804aC59X/C59X 
mutants have been replicated in subsequent studies (Eddy, unpublished data). 
   
6.4.5 Genetic explanation for the findings 
The behavioural findings with the Zfp804a mutant lines to date are intriguing. 
There are clear differences between the lines and differences that are mediated 
by the dosage of the mutation. There also may be differences in the way these 
mutations interact with sex. These new data are interesting in view of a relevant 
paper that looked at the effects of 60 donor B23 cM DBA/2J genome segments 
in a C57Bl/6J wild-type mouse. Gale et al. (2009) then screened these mice for 
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behavioural quantitative trait loci using measures of activity, anxiety and novel 
object tests. The mice where the donor segment spanned the Zfp804a region 
(2d - distal) were hyperactive in the LMA, open field and novel object task. 
There were no differences between the mice in the EPM other than the 
maintenance of hyperactivity, although the mice didn’t have the same ‘freeze’ 
responses as other mice when confronted with anxiety-inducing stimuli. This 
data is interesting in the context of findings in this thesis as it suggests that the 
B23cM segment of genome containing the Zfp804a locus is influential in activity 
and reactivity to fear-inducing stimuli. Of course it is not known what genes or 
precisely what loci were responsible for these effects and, indeed the effect the 
donor segment had on Zfp804a expression. 
We have seen that Zfp804a is likely to have some impact on emotion-led 
behaviour although firm conclusions cannot really be drawn from the present 
data and investigations are very much in preliminary stages. Both activity and 
anxiety are potentially influenced by the gene and this requires further work. 
These findings should also be taken into account when interpreting future 
behaviour of these mice. 
 
6.4.6 Summary  
In summary the work in this chapter has provided a preliminary insight into 
some emotion-related behaviour in the Zfp804a mutant mice.  A picture is 
beginning to emerge that this gene has some important influences on 
behaviour, and possibly affect, although the data so far is inconclusive. 
Continued research with these mice with larger cohorts, further characterising 
their behavioural profile is needed. 
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 The C59X line were less active than the C417Y line in the locomotor 
activity task 
 Homozygous mutant mice were more active than wild-type mice, 
independent of line in the LMA task 
 C59X males appeared less anxious than C417Y males by exploring the 
open arm of the EPM more. C59X homozygous mutants were more 
willing to explore open arms than C417Y homozygous mutants 
 Mutant mice were more active in the inner zones of the open field 
(independent of line) 
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CHAPTER 7: General Discussion 
 
The experiments described in this thesis identified, developed and screened 
novel mouse mutants to investigate the function of Zfp804a, a mouse 
orthologue of ZNF804A, the schizophrenia susceptibility gene.  Two ENU-
derived mutations in coding regions of Zfp804a were identified and developed 
to compare the behaviour in mice carrying those mutations with wild-type 
littermate controls. Largely, the studies described herein address the 
experimental aims stated in the General Introduction (1.8): to identify, select 
and re-derive two lines of mutant mice carrying mutations in Zfp804a and to 
carry out a preliminary assessment of these lines. 
 
7.1 Utility of the models: advantages and limitations 
The discovery and development of the mouse mutants described in this thesis 
presented an excellent opportunity to investigate the relatively unknown 
function of ZNF804A. As discussed in the General Introduction, using the 
mouse as a model species for studying the effects of genetic variation brings a 
number of opportunities for manipulating and examining gene function and the 
effect on behaviour. Biochemical characterisation of the models created in this 
thesis would greatly aid translating findings from these mutant lines into 
information and knowledge about Zfp804a and indirectly, ZNF804A. The 
possibility that the phenotypes observed in Zfp804a mutants reflects the 
presence of unwanted (linked or not linked) mutations was argued fully in the 
Discussion of Chapter 4. Althought residual mutations may produce some 
unwanted noise in the behavioural data, they are extremely unlikely to 
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confound the results of the experiments discussed in this thesis. In terms of the 
behavioural characterisation of the models, there are two criticisms that could 
be levied at the present studies. Firstly, the group sizes are small, particularly 
the male homozygous mutants of the C59X line. Second, the existence of the 
phenotypes seen would be supported by reversing these effects by 
pharmacological means.  
The male homozygous mutants of the C59X line are low in number 
compared with the other testing groups (n=4). This was the first cohort of 
homozygous mutant mice of either line bred. Further backcrossing of the 
mutants and generation of F7 male homozygous mutants of the C59X line has 
seemed to be hindered by similar difficulties in generating a group size 
comparable to other genotype, line and gender groups (Eddy 2012, personal 
communication), with indications of increased infanticide by Zfp804a+/C59X 
mothers. As already mentioned, further work with F7 mice on the same tasks 
will increase the overall group size and so increase the power. The fact that 
some effects were observed with the mice is very telling however. 
Rescuing phenotypes by pharmacological (often antipsychotic) means is 
considered the ‘gold standard’ for a mouse model for schizophrenia (e.g. 
reviewed by Lu et al., 2011). However, it is questionable whether this 
pharmacological reversal or rescue is in fact informative to a model’s validity. 
Mouse models for schizophrenia (as discussed in 1.6), are only partial models 
as some symptoms of schizophrenia, particularly the positive symptoms, are 
unique to humans and we are not able to assay them reliably in mice. 
Antipsychotics (in humans) are most effective on the positive symptoms and 
are well-documented as being ineffective for the cognitive and negative 
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symptoms of schizophrenia in humans (reviewed in Miyamoto et al., 2012). 
Given this evidence and the evidence from this study of disrupted emotional 
behaviour (anxiolytic behaviour), it is questionable whether the use of 
antipsychotics with the Zfp804a models would be valid or informative.  
  Finally, there is of course the limitation frequently levied at such 
research: we are studying mice to inform us of a uniquely human disorder, how 
many useful inferences can be drawn between the species? To answer this 
understandable question, firstly it should be again emphasised that the models 
studied in this thesis are not intended to be models of schizophrenia by any 
means. These models are investigating the function of the relatively unknown 
schizophrenia candidate gene, ZNF804A. As the gene is a candidate gene for 
schizophrenia and bipolar disorder and is known to be highly expressed in the 
brain, the main focus of investigations is logically cognition and behaviour. 
There are many successes of using mouse models for such means as 
investigating gene function (some of the successes relating to schizophrenia 
are reviewed in Young, Zhou & Geyer, 2010), demonstrating the utility of the 
mouse as a model species. Whilst it may not be ideal, it serves as a good 
approximation and is never intended to be the sole means of investigating gene 
function in a thorough investigation of gene function. Used in tandem with in 
vitro investigations and parallel studies in human participants, mouse models 
are an invaluable and versatile tool, that are able to contribute to molecular, 
cellular and behavioural level investigations. 
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7.2 Main findings 
 
7.2.1 Development of the mutants 
Mutations were discovered at a rate of 1 in 0.61Mb (non-synonymous mutation 
discovery rate was 1 in 0.73Mb). This was a higher than expected rate of 
discovery (with the expected rate of 1 mutation in 1.82Mb taken from Quwailid 
et al., 2004). From the 12 mutations discovered, 2 were selected to take 
forward for phenotyping as these mutations had the most severe predicted 
effects on the protein. The C59X mutation introduces a premature stop codon 
early on in Zfp804a, in the zinc finger binding domain of the protein. The C417Y 
mutation substitutes a cysteine for a tyrosine residue in a highly conserved 
region of the protein. These mutations were then backcrossed onto the 
C57Bl/6J background to isolate the mutations for phenotyping as models of 
Zfp804a function.   
 
7.2.2 Preliminary phenotype screen 
Following the creation of the mutant lines, the mice were then screened for any 
gross physical deficits that could interfere with further behavioural and cognitive 
testing. The tests revealed no major physical deficits and no differences in 
terms of mortality and general health between the lines and wild-types. From 
the assessments done, the C59X homozygous mutants performed better on the 
RotaRod than wild-type and heterozygous counterparts (and were also lighter 
in body weight) but there were no other behavioural differences observed in this 
chapter. Importantly for the validity of the model, there was no excessive 
variation observed in behaviour between animals in the same (gender, line and 
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mutation) group, which would have been expected if other, residual mutations 
were interfering with the behaviour assayed. This chapter (5) provided 
important evidence that the mutations breed well and the (G4) mutants are 
suitable for behavioural testing.  
 
7.2.2.1  Performance on the RotaRod 
The finding of enhanced performance on the RotaRod in Zfp804aC59X/C59X male 
mice appears to be unique to genetic animal models for schizophrenia. As 
mentioned in 5.4.3, another genetic mutant study (Benoit et al., 2010) found 
enhanced RotaRod performance in QR2 knockout mice. These mice also had 
enhanced learning abilities in the Morris water maze and object recognition. It 
would be interesting to investigate the cognitive phenotype (particularly learning 
abilities) of the Zfp804a mutants in further studies. In this thesis, the LMA task 
and observation in the phenotyper cages offer opportunities to assay aspects of 
learning. No differences were seen between the mice indicative of differences 
in learning on these tasks although there are other factors involved that may 
complicate interpretation (such as baseline activity, anxiety etc).  
Dopamine, 5-HT and GABA have all been demonstrated to influence 
performance in mice on the RotaRod task (e.g. Shiotsuki et al., 2010; Peng et 
al., 2008; Rustay et al., 2003 respectively). Given this, no one neurochemical 
hypothesis to explain the findings from the Zfp804aC59X/C59X males is 
immediately obvious. The effect of dopamine on motor activity and co-
ordination is perhaps the best documented in the literature (reviewed by Sasa 
et al., 2003). A recent study (Shiotsuki et al., 2010) found that increased 
availability of dopamine in a mouse model (by administering nomifensine, a 
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dopamine-uptake inhibitor) improved learning on the RotaRod whereas 
apomorphine, a dopaminergic toxin impaired learning in the task.Other 
researchers have found substances not directly acting on the dopaminergic 
system to also influence performance on the RotaRod. For example, ethanol in 
small doses can improve performance (Rustay et al., 2003). Ethanol has been 
shown to act on NMDA, 5-HT(3) and GABA(A) receptors.Sertraline, an SSRI 
that increases availability of serotonin has also been shown to enhance 
performance in the RotaRod, but only in R6/2 mice (a model for Huntington’s 
disease (HD), carrying a transgene with a portion of HTT (Huntingtin), the 
human HD gene and not in controls (Peng et al., 2008). This finding was 
interesting as it reveals a potential interaction of neurotransmitter systems in 
determining RotaRod performance. Given the different neurotransmitter 
systems that influence RotaRod performance and the lack of knowedge of the 
mechanism of action of Zfp804a/ZNF804A, further evidence is necessary to 
hypothesise about the neurochemical basis of the findings with the Zfp804a 
mutant models (see 7.5). 
 
7.2.3 Emotion-related behavior 
The work in Chapter 6 provided a preliminary insight into some emotion-related 
behaviours in the Zfp804a mutant mice.  In terms of activity, homozygous 
mutant mice (independent of line) overall were more active in the locomotor 
activity boxes, although this same finding was not seen in the phenotyper home 
cage environment (Chapter 5) or other measures where activity could be 
measured. Similarly, the C59X line was less active than the C417Y line (in the 
locomotor activity task) although this finding wasn’t supported by other 
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behavioural tasks. The findings from tasks looking at anxiety were interesting. 
C59X males appeared to be less anxious than C417Y males by exploring the 
open arm of the EPM more. The same findings were not observed in the open 
field although mutants (independent of line), were more active in the inner 
zones of the open field. There is some uncertainty however about whether or 
not exploration of the open field and the elevated plus maze are measures of 
the same underlying behavioural process (discussed in Chapter 6). The data at 
present is not clear-cut but it does suggest that the Zfp804a gene has some 
important influences on behaviour, and possibly affect. Continued research with 
these mice with larger cohorts and further characterising their behavioural 
profile will improve our understanding of some of the influences the gene might 
have at a behavioural level in mice. 
 It is interesting to note that several other researchers have found an 
anxiolytic effect of mutations in schizophrenia-relevant genes in mouse models, 
particularly in genes affecting the glutamatergic system. Labrie et al. (2009), 
found an anxiolytic phenotype on the EPM, OF and novel object test in 
GRIN1(D481N) mutant mice that displayed a 5-fold reduction in NMDA receptor 
glycine affinity. These effects were reversed by pharmacological means. 
Deletion of the glutamate receptor Grik4, which has been associated with 
susceptibility to depression, bipolar and schizophrenia (Catches et al., 2012) 
has also been robustly shown to have have an anxiolytic effect on the 0-maze, 
marble-burying and novelty-induced suppression of feeding tasks. Halene et al. 
(2009), found similar effects in NMDA receptor NR1 mutants (Nr1[neo]-/-) mice 
(Mohn et al., 1999), with mutants showing a preference for the open arms of 
the 0-maze and the centre of the open field although no differences in LMA, 
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similar findings to those presented in this thesis.There have been several 
reports of an anxiolytic phenotype in Nrg1 mutants including Karl et al. (2007), 
Long et al. (2010) and Desbonnet et al. (2012). However, overexpressing Nrg1 
does not necessarily lead to increased anxiety in the mice (Deakin et al. (2009). 
Findings of anxiolysis co-segregating with involvement of the glutamatergic 
system are interesting. Further investigation of the mechanism by which the 
mutation has an anxiolytic effect, perhaps by using pharmacological 
interventions with the Zfp804aC59X/C59X males would prove interesting and may 
be informative to the function and mechanisms of action of this gene.  
 
7.3 Interpretation of findings 
The findings of this thesis contribute to the growing body of data on the function 
of ZNF804A/Zfp804a. Research so far on the neurocognitive role of ZNF804A 
has shown that the gene is likely to play a role in cognition but the role it plays 
is somewhat unclear. This research is discussed in the Introduction (1.5.2.9). 
Some research has suggested that the risk allele at rs1344706 influences 
patients but not controls (Walters et al., 2010; Hashimoto et al., 2010, Donohoe 
et al, 2010), some research has suggested it influences patients and close 
(unaffected) relatives (Rasetti et al., 2011) and some research has suggested 
the gene influences controls but not patients (Hargreaves et al., 2012). None of 
the studies, however, explicitly measured the same thing so the findings are not 
necessarily conflicting.  The mouse research presented in this thesis is not 
incompatible with the human research to date and does indeed suggest the 
gene plays a role in behaviour. Parallels between the mouse and human work 
beyond this, at this stage are not possible to draw. Further behavioural genetic 
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investigations with the C59X and C417Y lines and with human participants is 
warranted before any hypotheses on the gene’s role in cognition and behaviour 
can be formed.  
 
7.3.1 Comparison of the Zpf804a models to other genetic models for 
schizophrenia 
To accurately compare the Zfp804a mutant models with other genetic mouse 
models for schizophrenia, further characterisation of the mutants with a larger 
group of the Zfp804aC59X/C59X males is needed. Nonetheless, important findings 
from the models have emerged, the mutants are viable and to date, are the 
only available animal models of altered Zfp804a function. The pattern of results 
seen warrant further investigation of the RotaRod and anxiolytic phenotypes. 
As discussed previously (7.2.2.1), dopamine, 5-HT and GABA all have been 
demonstrated to have an influence on performance in the RotaRod task. 
Pharmacological intervention with antagonists/agonists for these 
neurotransmitters would be interesting and may help to elucidate the 
mechanism by which the the Zfp804aC59X/C59X mutation aids RotaRod 
performance. In terms of the findings from the EPM and OF, in the literature, 
anxiolysis in genetic mouse models seems to be associated with alterations to 
the glutamatergic system (see 7.2.3). Glutamate agonists and antagonists 
would prove interesting to investigate the anxiolytic phenotype of the 
Zfp804aC59X/C59X mice further and the mechanism by which it works. 
 To date, most genetic mouse models for schizophrenia have been 
knockout models or transgenic animals. Despite the merits of ENU 
mutagenesis to generate models, there are (to date) only two other ENU 
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mutant models for schizophrenia: Q31L and L100P Disc1 mutants (Clapcote et 
al., 2007). In the Neuron paper, the two models showed different phenotypes 
with the Q31L model showing depressive-like behaviour (deficits in the forced 
swim task, reversed by bupropion) and the L100P model showing PPI and 
latent inhibition deficits that were reversed by antipsychotics. However, a more 
recent study, using the same model but bred to C57Bl/6J for a further two 
generations, failed to replicate the findings finding no differences between the 
Q31L mice and wild-types and the L100P mice and wild-types, but for an 
increase in locomotor activity (consistent with Clapcote et al., 2007), (Shoji et 
al., 2012).These studies emphasise the need for findings to be replicated and 
add strength to the anxiolytic findings in this study, which have been 
successfully replicated in the same tasks and another task (0-maze) after the 
mutants have been bred onto C57Bl/6J for a further two generations (Eddy, 
personal communication, 2011). 
 
7.4 Recent work 
The association of the schizophrenia susceptibility gene, ZNF804A, was first 
described by the (then) Department of Psychological Medicine, Cardiff 
University (O’Donovan et al., 2008). Since the discovery of the gene’s potential 
involvement in schizophrenia pathogenesis, a multi-discilinary program of work 
has grown in the Department, to investigate the gene’s function at a molecular, 
cellular and behavioural level (in both humans and mice) and how it may confer 
risk to schizophrenia and bipolar disorder.  
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7.4.1 Molecular biology 
In terms of the gene’s molecular function, the central hypothesis is that the 
gene may have a role in regulating gene expression based on sequence 
homology with other genes that regulate expression (Knight, personal 
communication, 2012).  Currently, the function of this gene is being investigated 
by Debbie Knight (PhD student) by using the C59X line generation to examine 
the consequences of altered Zfp804a expression in the brains of mice carrying 
a nonsense mutation. To identify genes which are differentially expressed 
between C59X homozygous mutant mice and wild-type controls, Knight is also 
using microarray analysis and RNA-sequencing. Genes that show differential 
expression may be involved in mediating the effect of Zfp804a on behaviour 
and warrant further investigation both molecularly and statistically (in terms of 
their association with schizophrenia in humans). As well as this molecular 
genetic work, other ongoing work with ZNF804A, led by Professor Derek Blake, 
includes the development of a ZNF804A antibody, yeast two-hybrid screening 
to look for binding partners and developing stable cell lines expressing 
ZNF804A.   
 
7.4.2 Animal models 
Parallel behavioural work with the C59X and C417Y lines (F7) is also ongoing, 
led by Professor Lawrence Wilkinson and Jessica Eddy. A developmental 
assessment of the mice looking at body weight from birth and somatic indices 
such as ear development, eruption of teeth, appearance of fur and whiskers etc 
is being analysed, adding to the data generated in this thesis. The anxiety tasks 
in this thesis have also been repeated and the findings replicated, suggesting 
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the Zfp804aC59X mutation indeed has an anxiolytic effect (see figure 7.1, Eddy, 
unpublished data, reproduced with permission). Other ongoing experiments 
with the mice include looking at impulsivity, working memory, social interaction 
and anhedonia. 
    
 
 
 
 
 
 
 
 
 
Figure 7.1: Frequency of entry to the open arms of the EPM, Eddy (unpublished data), 
reproduced with permission 
  
7.4.3 Clinical work 
Since the discovery of the gene’s involvement with schizophrenia, clinical work 
in the Department has looked at clinical features and endophenotypes 
segregating with the risk allele, rs13447606 in patient and control populations, 
led by Dr James Walters.Findings so far have been interesting. The risk allele 
in ZNF804A seems to segregate with a subgroup of the (schizophrenia) patient 
population with relatively intact cognition (compared with other schizophrenia 
patients, Walters et al., 2010). The authors tested for an association in two 
samples (Irish and German) between the risk allele, A, at rs1344706 and 
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cognitive domains known to be affected in schizophrenia: IQ, episodic memory, 
working memory and attention. In the Irish sample, in patients but not in 
controls, the risk allele had a protective effect on episodic and working memory. 
The results replicated in the German sample supporting the protective action of 
the risk allele at rs1344706. Slightly elevated manic symptoms associated with 
the risk allele were also found in this population (Donohoe et al., 2010).  
 
7.4.4 In situ hybridisation 
Other ongoing work (by Tamara Al-Janabi and Dr William Davies) is the in situ 
hybridisation of ZNF804A in human foetal/embryonic brain tissue. The MRC-
Wellcome Trust Human Developmental Biology Resource (HDBR), based at 
UCL has a tissue bank of human foetal tissue and an in-house gene expression 
service (IHGES) that can be used to gather in situ hybridisation data on gene 
expression. In adult mice, the Zfp804a transcript (also known as 
C630007C17Rik) is most highly expressed in the septum, the thalamus and the 
hippocampus, and is weakly expressed elsewhere (Allen Brain Atlas, 2011). 
The brain expression throughout development in mice is largely unknown as is 
also the case in humans. 
According to Unigene, ZNF804A is expressed in human brain (10 transcripts 
per million), and in foetal tissue (15 transcripts per million), but as yet no 
published studies have explicitly assessed its distribution throughout the brain. 
As the function and developmental expression of ZNF804A is currently 
unknown, in situ hybridisation was performed on the tissue bank by the IHGES.  
Three anti-sense DIG-labelled probes were prepared from ZNF804A to cross 
exon-exon boundaries to ensure the probe did not hybridise to DNA.  Full 
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details of the methods used for the in situ hybridisation can be seen in 
Appendix 8.3. Figures 7.2 and 7.3, from a 12-week embryo, show specific 
staining in the posterior ganglionic neuroepithelium and subventricular zone 
and in the cortical plate.  The pattern of expression in these images is very 
interesting due to some similarities between the specific staining and some 
research by Yokota et al., (2007) that demonstrated that a particular type of 
GABAergic interneurons show a pattern of migration via these zones. 
Furthermore, GABAergic neuronal activity in the frontal cortex (which develops 
from the cortical plate) is thought to be involved in some of the cognitive deficits 
observed in schizophrenia (Lewis et al., 2005; Lewis & Moghaddam 2006). 
However, from the images, we cannot tell what type(s) of cells are stained so 
this hypothesis is merely speculative.  
  
 
 
 
 
 
 
 
 
 
 
Figure 7.2: Probe -ZNG2, F4 (12 developmental weeks), dorsal coronal section, showing 
staining (indicated by arrows) in the cortical plate, the cortical neuroepithelium (NEP) and 
subventricular zone (SVZ) and the posterior ganglionic NEP & SVZ, Al-Janabi, Davies, Fok, 
Gerelli and Owen (unpublished data) 
 
Cortical NEP and SVZ 
Posterior 
ganglionic NEP 
and SVZ 
Cortical plate 
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Figure 7.3: Probe - ZNF 1, F4 (12 developmental weeks), coronal ventral section, showing 
staining (indicated by arrows) in the posterior ganglionic NEP & SVZ Al-Janabi, Davies, Fok, 
Gerelli and Owen (unpublished data) 
 
In situ hybridisation in an 8 week embryo didn’t follow the same pattern but 
showed very specific staining in Rathke’s pouch (which becomes the anterior 
pituitary, see figures 7.4 and 7.5). One of the anterior pituitary’s functions is the 
production of prolactin. The anterior pituitary houses dopamine receptors and it 
is well-known that antipsychotics (which tend to block dopamine receptors in 
the brain, reviewed in Baumeister & Francis, 2002) are associated with 
hyperprolactinaemia (reviewed in Inder & Castle, 2011, Holt & Peveler, 2011). 
However this may, of course, be coincidental as the anterior pituitary has 
several functions other than housing dopamine receptors and producing 
prolactin (such as regulating stress, growth and reproduction). The results from 
the in situ hybridisation are nevertheless interesting and certainly warrant 
further investigation. 
 
Posterior 
ganglionic NEP 
and SVZ 
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Figure 7.4:  A magnified image (x8.0)(CS23, 8 weeks, coronal section,probe - ZNF 3), above of 
specific staining in Rathke’s pouch, Al-Janabi, Davies, Fok, Gerelli and Owen (unpublished 
data) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.5: An unmagnified image (x1.0)(CS23, 8 weeks, coronal section,probe - ZNF 3) of 
specific staining in Rathke’s pouch, Al-Janabi, Davies, Fok, Gerelli and Owen (unpublished 
data) 
Rathke’s pouch 
Rathke’s pouch 
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7.5 Possible Clinical Relevance 
Data suggesting a role for ZNF804A in cognition and behaviour is beginning to 
emerge although further work is needed to elucidate the function of ZNF804A 
and particularly, the role the gene plays in schizophrenia risk. In terms of the 
mouse models, the creation of two parallel lines that survive and breed 
successfully and show indications of behavioural phenotypes is encouraging.  
The findings with the C59X mutants, in terms of the EPM were 
interesting. We saw more exploratory behaviour in a fear-inducing environment, 
indicative of lower anxiety levels than the wild-type littermate controls. 
Presuming (although this is not known at this stage) that the C59X mutation 
reduces or destroys the Zfp804a protein, and that risk allele rs1344706 is 
associated with an increase in ZNF804A production (Williams et al., 2011) then 
we may expect to see increased anxiety in risk-allele carriers. Further work is 
necessary to explore this interesting finding, especially in the light of findings 
from the Edinburgh High Risk Study (Johnstone et al., 2005) that anxiety can 
predict the development of schizophrenia. In humans, the risk allele at 
rs1344706 is common. Any intervention/screening strategies based on this risk 
allele therefore not practicable. However, the replicated findings regarding 
differences in anxiety are nevertheless interesting and informative to future 
work. 
 There are also other potential clinical implications of the work contained 
in this thesis although these are speculative at this stage and would need 
substantial further investigation to support them. We observed that the C59X 
male homozygous mutants performed better on the RotaRod than other 
mutants. RotaRod performance has been shown by numerous studies to be 
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affected by dopamine (e.g. Mizoguchi et al., 2002; Sasa et al., 2003; Ogura et 
al., 2005; Shiotsuki et al., 2010) and dopamine is strongly associated with 
motor co-ordination (reviewed in Côté & Crutcher, 1991). The findings from the 
in situ hybridisation (see figures 7.3 and 7.4) suggest that ZNF804A is highly 
expressed in Rathke’s Pouch, the developing anterior pituitary, a region rich in 
dopaminergic neurons. A third line of evidence for the involvement of ZNF804A 
in the dopaminergic system comes from clinical work. Three independent 
studies have shown that antipsychotic response is linked to ZNF804A genotype 
(Xiao et al., 2011; Zhang et al., 2012; Mössner et al., 2012). Zhang et al and 
Mössner et al. both demonstrated that antipsychotics in patients either carrying 
the risk allele (Zhang et al.) or homozygous for the risk allele (Mössner et al.) 
showed poorer response to antipsychotic therapy than those patients either 
carrying (Mössner et al.) or homozygous for (Zhang et al.) the non-risk allele. 
Xiao et al. (2011) found that although rs1344706 didn’t affect antipsychotic 
response in a Han Chinese population, minor alleles at rs35676856 and 
rs61739288 in ZNF804A both predicted a slower response to antipsychotics. It 
is plausible therefore that Zfp804a/ZNF804A may therefore have some 
influence on the dopaminergic system although this area would need 
substantial further investigation before any treatment implications could be 
drawn. Similarly there are the findings from the in situ hybridisation that could 
relate to GABAergic interneurons (and it is known that GABAergic interneurons 
modulate dopamine release, reviewed in Fink & Göthert, 2007, see 7.4.3 and 
figure 7.2 and 7.3) although this again would need substantial further 
investigation before any treatment implications could be considered. 
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7.6 Future directions 
As highlighted in section 7.5, there is plenty of scope for further work 
developing and extending upon the findings in this thesis. Further work with the 
Zfp804a C59X and C417Y lines is focused on in this section, although there is 
a plethora of important work to be done beyond mouse models of Zfp804a to 
elucidate the mechanisms by which this gene confers risk to schizophrenia. 
 In terms of probing the findings relating to anxiety further, there are 
numerous behavioural assays that would yield further information. The EPM 
and OF findings would be supported by repeating the results with larger cohorts 
(particularly larger numbers of Zfp804aC59X/C59X males). Results from other 
anxiety-assaying tasks including the 0-maze, novelty-place preference and 
social anxiety tasks would also be interesting, particularly, perhaps, social 
anxiety tasks given Johnstone et al.’s (2005) findings that it is social anxiety 
rather than other forms of anxiety that best predicts the development of 
schizophrenia in those deemed to be a high genetic risk.  
 To explore the idea of a possibly altered dopaminergic system in 
Zfp804a mutant mice, pharmacological manipulations on behavioural tasks, 
particularly the LMA and RotaRod tasks involving movement and motor co-
ordination would likely yield the most interesting results. Antagonist drugs such 
as antipsychotics and agonists such as L-DOPA, mephadrone and 
methamphetamine would likely be the best pharmacological candidates.  
 The possibility that ZNF804A may be highly expressed in GABAergic 
interneurons first and foremost needs confirmation that this is the case before it 
may be explored. Cell-staining techniques in tissue samples would be the 
easiest method of doing this (Gerrelli, personal communication, 2012). If this is 
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confirmed then exploration of behaviour (such as LMA) using GABAergic 
antagonists such as GABAA , bicuculline and agonists such as 
benzo/nonbenzodiazipines, barbiturates and ethanol would prove useful. 
 Aside from behaviourally, these mice are also of great use biologically. 
Histology using the brains of the mice would be useful to further investigate 
indications of differences in brain weights between the lines and genotypes, as 
would the technology now available of using MRI to image the brains of the 
mice.  
 However, before any further work on the models is truly informative, the 
biochemical characterization of the mutations is imperative. Without this, we 
can only estimate the effects the mutations are having and thus can only draw 
conclusions that any phenotypes are associated with a change on the Zfp804a 
protein, rather than anything more concrete. Discovering the effect the 
mutations have on the protein would add to the utility of these models 
enormously.  
 Beyond the areas raised for further investigation in this thesis, 
there is ample opportunity to extend the research. One such area that would be 
useful to explore would be creating alternative mouse models such as a 
conditional knockout and a mouse model with up-regulated Zfp804a. In 
conditional knockout models, Zfp804a could be spatially and temporally 
manipulated to refine where and when the gene has the most influence on 
phenotype. This would begin to give better indications of how this gene may 
confer risk of schizophrenia.  
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7.7 Final comments 
Although work to understand the mechanisms by which ZNF804A confers risk 
for schizophrenia (and therefore can translate laboratory findings to clinical 
utility) has only just begun, initial investigations are promising, both with the 
mouse lines created in this thesis and beyond. The ultimate goal is however not 
scientific, or intellectual, it is to improve the lives of people with schizophrenia 
and those close to them. This research, whilst it cannot have any direct clinical 
impact, makes a small but useful contribution to the understanding of 
ZNF804A, which will in turn, improve our understanding of schizophrenia. 
These steps, albeit small, are necessary if we are to understand and therefore 
satisfactorily classify, treat and prevent schizophrenia.  
 
 
7.8 Summary 
The results reported in this thesis contribute to a rapidly growing and rapidly 
developing field of schizophrenia genetics. As the first mouse models available 
for Zfp804a, the lines created within this thesis will be of great use for 
understanding the function of ZNF804A.  The mutant lines will not only be 
useful in understanding how Zfp804a may influence behaviour but can also be 
used at molecular and cellular levels. Preliminary indications suggest that 
Zfp804a may have a role in anxiety. However, substantial further work is 
necessary with these models to investigate this and other findings from this 
thesis further.  
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CHAPTER 8: Appendices 
 
8.1:  Sequencing traces of mutations discovered 
a) 
 
 
b) 
c) 
 
 
 
 
Output from the LightScanner (see 
Figure 4.1 for a more detailed 
explanation of the images generated). 
Diagram a) shows the 96-well plate and 
the location of the identified variant (E1, 
red). b) shows the melt curve of this 
sample and c) shows the difference 
curves. d) shows the sequencing trace 
demonstrating that the red sample, E1, 
was a true variant where wild-type 
sequence is the top row and mutant 
sequence (A>G, complement is 
shown)is shown below. 
     For the remainder of the mutations 
discovered, the melt curves (b) only are 
shown. 
     The blue variant was a false positive. 
 
d) 
 
Figure 8.1.1: LightScanner and sequencing traces of mutation X14,E1 
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a)  
 
Figure showing melt 
profile (a) of sample X23, 
E5 (blue) and the wild-
type (top) and mutant 
(bottom) sequencing trace 
(b, TGT>TAA, 
complement is shown).  
b) 
 
 
 
 
 
 
 
 
 
 
  
Figure 8.1.2: LightScanner and sequencing traces of mutation X23, E5 
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a)  
 
Figure showing melt 
profile (a) of sample X33, 
E8 (green) and the wild-
type (top) and mutant 
(T>C, complement is 
shown) (bottom) 
sequencing trace (b).  
b) 
 
 
 
 
 
 
 
 
 
 
  
Figure 8.1.3: LightScanner and sequencing traces of mutation X33, E8 
 
 
 
 
 
 
 
 203 
a)  
 
Figure showing melt 
profile (a) of sample X32, 
E3 (green) and the wild-
type (top) and mutant 
(T>A) (bottom) 
sequencing trace (b).  
b) 
 
 
 
 
 
 
 
 
 
 
  
Figure 8.1.4: LightScanner and sequencing traces of mutation X32, E3 
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a) 
 
 
 
 
 
Figure showing melt profile 
(a) of sample X13, A5 
(green) and the wild-type 
(top) and mutant (bottom) 
sequencing trace (b) of the 
A>G mutation. The 
sequencing trace of the 
wild-type and mutant 
sample showing the T>C 
mutation is shown in (c). 
b)  
 
 
 
 
c) 
 
 
 
Figure 8.1.5: LightScanner and sequencing traces of mutations in X13, A5 
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a)  
 
Figure showing melt 
profile (a) of sample X13, 
D5 (blue) and the wild-
type (top) and mutant 
(T>A)(bottom) sequencing 
trace (b).  
b) 
 
 
 
 
 
 
 
 
 
 
  
Figure 8.1.6: LightScanner and sequencing traces of mutation X13, D5 
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a)  
 
Figure showing melt 
profile (a) of sample X13, 
E2 (blue) and the wild-
type (top) and mutant 
(A>G)(bottom) 
sequencing trace (b).  
b)  
 
 
 
 
 
 
 
 
 
 
  
Figure 8.1.7: LightScanner and sequencing traces of mutation X13, E2 
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a)  
 
Figure showing melt 
profile (a) of sample X42, 
G9 (red) and the wild-type 
(top) and mutant 
(G>A)(bottom) 
sequencing trace (b).  
b)  
 
 
 
 
 
 
 
 
 
 
  
Figure 8.1.8: LightScanner and sequencing traces of mutation X42, G9 
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a)  
 
Figure showing melt 
profile (a) of sample X9, 
G1 (aquamarine) and the 
wild-type (top) and mutant 
(T>C)(bottom) 
sequencing trace (b).  
b)  
 
 
 
 
 
 
 
 
 
 
  
Figure 8.1.9: LightScanner and sequencing traces of mutation X9,G1 
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a)   
 
Figure showing melt 
profile (a) of sample X29, 
A12 (blue) and the wild-
type (top) and mutant 
(A>G)(bottom) 
sequencing trace (b).  
b)  
 
 
 
 
 
 
 
 
 
 
  
Figure 8.1.10: LightScanner and sequencing traces of mutation X29,A12 
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a)   
 
Figure showing melt 
profile (a) of sample X15, 
E8 (red) and the wild-type 
(top) and mutant 
(A>G)(bottom) 
sequencing trace (b).  
b)  
 
 
 
 
 
 
 
 
 
 
  
Figure 8.1.11: LightScanner and sequencing traces of mutation X15, E8 
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8.2 In vitro fertilisation of mouse oocytes using HTF medium (from MRC 
Mammalian Genetics Unit, Harwell) 
 
 
EMMA and FESA, MRC Harwell, 11th – 14th February 2008 
 
A. Preparation of oocyte harvest dishes 
1. Add approximately 2-3ml of the HTF (with Pen/Strep/BSA) to a numbered 
35mm Petri Dish (Falcon 351008). One dish is required for every three 
superovulated females. 
2. Place the dishes in the incubator overnight at 37°C, in 5% CO2 in air to 
equilibrate. 
 
B. Preparation of Fertilisation/Wash/Culture dishes 
1. Prepare one 60mm Petri Dish (Falcon 351016) for every three 
superovulated females. 
2. Into each dish, carefully pipette 5 drops of HTF (with Pen/Strep/BSA) as 
follows: 
1 x 500µl for fertilisation 
4 x 150µl for washing and overnight culture 
 
3. Carefully overlay the drops with Mineral Oil (Sigma Chemical Co.; Cat. 
No. M8410, embryo culture tested) ensuring that they do not run together. 
Fertilisation 
drop (500µl) 
Wash drops 
(150µl each) 
Culture drops 
(150µl each) 
1 
2 3 
4 
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4. Equilibrate the dishes overnight at 37°C, in 5% CO2 in air. 
 
C. Preparation of sperm dispersal dish (for freshly harvested sperm) 
1. Pipette 500µl HTF into the centre of a 60mm Petri Dish (Falcon 351016). 
2. Overlay with Mineral oil and equilibrate overnight at 37°C, in 5% CO2 in 
air. 
 
D. Preparation of sperm samples: 
Freshly harvested sperm 
1. The selected male should be at least 8 weeks old, and not have been 
used for mating for at least 3 days before sperm collection. 
2. Sacrifice the male and dissect the cauda epididymides. 
3. Place on a clean paper tissue, and remove as much adipose and vascular 
tissue as possible, using size 5 watchmakers’ forceps. Work under a 
dissecting microscope lit from above, dissecting quickly to prevent the 
material from desiccating. 
4. Place the cauda epididymides into the oil next to the dispersal drop. Nick 
the tip of the cauda epididymides with a pair of fine scissors. Gently 
palpate the tissue to expel the sperm. 
5. Drag the blebs of sperm into the dispersal drop. 
6. Allow the sperm to disperse into the medium for between 10 and 90 
minutes, at 37°C in the CO2 incubator. 
7. Place IVF dishes on a heated stage or hot pad, then pipette 10µl of the 
sperm suspension into each fertilisation drop using a wide-bore tip and 
return the dishes to the incubator until the oocytes are harvested. 
 
Cryopreserved sperm 
1. Using forceps, hold the cryotube in air for 30 seconds. If liquid nitrogen is 
present in the cryotube, wait for it to evaporate and escape by rolling the 
cryotube around on the bench.  
2. Take special care that the cryotube is not filled with liquid nitrogen before 
plunging into the water bath (such tubes may explode).  
3. Thaw the sperm sample rapidly by placing in a 37°C water bath.  
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4. Once thawed, pipette 10µl of the sperm suspension into each fertilisation 
drop using a wide bore pipette tip and return the dishes to the incubator. 
 
E. Harvesting oocytes 
1. Dissect the oviducts from three superovulated female mice and place into 
a preincubated dish of HTF (for superovulation methods, see the protocol 
for harvesting and cryopreservation of in vivo derived embryos and the 
table below). 
2. Under a dissecting microscope, hold each oviduct down with forceps and 
gently tear the swollen ampulla with a second pair of forceps to release 
the cumulus masses into the HTF, then remove the oviduct from the dish. 
3. When all the cumulus masses have been extracted, gently draw them up 
into a wide bore pipette tip in a maximum of 30µl HTF. To stop them from 
sticking to the plastic, first wet the inside of the pipette tip by drawing up 
and expelling some HTF. Hold the pipette close to vertical to ensure the 
cumulus masses are aspirated with a minimal amount of medium. 
4. Transfer the cumulus masses to a fertilisation drop (containing sperm) 
being careful to transfer as little HTF as possible. 
5. Incubate the dishes at 37°C, in 5% CO2 in air for approximately 5-7 hours 
to allow fertilisation to occur. 
6. Repeat steps 1-5 for each fertilisation dish in succession (i.e. complete all 
of the steps from collecting the oviducts to returning the fertilisation dishes 
to the incubator for one batch of females before starting the next batch). 
Aim to take no more than 5 minutes from collecting the oviducts to 
returning the fertilisation drop (including oocytes) to the incubator. 
 
F. Washing and culturing the fertilised oocytes 
1. Between 5-7 hours after the cumulus masses were placed in the 
fertilisation drop, remove all of the oocytes and place them in wash drop 1 
(see diagram). 
2. Move the good quality oocytes from wash drop 1 to wash drop 2, cleaning 
the oocytes as much as possible in the process. Leave poor quality 
oocytes in wash drop 1. 
3. Divide the washed oocytes approximately equally between the two culture 
drops (3 and 4). 
4. Incubate overnight at 37°C, in 5% CO2 in air. 
 
 214 
 
G. Preparing fertilised oocytes for embryo transfer or freezing 
1. Next morning, separate the 2-cell embryos from those which have not 
fertilised or cleaved, or have degenerated. Place all the 2-cell embryos in 
drop 4 and the 1-cell or degenerated oocytes/embryos in drop 3. 
2. Prepare a drop of hyaluronidase solution (300µg/ml made up in M2) in a 
Falcon 351008 petri dish. NB: This hyaluronidase washing step is only 
required when it is necessary to remove the adherent cumulus cells 
from the zona pellucida. 
3. Collect the 2-cell embryos into a drop of M2 in a Falcon 351008 petri dish. 
4. Transfer these embryos into the drop of hyaluronidase. 
5. Incubate at 37°C for a few minutes with gentle agitation at intervals using 
a glass pipette until any adherent cells or sperm have fallen off. 
6. Wash the embryos through two drops of M2. 
7. Either transfer the 2-cell embryos to the oviducts of 0.5d pseudopregnant 
foster mothers, or: 
8. Prepare the 2-cell embryos for cryopreservation according to the standard 
protocol for in vivo derived embryos, or: 
9. Culture the embryos in KSOM. 
 
Timetable of events for IVF 
Day -3 
(e.g. Saturday) 
Day -1 
(e.g. Monday) 
Day 0 
(e.g. Tuesday) 
Day 1 
(e.g. Wednesday) 
Superovulate 
between ten and 
thirty 3-4 week old 
females by 
injecting 0.1ml 
(5iu) PMS at 
17.30-18.00. 
Prepare dishes for 
oocyte harvest, 
fertilisation/wash/ culture 
and sperm dispersal (if 
using a freshly 
harvested sample). 
07:45 Thaw 
cryopreserved sperm 
sample, or collect and 
disperse freshly 
harvested sperm. 
Morning: score the 
IVF success (2-cell 
vs others). 
 Induce ovulation in the 
females by injecting 
0.1ml (2.5iu) hCG at 
18:00 
08:00-09:00 Harvest 
oocytes and place into 
diluted sperm 
preparation. 
Prepare the 2-cell 
embryos for 
cryopreservation, 
embryo transfer or 
culture. 
  15:00 Wash the 
presumptive zygotes 
and place into culture 
drops. 
 
This timetable assumes that the mice are exposed to 12 hours of darkness 
between 19:00 and 07:00. 
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8.3 In situ hybridisation methods 
 
In situ hybridisation was carried out on human brain tissue for ZNF804A 
expression and on mouse brain tissue for Zfp804a. The in situ hybridisation on 
human tissue for ZNF804A was carried out by the MRC-Wellcome Human 
Developmental Biology Resource In-House Gene Expression Service.  The 
probes were prepared by Dr Wiliiam Davies and myself.  
 
8.3.1 In situ hybridisation of ZNF804A in human embryonic and foetal tissue 
In situ hybridisation was carried out as described by Wilkinson (1992). Human 
fetal tissue, at 9 weeks of gestation, was dissected and fixed in 4% 
paraformaldehyde (PFA) in phosphate-buffered saline (PBS) overnight at 4°C. 
Following fixation, tissues were dehydrated and embedded in paraffin wax. 
Sagital sections of the head where cut at 8 µm using a standard microtome and 
attached to Superfrost Plus microscopic slides (VWR). Before hybridization, 
tissue sections were de-waxed, hydrated, fixed in 4% PFA/PBS and rinsed 
twice with PBS. Proteins were removed by incubation with proteinase K (20 
mg/ml) in PBS. After washing with PBS, the sections were re-fixed in the same 
PFA solution, and treated with 0.1 M triethanolamine containing 0.25% acetic 
anhydride. Slides were dehydrated through an alcohol series and air-dried.  
 
Three probes were prepared from ZNF804A (Genbank accession number and 
position of inserts are as follows: ZNG2: NM_194250.1, bp1049-1755; ZNG3: 
NM_194250.1, bp2072-2787; ZNG4: NM_194250.1, bp 3322-4062) ligated into 
pGEM –T Easy (Promega). Anti-sense and sense probes were prepared by 
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linearising plasmids with SaII and NcoI respectively. Digoxigenin-UTP was 
incorporated into riboprobes during in vitro transcription using the DIG RNA 
labelling mix (Roche) according to the manufacturer’s instructions. Antisense 
and sense probes were generated using T7 and SP6 polymerase respectively.  
 
Hybridisation solution contained riboprobe (300ng DIG-labelled RNA probe), 
RNAguard (1 ml/ml) and tRNA (0.5 mg/ml) in hybridization buffer (50% 
formamide, 0.3 M NaCl, 20 mM Tris-HCl pH 7.5, 5 mM EDTA pH 8.0, 10% 
dextran sulphate and 1x Denhardt's solution). A 100 µl aliquot of hybridization 
probe was added to each slide, which was incubated in a sealed chamber 
moistened with 50% formamide/1x standard saline citrate (SSC) overnight at 
65°C. Stringency washes were performed in the following order: 2x SSC (twice 
at 65°C); 50% formamide/2x SSC (twice at 65°C); 2x SSC (twice at 65°C); 0.2x 
SSC (65°C) and 0.2x SSC (65°C cooled to room temperature). Slides were 
then incubated for 1 h in 150 mM NaCl and 100 mM Tris-HCl pH 7.5 containing 
10% fetal calf serum (FCS). For antibody detection, slides were incubated in 
anti-digoxigenin antibody conjugated with alkaline phosphatase (anti-Dig 
antibody diluted 1:1000, containing 2% FCS) overnight at 4°C. Expression 
patterns were visualized using the NBT/BCIP system (Roche). Sections were 
mounted in VectaMount (Vector Labs) and analysed using the Axioplan 2 
imaging system (Zeiss).  
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